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ABSTRACT 
 
Background: Myocardial oxidative fuel supply is increased in obese conditions. How 
this metabolic environment and altered cardiometabolic phenotype associated with pre-
diabetic obesity impacts on cardiac function and tolerance to ischaemia/reperfusion 
injury remains uncertain. While obese individuals are likely to be treated with PPARα 
agonists, controversy exists as to how activation of the PPARα receptor influences 
cardiovascular function and post-ischaemic recovery. Aims: To determine in a model of 
hyperphagia-induced obesity 1) whether protracted obesity is associated with left 
ventricular (LV) mechanical dysfunction; 2) the responsiveness of these hearts to insulin 
stimulation; 3) whether insulin can afford cardioprotection against ischaemia/reperfusion 
damage; and 4) how obesity and chronic PPARα agonist (K-111) treatment influences 
myocardial function, substrate metabolism, mitochondrial function and post-ischaemic 
outcomes.  
 
Methods: Male Wistar rats were fed standard rat chow or a high caloric diet. 1) In vivo 
LV mechanical function was assessed echocardiographically in 32 week fed animals. Ex 
vivo LV function was measured in the presence of glucose, insulin and/or fatty acid (FA); 
2) Ex vivo myocardial insulin sensitivity was assessed by measuring insulin stimulated 
glycolytic flux in 16 week fed rats. Insulin was also administered prior to and during 
regional ischaemia to determine its effect on post-ischaemic function and infarct size; 3) 
K-111 was added to the drinking water during the last 10 weeks of feeding (feeding 
period of 18 weeks); a) Ventricular mitochondrial function was determined 
polarographically in the presence of either glutamate or palmitoyl-L-carnitine as 
substrates; b) Myocardial carbohydrate and lipid metabolism, and in a separate series of 
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perfusions, myocardial infarct size were determined in the presence of physiological or 
high insulin (30 or 50μIU/ml) and FA (0.7 or 1.5mM) concentrations. 
 
Results: 1) Obese animals maintained normal in vivo LV mechanical function. Glucose 
perfused hearts from obese animals had depressed aortic outputs compared to the 
control group (32.58±1.2 vs. 46.17±0.91 ml/min; p<0.001) which was abolished by the 
presence of FA; 2) Hearts from obese animals had reduced insulin stimulated glycolytic 
flux rates (1.54±0.42 vs. 2.16±0.57 μmol/g ww/min, p<0.01). Although insulin reduced 
infarct size in the obese group (20.94±1.60 vs. 41.67±2.09 %, p<0.001), its 
cardioprotective effect was attenuated in the presence of FA; 3) By simulating the in vivo 
metabolic environment of control and obese animals in ex vivo perfusions, elevated 
insulin and FA levels associated with obesity increased infarct sizes in the obese group 
compared to the control group (47.44±3.13 vs. 37.17±2.63 %, p<0.05); 4) While chronic 
K-111 treatment reversed systemic metabolic abnormalities associated with obesity, 
neither obesity nor the drug influenced myocardial and mitochondrial function or post-
ischaemic outcomes. K-111 was able to reduce palmitate oxidation in the obese group.  
 
Conclusion: Elevated levels of circulating FFA may be important in maintaining normal 
LV mechanical function in the obese condition. While obesity had no impact on 
myocardial mitochondrial function and post-ischaemic outcomes during comparable 
perfusion conditions, the specific metabolic environment associated with obesity may 
augment post-ischaemic injury. K-111 is effective in reducing obesity related metabolic 
abnormalities, but has no effects on myocardial function, mitochondrial function or 
ischaemic tolerance.  
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OPSOMMING 
 
Agtergrond: Miokardiale oksidatiewe substraat voorsiening is verhoog in vetsug. Hoe 
hierdie metaboliese omgewing en veranderde miokardiale metaboliese fenotipe in pre-
diabetiese vetsug miokardiale funksie en iskemie/herperfusie skade beïnvloed, is 
onseker. Alhoewel vetsugtige individue met PPARα agoniste behandel kan word, is die 
resultate verkry van hierdie reseptor aktivering op miokardiale funksie en iskemiese 
skade teenstrydig.  
Doelwitte: Om te bepaal of 1) verlengde vetsug linker ventrikulêre (LV) funksie 
beïnvloed; 2) hierdie harte sensitief vir insulien stimulasie is; 3) insulien die hart teen 
iskemie/herperfusie beskadiging beskerm; en of 4) vetsug en chroniese K-111 
behandeling miokardiale funksie, substraat metabolisme, mitochondriale funksie en 
post-iskemiese herstel in vetsugtige, insulienweerstandige rotte beïnvloed. 
 
Metodes: Manlike Wistar rotte is met gewone rotkos, of ŉ hoé kalorie dieet gevoer. 1) In 
vivo LV funksie in 32 week gevoerde rotte is met behulp van eggokardiografie bepaal. 
Ex vivo LV funksie is met of sonder insulien en/of vetsure in die perfusaat bepaal; 2) Die 
ex vivo insuliensensitiwiteit is in 16 weke gevoerde rotte bepaal deur miokardiale 
glikolise te meet. Insulien is ook voor en tydens streeksiskemie toegedien, ten einde sy 
effek op miokardiale beskerming te bepaal; 3) K-111 is in die drink water van rotte 
toegedien vir die laaste 10 weke van hul dieet (voedingsperiode van 18 weke); a) 
Ventrikulêre mitochondriale funksie is polarografies bepaal in die aanwesigheid van 
glutamaat of palmitiel-L-karnitien; b) Miokardiale koolhidraat- en lipied metabolisme, en 
in ŉ aparte groep rotte, infarktgrootte, is bepaal in die teenwoordigheid van fisiologiese 
of hoë insulien- (30 of 50µIU/ml) en vetsuurvlakke (0.7 of 1.5mM).  
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Resultate: 1) Vetsugtige rotte het normale in vivo LV funksie gehandhaaf. Glukose 
geperfuseerde harte van vet rotte se LV funksie was laer as die van kontroles (Aorta 
omset: 32.58±1.2 vs. 46.17±0.91 ml/min; p<0.001), maar dit het verbeter in 
teenwoordigheid van vetsure; 2) Harte van vetsugtige rotte het verlaagde insulien-
gestimuleerde glikolise getoon (1.54±0.42 vs. 2.16±0.57 μmol/g ww/min, p<0.01). 
Alhoewel insulien infarktgrootte in die vetsugtige groep verlaag het (20.94±1.60 vs. 
41.67±2.09 %, p<0.001), is sy beskermende effekte in die teenwoordigheid van vetsure 
verlaag; 3) deur die in vivo metaboliese omgewing van kontrole en vetsugtige rotte in die 
perfusaat van die harte ex vivo te simuleer, is dit aangetoon dat die verhoogde vlakke 
van insulien en vetsure, geassosieer met vetsugtigheid, infarktgroottes in die vetsugtige 
groep teenoor die kontrole groep verhoog het (47.44±3.13 vs 37.17±2.63 %, p<0.05); 4) 
Hoewel chroniese gebruik van K-111 die metaboliese abnormaliteite gepaardgaande 
met vetsug normaliseer het, het beide vetsug en die middel geen invloed op miokardiale 
of mitochondriale funksie of vatbaarheid vir iskemiese beskadiging gehad nie. K-111 het 
miokardiale palmitaatoksidasie in die vetsugtige behandelde groep verlaag.  
 
Gevolgtrekking: Verhoogde bloed vetsuurvlakke in vetsug mag n belangrike rol in die 
handhawing van sistoliese funksie speel. Dit blyk dat die spesifieke in vivo omgewing 
geassosieer met vetsug wel tot verhoogte vatbaarheid vir iskemie/herperfusie skade 
mag lei. K-111 is effektief om die sistemiese metaboliese abnormaliteite gepaard met 
vetsugtigheid te verbeter, maar het geen effek op miokardiale funksie, mitochondriale 
funksie of vatbaarheid vir iskemie gehad nie. 
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CHAPTER 1: 
INTRODUCTION 
 
The prevalence of obesity is increasing world-wide. Not only are developed countries 
being affected, but also developing countries which are already burdened with 
various other disease epidemics (Pi-Sunyer, 2002; World Health Organization, 2002; 
Prentice, 2006). South Africa is not exempt from the obesity epidemic with 29.2% of 
men and 56.6 % of the women considered to be overweight or obese in 1998 
(Puoane et al. 2002). Global statistics from 2005, suggested that 396 million adults 
were estimated to be obese and an additional 937 million were thought to be 
overweight (Kelly et al. 2008). The predicted number of overweight and obese 
individuals is expected to escalate to 1.35 billion and 573 million people respectively 
by 2030 (Kelly et al. 2008). The reality of these statistics is that obesity will have an 
immense impact on global health-care systems considering the various non-
communicable diseases associated with the condition. In the United States of 
America, all-cause mortality resulting from obesity accounted for 280 184 deaths 
annually (Allison et al.1999) whereas 1 in 13 deaths in European countries have 
been attributed to obesity (Banegas et al. 2003) which is indicative of the detrimental 
nature of the epidemic. One of the major health concerns regarding obesity is its 
diverse and adverse effects on the cardiovascular system. 
 
Obesity often occurs concurrently with various co-morbidities (Stamler et al. 1978; 
Kannel et al. 1979; Van Itallie et al. 1985; Colditz et al. 1995; Abbasi et al. 2002), 
each of which is a risk factor for cardiovascular disease (Kannel and McGee, 1979; 
Barbir et al. 1988; O’Donnell et al. 1997; Abassi et al. 2002; Rewers et al. 2004). Due 
to the cluster of cardiovascular risk factors associated with obesity, a number of 
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factors may impact on the interaction between obesity and cardiac function and 
substrate metabolism (Lopaschuk et al. 2007). Consequently these factors may also 
influence other aspects of obesity related cardiovascular disease. Despite this, 
obesity has been shown to be a risk factor for the development of heart failure, 
independent of these traditional cardiovascular risk factors (Kenchaiah et al. 2002). 
 
The impact of protracted obesity on cardiac function is controversial. Although it is 
widely acknowledged that obesity is associated with left ventricular (LV) diastolic 
dysfunction, the influence of obesity on LV systolic function is less clear. While many 
authors report normal or augmented systolic function (Berkalp et al. 1995; Iacobellis 
et al. 2002, 2004; Pascual et al. 2003; Otto et al. 2004; Dorbala et al. 2006) in 
response to obesity, it has been postulated that over time, severe obesity may lead 
to LV systolic dysfunction, with the length of morbid obesity being a strong indicator 
for the development of congestive heart failure (Alpert et al. 1995; 1997). More 
concerning are the findings of sub-clinical systolic dysfunction in obese and 
overweight individuals (Ferraro et al. 1996; Peterson et al. 2004b; Wong et al. 2004; 
Di Bello et al. 2006; Tumuklu et al. 2007, Kosmala et al. 2008a). Data from animal  
studies are also unclear as to the impact of obesity on LV mechanical function (Du 
Toit et al. 2005; Carroll et al. 2006, Wilson et al. 2007; Ouwens et al. 2007; Wilson et 
al. 2007; Aasum et al. 2008; Yan et al. 2009). 
 
Both obesity and insulin resistance are risk factors for the development of type 2 
diabetes. Indeed it is evident that a specific diabetic cardiomyopathy may develop in 
the diabetic population. Nevertheless, many of the myocardial abnormalities 
associated with type 2 diabetes such as excess intramyocardial lipid accumulation, 
altered substrate metabolism, reduced cardiac efficiency and mitochondrial 
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dysfunction are already present in the obese pre-diabetic state (Szczepaniak et al. 
2003; Mazumder et al. 2004; Buchanan et al. 2005; Kankaanpää et al. 2006; Wilson 
et al. 2007; Aasum et al. 2008; Niemann et al. 2011). Since both obesity and type 2 
diabetes are risk factors for coronary artery disease and heart failure (Manson et al. 
1991; Eckel and Krauss, 1998; Aronow and Ahn, 1999; Kenchaiah et al, 2002; 
Boudina and Abel, 2007), it is important to understand to what degree these factors 
(intramyocardial lipid accumulation, altered substrate metabolism, reduced cardiac 
efficiency and mitochondrial dysfunction), when present, are detrimental to 
cardiovascular functioning in the obese state.  
 
Obesity is characterized by an overabundant supply of oxidative fuels and is often 
associated with abnormal myocardial substrate metabolism (Mazumder et al. 2004; 
Buchanan et al. 2005; Wilson et al. 2007; Aasum et al. 2008; Zhang et al. 2011) 
characteristic of an insulin resistant myocardium. Considering the various 
adaptations made by the myocardium in the obese state, hearts from obese 
individuals may indeed be more vulnerable to damage caused by ischaemic events. 
While it is clear that obesity (waist to hip ratio) is associated with a higher risk of 
developing myocardial infarction (Yusuf et al. 2005), the outcomes following 
myocardial infarction are more controversial. In vivo post-ischaemic outcomes in 
obese animals also provide no clear answer (Thim et al. 2006; Clark et al. 2010). An 
investigation promoting our understanding of the factors that could potentially 
contribute to adverse post-ischaemic outcomes in obesity in the absence of diabetes 
is warranted. 
 
Peroxisome proliferator activated receptor alpha (PPARα) agonists are a family of 
pharmacological agents that show impressive results in improving whole body insulin 
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sensitivity and lipid profiles (Guerre-Millo et al. 2000; Robins et al. 2001). Due to the 
localization of the PPARα subtype in hepatocytes, cardiomyocytes and skeletal 
myocytes, PPARα agonists in particular represent an exciting option for the treatment 
of the cardiometabolic syndrome associated with obesity. Although the lipid lowering 
and insulin sensitizing capabilities of PPARα agonists are well known, the impact of 
manipulating this particular receptor in the heart in the context of 
ischaemia/reperfusion injury is controversial (Yue et al. 2003; Sambandam et al. 
2006; Bulhak et al. 2009; Hafstad et al. 2009). Given that obese/diabetic patients are 
the most likely candidates to receive such interventions, notwithstanding their already 
high risk for acute myocardial infarction (AMI), it is imperative that more 
investigations are performed to determine the impact of chronic PPARα agonist 
treatment on the myocardial susceptibility to ischaemia/reperfusion injury, especially 
when new promising PPARα agonists emerge. Furthermore, as PPARα is a 
transcription factor involved in the up-regulation of many proteins involved in fatty 
acid metabolism (oxidation), the investigation of the impact of chronic PPARα 
agonism on the integrity of mitochondrial respiration is warranted. 
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CHAPTER 2 
LITERATURE REVIEW 
 
Obesity results from a constant imbalance between caloric intake (oxidative fuel 
supply) and utilization, genetic factors and reduced physical activity. Body mass 
index (BMI) represents a universal means of quantifying general adiposity. Normal 
body weight, pre-obesity/overweight and obesity are assigned BMI values of 18.5 - ≤ 
24.9, 25.0 – 29.9 and ≥ 30 respectively (NHLBI Panel on the Identification, Evaluation 
and Treatment of Overweight and Obesity in Adults, 1998). However other measures 
such as waist circumference and waist to hip ratio’s may also be used. The impact of 
obesity on the risk of developing cardiovascular disease is of great concern. BMI has 
been found to correlate positively with various risk factors (inverse correlation with 
HDL-C) implicated in the development of coronary heart disease (Lamon-Fava et al. 
1996) and is itself a risk factor for coronary heart disease development (Manson et 
al. 1990; Eckel and Krauss, 1998). Obesity has further been shown to be an 
independent risk factor for congestive heart failure (Kenchaiah et al. 2002), and a 
strong predictor of increased left ventricular wall thickness (Peterson et al. 2004b), an 
indicator of cardiac hypertrophy. Of greater concern is that being overweight also 
confers risk for cardiovascular disease (Wilson et al. 2002). 
 
Obesity seldom exits in isolation and is usually associated with various systemic and 
metabolic abnormalities. Obesity and particularly visceral obesity is associated with 
various co-morbidities including dyslipidaemia, insulin resistance, hyperinsulinaemia, 
diabetes and hypertension (Stamler et al. 1978; Kannel et al. 1979; Van Itallie et al. 
1985; Colditz et al. 1995; Abbasi et al. 2002), all of which are considered strong risk 
factors for cardiovascular disease (Kannel and McGee, 1979; Barbir et al. 1988; 
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O’Donnell et al. 1997; Abassi et al. 2002; Rewers et al. 2004). In addition, the co-
occurrence of these disorders within an individual constitutes the metabolic 
syndrome, a condition originally described by Reaven et al. (1988). Obesity together 
with changes in adipose tissue secretory function, insulin resistance and various 
other independent factors are thought to contribute greatly to the development of the 
metabolic syndrome (Grundy et al. 2004). Recently a collective definition of the 
metabolic syndrome was compiled to aid in the diagnosis thereof. To be diagnosed 
with the metabolic syndrome any 3 of the following conditions must be present: 
raised waist circumference (cut-off is population specific), elevated triglycerides 
(Trig’s) levels (≥ 150 mg/dl), reduced HDL-C levels (< 40.0 mg/dL in males; < 50 
mg/dL in females), raised fasting glucose levels (≥ 100 mg/dL) and elevated blood 
pressure (systolic ≥ 130 and/or diastolic ≥ 85 mmHg) (Alberti et al. 2009). The 
metabolic syndrome is associated with an increased risk of cardiovascular events, 
developing coronary heart disease and cardiovascular related and overall mortality 
(Lakka et al. 2002; Malik et al. 2004; Butler et al. 2006). Furthermore, the risk of 
developing cardiovascular disease may increase as the number of individual 
components of metabolic syndrome present within an individual increases (Klein et 
al. 2002). Due to the plethora of co-morbidities associated with obesity, it is evident 
and should be emphasized that it is exceptionally difficult to ascertain the direct 
effects of isolated obesity on cardiac function, structure and ischaemic complications 
since these endpoints may be influenced by the various co-morbidities present in 
metabolic syndrome patients. Data available on the cardiac effects of obesity should 
thus be carefully assessed in order to determine which co-morbidities are present. 
When comparing data generated from animal models of obesity, additional caution in 
the interpretation of data is required depending on whether genetic or diet induced 
models of obesity have been used.  
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2.1 Comparing the cardiovascular disease risk indexed by BMI or body fat 
distribution 
 
Accumulating evidence suggests that the localization of excess adipose tissue in the 
viscera, at times occurring in the absence of general obesity, plays an important role 
in various metabolic complications associated with obesity. Although obesity is a risk 
factor for coronary heart disease (Manson et al. 1990; Eckel and Krauss, 1998), it 
has been shown that visceral/central obesity (sub-scapular skin-fold thickness) is a 
strong predictor of coronary heart disease independent of BMI (Donahue et al. 1987). 
Convincing evidence supporting the premise of the importance of body fat distribution 
in the development of coronary artery disease has been demonstrated in non-obese 
subjects (Nakamura et al. 1994; Kobayashi et al. 2001). Here it is thought that the 
presence of visceral fat may lead to coronary artery disease through the 
development of insulin resistance and altered lipid/lipoprotein profiles (Kobayashi et 
al. 2001). It may be that the metabolic profile of non-obese individuals that are 
viscerally obese may be similar to those with general obesity displaying signs of 
metabolic syndrome. Consequently, even in the absence of general obesity (as 
assessed from BMI), the presence of visceral obesity alone may be key to the 
development of insulin resistance, type-2 diabetes, metabolic syndrome and 
cardiovascular disease. 
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2.2 The impact of obesity on cardiac remodelling 
 
Besides its associated vascular complications, obesity is associated with cardiac 
remodelling. Early studies characterizing cardiac remodelling in normotensive obesity 
indicated that obesity is generally associated with eccentric cardiac remodelling 
coupled with altered functional (increased cardiac output, stroke volume) and 
haemodynamic (increased central blood volume, plasma and total blood volume and 
reduced total peripheral resistance) parameters (Messerli et al. 1983a; Messerli et al. 
1983b). Although a positive association between body mass, LV mass and LV wall 
thickness has been clearly demonstrated (Lauer et al. 1991; Crisostomo et al. 2001; 
Powell et al. 2006), data from various groups have argued that increased LV mass in 
the obese population is mediated by the degree of insulin resistance and/or 
hyperinsulinaemia (Sasson et al. 1993; Iacobellis et al. 2003), possibly independent 
of obesity and blood pressure (Sasson et al. 1993). This may be related to insulin’s 
growth promoting effects (Samuelsson et al. 2006). Regardless of the aetiology of 
obesity related cardiac remodelling, augmented LV mass has been shown to be 
associated with a higher incidence of clinical cardiovascular events (Levy et al. 
1990). 
 
2.2.1 Mechanism of obesity induced cardiac remodelling 
Obesity or excessive weight gain in humans is associated with an increase in both 
lean body mass and fat mass (Forbes and Welle, 1983), which implies that additional 
vascularization of this tissue would be required. BMI further correlates positively with 
whole body oxygen consumption (Bray et al. 1970) probably due to the increased 
metabolic demands, especially tissue oxygen requirements, associated with obesity. 
To meet the increased demand for oxygen, cardiac output is increased, which is 
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thought to primarily be due to augmented stroke volume resulting from an obesity 
associated elevation in blood volume, as studies show that heart rate in obese 
individuals remains normal compared to lean individuals (Messerli et al. 1982). The 
increase in stroke volume may be explained by the increased blood volume (preload) 
associated with obesity as LV filling pressure and end diastolic volume subsequently 
increase, which in turn leads to a direct increase in stroke volume and consequently 
cardiac output. Over an extended time, the volume overload associated with obesity 
together with the increased cardiac output induces adaptational structural 
remodelling, which is evident by an increase in LV mass. Increased LV filling 
additionally induces alterations in LV cavity dimensions (eccentric left ventricular 
remodelling). Ultimately adaptive left ventricular hypertrophy and dilatation occur 
(Lauer et al. 1991; Paulson and Tahiliani, 1992; Kopelman et al. 2000). 
 
Besides the preload-induced changes in cardiac structure associated with obesity, 
the co-occurrence of systemic hypertension (elevated afterload) may further impact 
on cardiac structure. Indeed the combination of the two conditions (increased preload 
and afterload) has a more pronounced effect on left ventricular remodelling and 
structure and has been proposed to enhance the long-term risk of congestive heart 
failure (Messerli et al. 1983a; Schmieder and Messerli, 1993).  
 
Although for many decades the impact of obesity on LV structural remodelling has 
been well documented, the last few years have highlighted the importance of an 
altered obesity related cardio-metabolic phenotype in relation to parameters of 
cardiovascular functioning. Many of these myocardial metabolic alterations are 
similar in nature to those evident in type 2 diabetes. They include excessive 
intramyocardial lipid accumulation, altered myocardial substrate metabolism, reduced 
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cardiac efficiency and myocardial mitochondrial dysfunction (Szczepaniak et al. 
2003; Mazumder et al. 2004; Buchanan  et al. 2005; Kankaanpää et al. 2006; Wilson 
et al. 2007; Aasum et al. 2008; Niemann et al. 2011). These abnormalities may 
predispose the heart to future contractile complications especially when combined 
with the additive pre-existing co-morbidities associated with obesity. Furthermore, 
while contractile dysfunction may take decades to manifest, it is feasible that the 
altered cardiometabolic phenotype associated with obesity could itself leave the heart 
vulnerable to worse post-ischaemic outcomes.  In order to better understand the 
altered metabolic phenotype associated with obesity, a brief overview of myocardial 
substrate metabolism in the healthy heart is warranted.  
 
2.3 Metabolism 
 
2.3.1 Substrate metabolism in the healthy heart 
The heart is a dynamic organ, constantly requiring energy in the form of adenosine 
triphosphate (ATP) to meet its various metabolic and contractile demands. This is 
achieved through a constant supply of oxidizable substrates via the circulation. The 
most important substrates utilized by the heart include fatty acids (FA’s), glucose and 
lactate. Although the adult heart is capable of oxidizing a variety of substrates, the 
majority of ATP (60-70%) generated by the heart originates from the oxidation of 
FA’s (Zierler, 1976; Opie, 1998). However, in the presence of elevated glucose and 
insulin levels as occurs following a meal, 60-70% of ATP may be derived from 
glucose metabolism (Bertrand et al. 2008). 
 
Circulating FA’s are taken up by the heart either in the free form (free fatty acids 
(FFAs’)) which are usually bound to albumin, or alternatively they can be released 
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from the Trig component of chylomicrons or very-low-density-lipoproteins (Van der 
Vusse et al. 2000). The concentration of FA’s present in the blood greatly dictates 
their uptake and metabolism by the heart (Scott et al. 1962). Under normal 
physiological conditions, long chain FA’s (LCFA’s) are the principal FA oxidized by 
the heart (Coort et al. 2007). The entry of LCFA’s across the sarcolemma into the 
cytoplasm of the cardiomyocyte occurs through passive diffusion or membrane 
protein mediated transport, the latter accounting for the majority of FA translocation 
into the cytosol (Figure 2.1) (Luiken et al, 1997). This membrane protein mediated 
transport is facilitated by fatty acid translocase (FAT)/CD36, plasma membrane fatty 
acid binding protein (FBPpm) or fatty acid transport protein (Luiken et al, 1997). Once 
inside the cell, it is thought that non-esterified LCFA’s are transported via cytoplasmic 
heart-type fatty acid binding proteins through the cytoplasm to the location where 
they will be utilized (Fournier et al. 1978; Vork et al. 1993; Schaap et al. 1999). 
Hereafter LCFA are activated or esterified by acyl-CoA synthetase forming long chain 
fatty acyl-CoA’s (LCFA-CoA) (Luiken et al. 2004). At this point, LCFA-CoA’s can 
either be stored in intracellular lipid pools where they can be converted to additional 
lipid intermediates, or are transported to mitochondria where they undergo β-
oxidation.  
 
The transport of LCFA-CoA’s across the mitochondrial membrane is facilitated by 
three enzymes (carnitine palmitoyltransferase 1 (CPT-1), carnitine:acylcarnitine 
translocase (CAT) and carnitine palmitoyltransferase 2 (CPT-2)) of which carnitine 
forms a major component (reviewed by McGarry and Brown, 1997). CPT-1, located 
on the surface of the outer mitochondrial membrane, converts the fatty acyl-CoA to 
fatty acylcarnitine. This conversion is vital in allowing the fatty acyl-CoA to transverse 
the space between the outer and inner mitochondrial membranes. CAT translocates 
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the fatty acylcarnitine across the inner mitochondrial membrane space and once 
inside the mitochondrial matrix, the fatty acylcarnitine is converted back to a fatty 
acyl-CoA by CPT-2. The LCFA-CoA’s are then able to undergo β-oxidation, a 
process whereby two carbons are subsequently cleaved from the LCFA-CoA carbon 
chain producing acetyl-CoA, nicotinamide adenine dinucleotide (NADH2) and flavin 
adenine dinucleotide (FADH) (as summarized by Stanley et al. 2005). 
 
Due to CPT-1’s role in fatty acyl-CoA transport into the mitochondria, it follows that 
this enzyme may have a vital role in regulating the rate of FA β-oxidation. Indeed 
CPT-1 activity/expression is highly regulated at various levels. CPT-1 activity can be 
allosterically inhibited by malonyl-CoA, the activity of which is also tightly regulated. 
The cellular concentration of malonyl-CoA is related to its synthesis via acetyl-CoA 
carboxylase and its degradation by malonyl-CoA decarboxylase. Increased or 
reduced cardiac levels of malonyl-CoA correspond with reduced or increased levels 
of FA β-oxidation respectively (Paulson et al. 1984; Awan and Saggerson, 1993; 
Saddik et al. 1993; Kudo et al. 1995; Dyck et al. 1998; Onay-Besikci et al. 2006). 
Furthermore, enhanced glucose oxidation is also thought to suppress LCFA oxidation 
through the inhibition of CPT-1, resulting from an elevation in malonyl-CoA levels 
(Saddick et al. 1993). An additional regulator of CPT-1 activity is adenosine 
monophosphate (AMP)-activated protein kinase (AMPK) which inhibits acetyl-CoA 
carboxylase (Kudo et al. 1996). This mode of regulation is however more evident 
during stress related conditions where cytosolic AMP levels rise. Finally, LCFA 
themselves can indirectly influence the expression of CPT-1. LCFA are ligands for 
peroxisome proliferator activated receptor α (PPARα). PPARα, an orphan nuclear 
receptor transcription factor, is able to up-regulate genes transcribing proteins 
involved in FA metabolism such as CPT-1 (Mascaró et al. 1998). Murine models of 
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cardiac specific over-expressed PPARα are further characterized by elevated 
myocardial CPT-1 expression and increased myocardial FA β-oxidation rates (Finck 
et al. 2002).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: The pathways involved in LCFA uptake, storage and metabolism within 
the cardiomyocyte. ATP – Adenosine triphosphate; CPT – carnitine 
palmitoyltransferase; DAG – diacylglycerol; ER – endoplasmic reticulum; ETC – 
electron transport chain; FA – fatty acid; FA-CoA – fatty acyl-CoA; FACS – fatty acyl-
CoA synthase; FATP – fatty acid transport protein; MG – monoacylglycerol; Trig – 
triacylglycerol. Modified from Brindley et al. 2010. 
 
Another important substrate readily utilized by the heart as an oxidative fuel is 
glucose, which may enter the cardiomyocyte through either the basal uptake glucose 
transporter, GLUT 1, or via the insulin dependent glucose transporter, GLUT 4 
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(Figure 2.2) (Kraegen et al. 1993). GLUT 4 is stored within cytoplasmic vesicles 
within the cardiomyocyte. These vesicles are recruited to the sarcolemma either upon 
insulin stimulation or cardiac contraction. Glucose itself can induce GLUT 4 
translocation. Subsequently these events greatly determine the glucose flux into the 
cardiomyocyte (Zaninetti et al. 1988). Inside the cell the enzyme hexokinase, 
converts glucose to glucose-6-phosphate. Cytoplasmic glucose 6-phosphate can 
either be stored in the form of glycogen (conversion via glycogen synthase) or 
undergo glycolysis (an oxygen independent process) which eventually yields 
pyruvate and ATP. Another important enzyme of the glycolytic pathway involved in 
the eventual formation of pyruvate is phosphofructokinase 1 (PFK-1) which is 
responsible for the conversion of fructose-6-phosphate to fructose-1,6- bisphosphate. 
Although it will not be discussed in this review it is worth mentioning that glucose-6-
phosphate may also be processed via the pentose phosphate and the hexosamine 
biosynthetic pathway. Excess glucose flux through these pathways is associated with 
insulin resistance and the production of toxic intermediates (Gupte et al. 2006; Fülöp 
et al. 2007). 
 
During surplus oxygen supply, pyruvate is transported into mitochondria via a 
mitochondrial monocarboxylate transporter (Halestrap and Price, 1999) and 
subsequently oxidized by pyruvate dehydrogenase (PDH) producing acetyl-CoA 
(reviewed by Stanley et al. 1997). During anaerobic conditions such as during 
myocardial ischaemia, pyruvate may however be converted to lactate. 
 
It is important to mention that elevated FA β-oxidation rates can reciprocally inhibit 
glucose oxidation. The activity of hexokinase, PFK and PDH are all inhibited by 
various metabolic products produced during FA metabolism (discussed by Hue and 
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Taegtmeyer, 2009). Thus there is a delicate interplay between the different 
myocardial substrates utilized, which in turn is dependent on their relative circulating 
levels.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 2.2: The pathways involved in glucose uptake and metabolism. ATP – 
Adinosine triphosphate; ETC – electron transport chain; GLUT – glucose transporter; 
G-6-P – glucose-6-phosphate; GS – glycogen synthase; HK – hexokinase; LDH – 
Lactate dehydrogenase;  PFK – phosphofructokinase; PDH – pyruvate 
dehydrogenase complex; TCA – tricarboxylic acid cycle. See the text for 
mechanisms.  
 
The common endpoint of glucose and FA oxidation is the production of acetyl-CoA. 
Acetyl-CoA derived from both fuel sources (glucose and FA) enters the tricarboxylic 
acid/Krebs/citrate cycle producing the reducing equivalents NADH and FADH2. 
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Additional NADH and FADH2 are generated during the breakdown of FA and glucose 
(FA β-oxidation, glycolysis and the PDH reaction). These reducing equivalents play a 
central role in driving mitochondrial oxidative phosphorylation. Oxidative 
phosphorylation occurs in the electron transport chain, located in the inner 
mitochondrial membrane. In this process, NADH and FADH2 are oxidized, yielding 
NAD+, FAD, protons and electrons (Opie, 2004; Kim et al. 2008). 
 
The electron transport chain consists of a series of complexes through which the 
electrons are transferred. The electrons ultimately bind to O2 forming H2O while the 
protons are pumped into the inter-mitochondrial membrane space by complexes I, III, 
IV of the electron transport chain. ATP production is greatly dependent on the fate of 
the protons as the formation of a proton gradient across the inner mitochondrial 
membrane essentially drives the F1F0 ATPase which itself enables the 
phosphorylation of ADP into ATP. Upon its production, ATP is subsequently 
transported to the cytosol where it is utilized for various energy dependent cellular 
functions. Lastly, the effectiveness of the proton gradient in the intermitochondrial 
membrane space is greatly determined by the amount of uncoupling proteins present 
in the membrane. Reducing the proton gradient via “proton leakage” through these 
uncoupling proteins would lead to the generation of heat instead of ATP, resulting in 
uncoupling of the respiratory chain (Opie, 2004; Kim et al. 2008). This essentially 
results in oxygen wastage which could compromise the cells’ integrity during 
ischaemia where oxygen wastage should be avoided. 
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2.3.2 Insulin signaling in the regulation of myocardial substrate metabolism 
The hormone insulin is an important regulator of myocardial substrate metabolism. 
Activation of the insulin receptor (IR) by insulin binding invokes a cascade of events 
which ultimately elicits enhanced glucose uptake and metabolism by the insulin 
sensitive tissue (Figure 2.3). Binding of insulin to its receptor results in 
autophosphorylation and activation of the IR’s intrinsic tyrosine kinases which upon 
phosphorylation, further phosphorylates proteins such as the insulin receptor 
substrate (IRS) proteins. Phosphorylated IRS1 subsequently associates with 
phosphoinositide 3-kinase (PI3K) via its p85 subunit (Myers et al. 1992; Yonezawa et 
al. 1992), an event vital for initiating insulin’s effects on glucose metabolism 
(reviewed by White and Kahn et al. 1994; Shepherd et al. 1998; Chang et al. 2004). 
Activated PI3K consequently induces (via various signaling mechanisms) insulin’s 
major effector molecule, protein kinase B (PKB/AKT) (Alessi et al. 1996). PKB/AKT is 
a major signaling molecule which plays a pivotal role in glucose metabolism, 
regulating the translocation of the cytosolic glucose transporter, GLUT 4, to the 
sarcolemma (Alessi and Cohen, 1998; Foran et al. 1999). Due to the vital role played 
by PI3K and PKB/AKT in glucose metabolism, inhibiting the activity of these proteins 
greatly attenuates sarcolemmal translocation of GLUT 4, effectively reducing insulin 
stimulated glucose uptake (Clarke et al. 1994; Summers et al. 1998).  
 
PI3K contains a catalytic (p110) and regulatory subunit (p85 (α and β isoforms)). The 
p85 subunit is important in insulin signaling as it enables the interaction of the PI3K 
catalytic subunit with IRS-1 (Yonezawa et al. 1992). Although PI3K activity is 
normally assessed as an indicator of the extent of insulin stimulation, phosphorylation 
of the p85 subunit (Tyr458) has been shown to increase with insulin stimulation, while 
in the presence of oleic acid and insulin, its phosphorylation is attenuated (Kim et al. 
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2009). Significantly, PI3K p85 (Tyr458/199)/p55 phosphorylation increases with 
cardiomyocyte glucose uptake upon insulin stimulation (Florian et al. 2010).  
 
Besides facilitating glucose uptake via GLUT 4, insulin stimulation greatly increases 
glycolytic flux. This is achieved through activation of PFK-2 which in turn enhances 
the production of fructose-2,6-bisphosphate from fructose-6-phosphate (Rider and 
Hue, 1984; Hue and Rider, 1987; Hue et al. 2002). Fructose-2,6-bisphosphate 
stimulates PFK-1 activity, which will aid in enhancing glycolysis (summarized by Hue 
et al. 2002). 
 
Elevated insulin levels further suppress tissue FA β-oxidation rates (Figure 1). This is 
most likely due to the impact of by-products of elevated glucose oxidation on 
malonyl-CoA levels (Saddik et al. 1993). In slight contrast, insulin facilitates the 
transport of LCFA into the cardiomyocyte by increasing the sarcolemmal distribution 
of FAT/CD36 (Luiken et al. 2002). Regardless of this, the augmented LCFA uptake 
resulting from insulin stimulation does not translate into enhanced FA β-oxidation, but 
rather increased esterification (Luiken et al. 2002). Insulin thus has a significant 
impact on both glucose and lipid metabolism. 
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Figure 2.3: The mechanism of insulin stimulated glucose uptake. GLUT – glucose 
transporter; IR – insulin receptor; IRS – insulin receptor substrate; P – 
phosphorylated substrate. Adapted from Bertrand et al. (2008) and Feuvray, (2004). 
 
2.3.3 The impact of obesity on myocardial insulin sensitivity and myocardial 
substrate metabolism 
Insulin resistance ensues when normal physiological concentrations of insulin are no 
longer able to induce effective uptake of glucose by insulin sensitive tissue. 
Myocardial insulin resistance is demonstrated by reduced glucose oxidation rates 
and compromised intracellular insulin signaling pathways in experimental animal 
models of obesity (Zhang et al. 2010). As a compensatory mechanism aiming to 
maintain euglycaemia, pancreatic insulin secretion increases leading to a state of 
hyperinsulinaemia. The degree of glucose intolerance in insulin resistant individuals 
is thus dependent on the extent of the loss of the in vivo function of insulin, and the 
ability of the pancreas to adjust for this by secreting more insulin (Reaven, 1988; 
Reaven, 1995). Once elevated circulating levels of insulin are no longer able to 
maintain euglycaemia, a diabetic state ensues.  
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In most instances, obesity occurs concurrently with some degree of systemic insulin 
resistance. Many cardiovascular risk factors are speculated to be derived from the 
combination of obesity and insulin resistance (Leichman et al. 2006). Both insulin 
resistance and the probable ensuing type II diabetes are suggested to be prevented 
by lifestyle modification in the form of increased physical activity and dietary 
intervention (Seidell, 2000).  
 
Obesity is mostly associated with an insulin resistant myocardium similar to that seen 
in the diabetic heart. Myocardial FA oxidation rates are normal or elevated, while 
more importantly, glucose oxidation rates are reduced with or without insulin 
stimulation (ex vivo experiments) (Mazumder et al. 2004; Buchanan et al. 2005; 
Wilson et al. 2007; Aasum et al. 2008; Zhang et al. 2010). Even in certain instances 
of obesity and insulin resistance where myocardial FA and glucose oxidation rates 
are similar to those reported in lean control animals, insulin stimulated myocardial 
glycolytic flux rates remain suppressed (Lopaschuk and Russell, 1991; Atkinson et al. 
2003). In humans similar pronounced features of obesity related myocardial insulin 
resistance are not as common. Nevertheless, while myocardial glucose uptake and 
utilization and FA uptake, utilization and oxidation rates are not significantly different 
between obese and non-obese subjects, it has been shown that the degree of 
systemic insulin resistance in women relates to the degree of myocardial FA uptake, 
utilization and oxidation (Peterson et al. 2004a). It also seems that the myocardial 
metabolic response to obesity differs between men and women as it was shown that 
the female gender independently predicted lower myocardial glucose uptake, 
utilization and utilization/plasma insulin (Peterson et al. 2008).  
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Interestingly, two studies have reported data on diabetic patients with or without 
ischaemic heart disease displaying systemic insulin resistance while presenting 
similar rates of myocardial glucose uptake compared to control subjects in response 
to insulin infusion (Utriainen et al. 1998; Jagasia et al. 2001). Thus, although it is 
generally believed that obesity and diabetes are associated with altered myocardial 
FA metabolism in conjunction with reduced glucose metabolism, the previously 
mentioned studies allude to the possibility that systemic insulin resistance does not 
always lead to myocardial insulin resistance in humans. Unfortunately myocardial 
glucose oxidation rates were not determined in the two previously mentioned studies.  
 
The mechanisms whereby obesity contributes to reduced muscle insulin sensitivity 
have been extensively investigated. In particular, the downstream impact of altered 
adipocyte function characteristic of the obese state is implicated in the development 
of insulin resistance. These alterations include 1) increased release of FFA (Randle 
et al. 1963; Roden et al. 1996), 2) reduced secretion of the insulin sensitizing 
adipokine, adiponectin, coupled with lower adiponectin receptor densities (Kadowaki 
et al. 2006) and, 3) increased secretion of pro-inflammatory cytokines such as TNFα 
from macrophages (Rydén and Arner, 2007). Lastly, as the use of antioxidants 
abolishes the ensuing insulin resistance in animal models of obesity, oxidative stress 
may also contribute to the development of insulin resistance (Nduhirabandi et al. 
2011). In this review, only the role of FFA’s in the development of muscle insulin 
resistance will be covered. 
 
Probably the most influential determinant of systemic insulin sensitivity is increased 
levels of circulating FFA (Kahn et al. 2006). As over-nutrition is the primary cause of 
obesity, it is not surprising that the abundant availability of circulating oxidative fuels 
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is implicated in the development of systemic insulin resistance. The concentration of 
circulating FFA is largely governed by the rate of lipolysis. In obesity, the rate of 
lipolysis in response to β-adrenergic stimulation may be elevated in certain fat depots 
(Lönnqvist et al. 1995). Due to the oversupply of FFA, obesity and particularly 
diabetes are further characterized by the storage of excess lipids in non-adipose 
tissue such as skeletal muscle (Manco et al. 2000) and in certain instances, cardiac 
muscle (Szczepaniak et al. 2003; Kankaanpää et al. 2006; McGavock et al. 2007; 
Rijzewijk et al. 2008). Besides its association with myocardial insulin resistance, 
excess intramyocardial lipid accumulation is further implicated in cardiac dysfunction 
(see section 2.4.3).  
 
The notion that elevated levels of circulating FFA play an important contributory role 
in the development of cellular insulin resistance has been repetitively demonstrated. 
As most of the mechanistic experiments focusing on the development of insulin 
resistance have been performed in skeletal muscle, the interaction between 
circulating FFA, intracellular lipid accumulation and insulin resistance in both skeletal 
and cardiac muscle will be discussed.  
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2.3.4 The interaction between circulating free fatty acids, intracellular lipid 
accumulation and insulin resistance  
 2.3.4.1 Skeletal muscle 
An inverse correlation exists between intramuscular lipid content and insulin 
sensitivity. Measurements of insulin sensitivity (120 min euglycaemic 
hyperinsulinaemic clamp) in skeletal muscle from healthy humans demonstrated that 
subjects with higher levels of intramuscular lipid content had lower whole body insulin 
stimulated glucose uptake. These individuals also had higher circulating FFA’s during 
hyperinsulinaemia, reduced tyrosine phosphorylation of the IR and lower IRS-1 
mediated PI3K activation than subjects with low intramuscular lipid content 
(Virkamäki et al. 2001). Comparisons between lean and obese individuals have 
made similar observations (Manco et al. 2000; Sinha et al. 2002). Boden et al. (2001) 
identified strong associations between serum FFA levels, intramuscular lipid content 
and insulin resistance. Elevated circulating FFA levels, achieved by lipid injection, 
were shown to be associated with a gradual increase in intramuscular lipid content, 
an observation which correlated with a 40% increase in insulin resistance. These 
findings are supported by Kelley et al. (1993) who similarly observed reduced 
skeletal muscle glucose uptake in response to elevated levels of FFA in humans. 
 
 2.3.4.2 Cardiac muscle 
Similar associations between excess intramyocellular lipid accumulation and reduced 
insulin sensitivity as noted in skeletal muscle, have been observed in cardiac tissue 
from obese insulin resistant animals (Young et al. 2002; Atkinson et al. 2003; Yan et 
al. 2009). Indeed, in obese insulin resistant JCR:LA-cp rats, the increased supply of 
circulating FFA was associated with a 50% increase in myocardial Trig content, 
which corresponded with a 50% reduction in myocardial glycolytic flux rates (Atkinson 
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et al. 2003). Significantly in humans, plasma FFA levels correlate with 
intramyocardial Trig levels (Kankaanpää et al. 2006), which are also evident in obese 
(Szczepaniak et al. 2003; Kankaanpää et al. 2006), obese glucose intolerant 
(McGavock et al. 2007) and diabetic (McGavock et al. 2007; Rijzewijk et al. 2008) 
individuals. Excessive intramyocardial Trig accumulation thus precedes the 
development of type II diabetes. Furthermore intramyocardial Trig levels tend to 
increase linearly with the degree of systemic insulin resistance (McGavock et al. 
2007). Unfortunately no human data exist that quantify and correlate intramyocardial 
Trig content and the degree of myocardial insulin resistance. It should be 
emphasized that although in many cases intracellular Trig accumulation is associated 
with skeletal and cardiac muscle insulin resistance, the accumulation of more specific 
lipid intermediates such as ceramide and diacylglycerol may play a more causal role 
in the development of tissue specific insulin resistance (Turinsky et al. 1990; Ussher 
et al. 2010; Zhang et al. 2010), since not all cases of myocardial insulin resistance 
are associated with elevated intramyocardial Trig levels (Aasum et al. 2008).  
 
Excess intracellular lipids accumulating within the myocardium are believed to stem 
from either 1) increased FA supply to the heart which is in excess of its oxidative 
capacity, or 2) suppressed myocardial FA oxidation rates (Lopaschuk et al. 2010).  
 
While the majority of studies indicate that myocardial FA β-oxidation rates are 
elevated in obesity (Mazumder et al. 2004; Buchanan et al. 2005; Wilson et al. 2007; 
Aasum et al. 2008; Zhang et al. 2010), a limited number of studies suggest that 
reduced myocardial FA β-oxidation rates are responsible for intramyocardial lipid 
accumulation (Young et al. 2002). While non-fasted obese Zucker rats have 
comparable myocardial FA oxidation rates and intramyocardial lipid content 
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compared to lean control rats, an increased supply of FFA’s, induced by fasting, was 
shown to significantly increase myocardial FA oxidation rates and myocardial 
function and decrease intramyocardial lipid content in control animals. In strong 
contrast to this data, hearts from obese Zucker rats were unable to augment FA 
oxidation rates or myocardial function, while the intramyocardial lipid content rose 
significantly in response to the fasting induced increased myocardial FFA supply 
(Young et al. 2002). Lopaschuk et al. (2010) has cautioned the implications of these 
findings as the authors did not consider the contributory effect of the excess pool of 
intramyocardial lipids on the overall rate of myocardial FA oxidation. Nevertheless, 
while the hypothesis that reduced FA oxidation rates may contribute to intracellular 
lipid accumulation is an attractive one, the majority of the available data indicate that 
myocardial FA oxidation rates in obesity are seldom lower than in lean controls 
(Mazumder et al. 2004; Buchanan et al. 2005; Wilson et al. 2007; Aasum et al. 2008; 
Zhang et al. 2010).  
 
2.3.5 The cellular mechanisms of lipid induced insulin resistance 
As previously mentioned, an increase in the supply of one oxidative substrate (FA or 
glucose) will result in that particular substrate being favoured with regards to its 
utilization. Enhanced FA metabolism has been shown to inhibit glucose metabolism 
at multiple levels. Firstly, elevated levels of NADH/NAD+ and acetyl-CoA/CoA, 
produced during FA β-oxidation inhibits PDH activity possibly via PDH kinase 4 
(PDHK4) activation (an inhibitor of PDH) (Denton et al. 1975; Hansford and Cohen, 
1978; Holness and Sugden, 2003). Additionally, augmented FA β-oxidation causes a 
rise in citrate levels, an enzyme capable of directly inhibiting phosphofructokinase 
(Garland et al. 1963) which in turn inhibits hexokinase activity through the 
accumulation of glucose-6-phosphate (Regen et al. 1964). Secondly, FA’s may exert 
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direct inhibitory effects on components of the insulin signaling pathway. The 
presence of palmitate in the perfusate of glucose and insulin perfused hearts induced 
an inhibitory effect on PKB/AKT activity and phosphorylation which coincided with 
reduced myocardial glucose uptake, glycolysis and glucose oxidation rates (Soltys et 
al. 2002). In rat skeletal muscle cells, palmitate was shown to inhibit IR gene 
expression, possibly via protein kinase C (PKC) ε, thus disrupting the insulin 
signaling pathway (Dey et al. 2005). These inhibitory actions of FA’s become more 
relevant following chronic exposure to an elevated FFA supply and could contribute 
to decreased systemic and cellular insulin sensitivity.  
 
In conditions of over-nutrition, not all FA’s entering the cell are utilized for oxidative 
purposes. Non-oxidative pathways exist whereby the intracellular pool of long chain 
fatty acyl-CoA’s are increased. Consequently long chain acyl-CoA’s can enter lipid 
pathways for the formation of diacylglycerol, Trig and ceramide (Figure 2.1). 
Experimental evidence suggests that the intracellular formation and accumulation of 
diacylglycerol and ceramide in particular, adversely affect insulin signaling pathways 
and consequently carbohydrate metabolism (Figure 2.4) (Turinsky et al. 1990; 
Ussher et al. 2010; Zhang et al. 2010).  
 
In rat skeletal muscle, experimentally induced elevated circulating FFA were shown 
to increase intracellular acyl-CoA and diacylglycerol (a known activator of PKC) 
levels coupled with increased membrane bound and/or active protein kinase C (PKC) 
theta. These changes were accompanied by increased IRS-1 serine phosphorylation, 
reduced IRS-1 tyrosine phosphorylation and reduced IRS-1 associated PI3K activity 
(Griffin et al. 1999; Yu et al. 2002). Phosphorylation of IRS-1 at serine307 is sufficient 
to hinder IRS-1’s interaction with PI3K. Similarly, the development of myocardial 
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insulin resistance in obese rats coincided with elevated cardiac diacylglycerol levels 
and was accompanied by increased membrane translocation of PKCα, increased 
p70s6k activity and IRS-1 phosphorylation at Ser332/336 (Zhang et al. 2010). Both 
PKCα and p70s6k are capable of phosphorylating IRS-1 at serine/threonine residues 
thereby reducing IRS1 association with PI3K. It is subsequently speculated that 
myocardial diacylglycerol accumulation together with PKCα membrane translocation 
and phosphorylated p70s6k play a central role in specifically high fat diet (HFD) 
induced myocardial insulin resistance (Zhang et al. 2010).  Although various PKC 
isoforms are implicated in the aetiology of insulin resistance, these experimental 
observations are in agreement with the general view that PKC can exert inhibitory 
effects on IRS-1 activation (Hegarty et al. 2003). The net result is disrupted insulin 
signaling which prevents IRS-1’s association with insulin’s mediating molecule PI3K. 
Due to reduced IRS-1 associated PI3K activity following insulin stimulation, glucose 
transport into the cell may be reduced (Dresner et al. 1999).  
 
Another lipid intermediate implicated in the pathogenesis of insulin resistance is 
ceramide (Summers, 2006). Elevated cardiac and skeletal muscle ceramide levels 
have been observed in rodent models of obesity/diabetes and insulin resistance 
(Zhou et al. 2000; Ussher et al. 2010) and are thought to inhibit components of the 
insulin signaling cascade. While ceramide levels are increased in skeletal muscle of 
obese insulin resistant rats, it was further shown to be the only lipid intermediate to   
correlate significantly with glucose intolerance (Ussher et al. 2010). In the same 
study, myriocin was shown to abolish the development of insulin resistance which 
coincided with reduced skeletal muscle ceramide (but not diacylglycerol) content. 
The signaling pathway through which ceramide may induce insulin resistance is 
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poorly understood, but may involve the inhibition of PKB/AKT phosphorylation 
(Summers et al. 1998). 
 
The current data regarding the mechanism of lipid induced insulin resistance is in 
agreement with the hypothetical model previously proposed by Coort et al. (2007), in 
which an obesity/diabetes related permanent translocation of CD36 exists on the 
cardiomyocyte sarcolemma. This is associated with increased LCFA uptake with a 
subsequent rise in intracellular Trig’s. The intracellular pool of Trig intermediates 
such as acyl-CoA’s, ceramide and diacylglycerol are consequently increased which 
in turn impairs insulin signaling, possibly mediated via protein kinase C, resulting in 
decreased insulin-stimulated GLUT 4 translocation to the sarcolemma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: The proposed signaling involved in lipid induced insulin resistance. DAG 
– diacylglycerol; GLUT – glucose transporter; IR – insulin receptor; IRS – insulin 
receptor substrate; P – phosphorylated substrate. See text for references 
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2.4 Cardiac function 
 
2.4.1 Cardiac function in obese humans  
Many studies have demonstrated that obesity is associated with normal or increased 
LV mechanical function in the presence or absence of cardiac hypertrophy (Berkalp 
et al. 1995; Iacobellis et al. 2002, 2004; Pascual et al. 2003; Otto et al. 2004; Dorbala 
et al. 2006).  There is however a general consensus that protracted obesity is 
associated with some form of diastolic dysfunction (Berkalp et al. 1995; Iacobellis et 
al. 2002; Pascual et al. 2003; Otto et al. 2004). While obesity remains an 
independent predictor of heart failure (Kenchaiah et al. 2002), it is uncertain whether 
clinically significant LV mechanical dysfunction occurs as a result of protracted 
obesity.  
 
Alpert et al. (1995; 1997) has suggested that longstanding morbid obesity together 
with the associated LV hypertrophy could lead to cardiac dysfunction. A study 
conducted by the previously mentioned research group determined an association 
between the duration of morbid obesity, LV mass and reduced LV systolic and 
diastolic function. The authors further reported that weight reduction correlated with 
decreased LV mass and concomitant improvements in cardiac systolic and diastolic 
function (Alpert et al. 1995). In addition, morbid obese individuals with increased LV 
mass demonstrate reduced LV systolic function in response to exercise (Alpert et al. 
1989). In line with these findings, it is speculated that compensatory hypertrophy may 
over decades become maladaptive leaving a vulnerable ventricle that is simply 
unable to adapt to the volume overload, consequently leading to the manifestation of 
systolic dysfunction. Obesity associated with LV diastolic dysfunction, together with 
possible systolic dysfunction has been proposed to progress to heart failure 
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(Kopelman, 2000), a notion agreeing with the observation that obesity is an 
independent risk factor for heart failure (Kenchaiah et al. 2002).  
 
Although systolic dysfunction may be feasible in morbid obese individuals, the recent 
observation that general obesity may indeed be accompanied by sub-clinical systolic 
dysfunction is intriguing (Ferraro et al. 1996; Peterson et al. 2004b; Wong et al. 2004; 
Di Bello et al. 2006; Tumuklu et al. 2007, Kosmala et al. 2008a). Sub-clinical 
alterations in both LV structure and systolic function have even been reported in 
overweight individuals (Wong et al. 2004). Additionally, analysis of 295 apparently 
healthy overweight subjects revealed that BMI, fasting insulin and age were 
independent predictors of sub-clinical LV systolic dysfunction (strain, peak strain 
rate), while it was almost absent in the absence of hyperinsulinaemia (Kosmala et al. 
2008b). Wong and Marwick, (2007) have commented that preserved or augmented 
LV systolic function observed in obese individuals in many studies may be 
confounded by the insensitivity and load-dependency of the standard 
echocardiographical techniques used (fractional shortening and ejection fraction), 
while newer techniques investigating myocardial tissue velocity and strain index are 
sensitive enough to identify sub-clinical LV systolic alterations. Whether sub-clinical 
systolic dysfunction may progress to clinically relevant systolic dysfunction is 
uncertain.  
 
Due to the lack of longitudinal studies investigating obesity related cardiac 
dysfunction, it is not possible to establish whether obesity indisputably causes 
myocardial dysfunction (Abel et al. 2008). Indeed, the notion of the existence of an 
obesity cardiomyopathy has been questioned (Owan and Litwin, 2007). 
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2.4.2 Cardiac function in obese insulin resistant animals 
Valuable insights regarding the myocardial functional response to obesity have been 
gained from animal models of obesity, however as with the human data, it seems that 
animal models of obesity also yield inconclusive observations.  
 
Genetic animal models of pre-diabetic obesity display cardiac dysfunction (Young et 
al. 2002). Although genetic models of obesity do not accurately resemble the 
phenotype of human obesity, the recent development of a number of diet-induced 
models of obesity have contributed to a better understanding of the impact of obesity 
on myocardial function. Animal models of diet-induced obesity have reported normal 
(Carroll et al. 2006, Wilson et al. 2007; Yan et al. 2009) or reduced (Du Toit et al. 
2005; Ouwens et al. 2007; Wilson et al. 2007; Aasum et al. 2008) cardiac function. It 
is often difficult to identify the precise mechanism contributing to cardiac dysfunction 
as various animal models of obesity displaying both normal (Carroll et al. 2006) and 
abnormal (Yan et al. 2009) serum insulin and glucose levels have been associated 
with normal cardiac function. The possibility further exists that studies employing 
models of diet-induced obesity are too short in duration for cardiac dysfunction to 
develop. Wilson et al. (2007) only noted cardiac dysfunction in obese insulin resistant 
rodents following 32-48 weeks of Western diet feeding. Cardiac dysfunction may thus 
only be evident with protracted obesity during which the heart would be subjected to 
excess oxidative fuel supply and possibly extensive cardiac remodelling over a 
prolonged period of time. However adverse cardiac remodelling (indexed by 
increased ventricular weight) was absent in the study of Wilson et al. (2007).  
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2.4.3 Evidence supporting reduced cardiac function due to lipotoxicity  
The accumulation of excess myocardial metabolic byproducts derived from lipid 
metabolism and the hydrolysis of myocardial Trig’s are implicated in what has been 
termed cardiac lipotoxicity (Unger and Orci, 2002; McGavock et al. 2006). In 
particular the generation of ceramide is strongly implicated in cellular dysfunction and 
apoptotic cell death (lipo-apoptosis) (Zhou et al. 2000; Unger and Orci, 2002). 
Although excess intracellular ceramide accumulation may better explain lipotoxicity in 
a mechanistic manner, the majority of research has been aimed at determining the 
relationship between myocardial function and intramyocardial Trig content. This may 
not be the most appropriate approach as it has been proposed that the incorporation 
of excess FA into the pool of intracellular Trig’s prevents the formation of toxic lipid 
intermediates suggesting that these lipid stores may actually protect against 
lipotoxicity (Listenberger et al. 2003).  
 
In humans, associations exit between excess intramyocardial lipid accumulation and 
LV function. While reductions in intramyocardial lipid (Trig) content are associated 
with improved LV ejection fraction following exercise training in obese subjects 
(Schrauwen-Hinderling et al. 2010), an inverse relationship exists between septal 
lipid (Trig) content and LV systolic function (septal thickening) (Szczepaniak et al. 
2003). However, no correlation exists between septal Trig content and ejection 
fraction (Szczepaniak et al. 2003). Despite these associations in humans, causality 
between intramyocardial lipid accumulation and cardiac dysfunction remains to be 
shown.  
 
The use of animal models of obesity and/or diabetes allows for a more careful 
investigation into the relationship between intramyocardial lipid content and cardiac 
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dysfunction. The evidence available thus far suggests a close relationship between 
these two events. While increasing myocardial FA supply by lipid infusion is followed 
by myocardial lipid droplet accumulation and diminished in vivo cardiac function in 
rabbits (Hexeberg et al. 1995), the co-occurrence of excess intramyocardial lipid 
accumulation (intracellular phospholipid and Trig) and cardiac dysfunction is evident 
in certain obese insulin resistant animals (Ouwens et al. 2007). Further insight into 
this relationship is gained by studies using genetic manipulations aimed at enhancing 
myocardial FA metabolism. Mice over-expressing cardiac specific long chain acyl-
CoA synthase display high intramyocardial levels of Trig’s and ceramide, 
accompanied by increased DNA fragmentation and cytochrome c release, indicative 
of apoptosis. These mice develop early cardiac hypertrophy, followed by LV 
dysfunction and eventually die prematurely (Chiu et al. 2001). Furthermore, mice 
over-expressing cardiac specific human lipoprotein lipase, develop excess 
intramyocardial lipid accumulation which is associated with myocyte hypertrophy, 
dilated hearts and reduced LV systolic function (Yagyu et al. 2003).  In a separate 
study, fasting-induced elevations in circulating FFA levels were associated with 
increased myocardial FA β-oxidation rates, normal intramyocardial lipid content and 
augmented cardiac output in lean Zucker rat hearts. Obese Zucker rat hearts 
however failed to increase myocardial FA β-oxidation rates, displaying elevated 
intramyocardial lipid levels and were further unable to elevate their cardiac output 
relative to the values obtain by the lean animals, indicative of cardiac dysfunction 
(Young et al. 2002). The authors ascribe such cardiac dysfunction to the heart’s 
inability to increase FA β-oxidation in response to elevated FA availability. This 
finding coincided with a reduced expression of genes regulating myocardial FA 
metabolism with a concomitant rise in intracellular Trig content. Lastly, one of the 
most significant findings in this regard was the observation that by reducing cardiac 
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Trig and ceramide levels pharmacologically, myocardial lipoapoptosis was prevented 
while cardiac dysfunction was reduced in obese diabetic animals (Zhou et al. 2000). 
 
Despite these convincing reports, Wilson et al. (2008) reported ex vivo cardiac 
dysfunction in rodents following long term consumption of a western diet in the 
absence of elevated intramyocardial lipid (Trig) content. These results either argue 
against a causal role of intramyocardial lipid accumulation in the pathogenesis of 
cardiac dysfunction, or more specifically allude to the importance of determining the 
levels of lipid intermediates such as ceramide. Indeed, of the various lipid 
metabolites, ceramide may be the most detrimental in inducing myocardial lipo-
apoptosis (Zhou et al. 2000), while diacylglycerol accumulation may be more 
involved in the pathogenesis of myocardial insulin resistance (Zang et al. 2010). 
Alternatively other mechanisms may exist whereby excess calories may induce 
cardiac dysfunction. 
 
2.4.3.1 Possible mechanisms of lipid induced cardiotoxicity 
Models of cardiac lipotoxicity have demonstrated the co-occurrence of elevated 
myocardial ceramide levels together with increased indices of apoptosis (Zhou et al. 
2000; Chiu et al. 2001). Similarly neonatal cardiomyocytes incubated with 
physiological concentrations of palmitate have increased intracellular Trigs and 
ceramide levels coupled with increased levels of apoptosis (Hickson-Bick et al. 
2000). A mechanism implicated in ceramide-induced apoptosis has been proposed 
(Unger and Orci, 2002) and although the pathway is poorly delineated, it may involve 
activation of nuclear factor-kappa β (Machleidt et al. 1994), which in turn up-regulates 
the expression of the inducible isoform of nitric oxide synthase (iNOS). The resulting 
increase in nitric oxide production (Shimabukuro et al. 1997) may cause a 
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subsequent rise in the formation of peroxynitrite, which has been shown to induce 
mitochondrial cytochrome c release (Ghafourifar et al. 1999) and subsequent 
apoptosis (see Figure 2.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Proposed mechanism of ceramide induced apoptosis. Although this is the 
recognized pathway in pancreatic β cells, it could be similar in other tissues including 
the heart. iNOS – inducible form of nitric oxide synthase; NfkB - nuclear factor kappa 
B; NO – nitric oxide; PKB/AKT – protein kinase B. Modified from Unger, (2005). 
 
 
2.4.4 Other potential causes of cardiac dysfunction in obesity/diabetes not 
highlighted in detail 
Although we have discussed lipotoxicity as a means of inducing cardiac dysfunction 
in obesity, it is important to mention that other mechanisms such as activation of the 
renin-angiotensin system, increased reactive oxygen species (ROS) production, 
abnormal calcium handling and toxicity caused by glucose intermediates (Clark et al. 
2003; Hu et al. 2005; Minhas et al. 2005; Cesario et al. 2006; Schwanke et al. 2006; 
Ceramide 
NfκB iNOS up-regulation 
↑NO ↑ Peroxynitrite 
↑Apoptosis 
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Boudina and Abel, 2007; Ballal et al. 2010) may additionally contribute to cardiac 
dysfunction in diabetes and at times in obesity.  
 
Most of these functional abnormalities described in the previous paragraph including 
lipotoxicity may be related to an oversupply of oxidative fuels or the source of the 
excess calories supplied to the heart. A series of impressive studies from the 
Taegtmeyer research group have yielded exciting evidence identifying novel 
mechanisms of obesity related cardiac dysfunction. Wilson et al. (2007) postulated 
that the source of the excess calories (i.e. derived from fat or carbohydrate) may be 
important in the aetiology of obesity related cardiovascular disease. In a well 
designed study Wilson et al. (2007) fed rats a normal diet (10% fat, 70% 
carbohydrate), high fat diet (60% fat, 20% carbohydrate) or Western diet (high fat 
and high carbohydrate) (45% fat, 35% carbohydrate) for an acute (1 day to 1 week), 
short (4-8 weeks), intermediate (16-24 weeks) or long (32-48 weeks) period. 
Interestingly, cardiac dysfunction was only evident in rats fed the Western diet and 
only after 32-48 weeks of feeding. This corresponded with an inability of myocardial 
FA response genes to be sufficiently activated. While both the high fat and Western 
diets were able to increase mRNA transcripts of proteins involved in uncoupling, the 
former was able to do this to a greater degree than the Western diet group. Further 
analysis implicated reduced anaplerotic flux of the Krebs cycle and oxidative stress 
(reduced anti-oxidant enzyme transcription and evidence of glucolipotoxicity) related 
injury as mechanisms contributing to cardiac dysfunction in the model. In addition, 
hearts from Western diet fed rats displayed increased apoptosis with reduced 
expression of anti-apoptotic Bcl2 and increased mitochondrial biogenesis (indicative 
of mitochondrial damage), all of which are implicated in the mechanism of cardiac 
dysfunction induced by long term Western-diet consumption (Ballal et al. 2010). 
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Many of these detrimental changes associated with Western diet feeding were 
absent in the HFD fed group after the same period of feeding.  
 
As a cautionary note to this section it should be emphasized that the FA composition 
of the diet may also play an important part in the mechanism of cardiac dysfunction. 
It is known that lipotoxicity is often seen when cardiomyocytes are treated with 
saturated FA’s (Hickson-Bick et al. 2000). While cells cultured with different doses of 
long chain saturated FA’s undergo cell death, it is intriguing to find that culturing cells 
with similar concentrations of unsaturated LCFA does not induce cell death 
(Listenberger et al. 2003). Furthermore cells co-cultured with saturated and 
unsaturated FA’s do not develop lipotoxicity (Listenberger et al. 2003). Indeed it has 
been suggested that a diet high in unsaturated fatty acids and low in refined 
carbohydrates may afford lipoprotection (Taegtmeyer and Stanley, 2011). We again 
emphasize that the relationship between FA metabolism, lipid accumulation and 
cardiomyopathy remains unclear in humans and causality remains to be shown 
(Lopaschuk et al. 2007).  
 
2.4.5 Myocardial substrate flexibility and cardiac function in hearts from 
healthy and obese animals 
While the majority of ATP produced from the heart is derived from the oxidation of 
FA’s (Zierler, 1976; Opie, 1998), experimental studies have shown that the healthy 
heart is metabolically flexible, able to achieve normal LV mechanical function even 
when substrate supply is shifted away from FA metabolism (Yan et al. 2009). This is 
further reflected by conditions where isolated hearts from healthy lean animals are 
able to achieve comparable indices of LV mechanical function regardless of whether 
being perfused with glucose alone or glucose in combination with FA’s (Lopaschuk et 
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al. 1999; Liu et al. 2002; Boudina et al. 2005). It has however been shown that acute 
elevations of the FA concentrations in the perfusate of isolated hearts from healthy 
mice fail to impact on LV mechanical function (How et al. 2005). With respect to 
hearts from obese animals, one study has shown that isolated hearts from ob/ob 
mice, when retrogradely perfused, are able to achieve comparable LV function 
compared to hearts from lean mice in the presence of glucose alone or glucose in 
combination with palmitate in the perfusate (Boudina et al. 2005). This is however in 
contrast to studies reporting reduced LV mechanical function in isolated glucose 
perfused working hearts from obese rats (Du Toit et al. 2005; Nduhirabandi et al. 
2011). The discrepancy between these findings may be related to the use of different 
perfusion models (non-working Langendorff perfused heart vs. working heart) used to 
assess LV function.  
 
In response to increased workload elicited by β-adrenergic receptor stimulation or the 
addition of calcium to the perfusion medium, the healthy heart reacts by increasing 
glucose oxidation rates, while FA oxidation rates have been reported to become 
slightly elevated, remain constant or even become reduced (Collins-Nakai et al. 
1994; Wilson et al. 2007; Yan et al. 2009). During this increased LV workload, the 
contribution of glucose to myocardial ATP production increases greatly (Collins-Nakai 
et al. 1994). Even then healthy hearts from lean animals are still able to achieve 
comparable peak LV function whether being perfused with glucose as the sole 
energy source or in combination with FA (Boudina et al. 2005). This is in contrast to 
hearts from obese ob/ob mice which fail to achieve comparable LV function to hearts 
from lean mice when perfused with glucose alone or in combination with FA in 
response to increased workload (Boudina et al. 2005). This study however failed to 
investigate the contributory effect of insulin on LV functional reserve, which is 
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important, given the hyperinsulinaemic state associated with obesity. Recently, LV 
functional reserve in response to epinephrine or calcium supplementation of the 
perfusate has been shown to be normal in isolated hearts from diet induced obesity 
rodents when perfused with glucose, insulin and FA. (Wilson et al. 2007; Yan et al. 
2009). Hearts from obese animals thus appear to have sufficient metabolic reserve in 
response to elevated workloads.    
 
2.5 Mitochondrial abnormalities related to obesity, insulin resistance and type II 
diabetes  
 
Normal mitochondrial function is vital to ensure adequate cellular energetics. Among 
various other factors, reduced mitochondrial function is thought to contribute to the 
LV dysfunction associated with the diabetic cardiomyopathy (Ren et al. 2010; Bugger 
and Abel, 2010) and as such any alteration in mitochondrial function even during pre-
diabetic obesity could induce risk for the development of LV dysfunction should 
disease progression advance. Mitochondrial dysfunction may culminate in reduced 
ATP production which could eventually contribute to LV dysfunction. Indeed 
mitochondrial dysfunction (reduced state 3 respiration rates) (Sharov et al. 2000) and 
decreased phosphocreatine, ATP and phosphocreatine/ATP (PCR/APT) ratios (Beer 
et al. 2002) are evident in patients with heart failure. 
 
2.5.1 Mitochondrial dysfunction in obese and diabetic humans 
Data regarding myocardial mitochondrial function in humans are limited and when 
available, relate to mitochondria isolated from atrial cardiomyocytes. While evidence 
of cardiomyocyte mitochondrial dysfunction is present in type II diabetic patients 
(Anderson et al. 2009), it is interesting to note that mitochondrial dysfunction is also 
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evident in young obese insulin resistant individuals as right atrial cardiomyocyte 
mitochondria isolated from young obese pre-diabetic (HbA1c < 6) humans display 
impaired respiratory capacity and a reduced biogenic response compared to age-
matched non-obese subjects. Furthermore these mitochondria displayed signs of 
enhanced oxidative stress and elevated mRNA levels of pro-apoptotic proteins 
(Niemann et al. 2011).  
 
A review by Lesnefsky et al. (2001) noted that although a reduction in electron 
transport chain enzymatic activity may lead to a reduced rate of ATP synthesis, 
respiratory chain enzymes are generally present in excess of the oxidative 
phosphorylation potential of the cell. Consequently only a 30-50% reduction in ETC 
enzymatic activity is thought to be adequate to attenuate mitochondrial ATP 
production (Lesnefsky et al. 2001). It however remains to be seen whether the 
reduction in myocardial mitochondrial respiratory chain capacity noted in obese pre-
diabetic individuals (Niemann et al. 2011) is sufficient to alter mitochondrial ATP 
production. In addition a study investigating the relationship between these 
mitochondrial abnormalities and load independent indices of LV systolic function is 
warranted. 
 
2.5.2 Mitochondrial dysfunction in obese and diabetic animals 
Animal models of obesity, insulin resistance and type 2 diabetes also reveal signs of 
mitochondrial dysfunction and inadequate mitochondrial biogenesis. While ventricular 
mitochondrial state 3 respiration rates appear to be normal in genetic (ob/ob) 
(Boudina et al. 2005) and diet-induced (Essop et al. 2009; Cole et al. 2011) obese 
insulin resistant pre-diabetic animals, protein levels of components of the respiratory 
chain appear to be reduced in these ob/ob non-diabetic mice (Boudina et al. 2005) as 
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is seen in diabetic db/db mice (Boudina et al. 2007). Despite the normal respiration 
rates described in these models, myocardial mitochondrial ATP/O ratios and in 
certain cases the amount of ATP synthesized/ADP phosphorylated were reduced in 
response to obesity (Boudina et al. 2005; Essop et al. 2009; Cole et al. 2011).  
 
2.5.3 Cardiac efficiency and mitochondrial uncoupling 
Cardiac mechanical efficiency is the term used to describe the relationship between 
external cardiac power and LV energy consumption (energy consumed to produce 
LV mechanical work) and can be indirectly determined by expressing the work 
performed by the heart as a ratio of its oxygen consumption (Bing and Michal, 1959; 
How et al. 2006; Lopaschuk et al. 2010). In other words, should there be an increase 
in myocardial oxygen consumption, without an equivalent increase in LV mechanical 
function, cardiac efficiency is said to be reduced. Reduced cardiac efficiency is 
evident in obese insulin resistant and diabetic animals as well as healthy hearts 
exposed to elevated FFA supply (Mazumder et al. 2004; Buchanan et al. 2005; How 
et al. 2005; How et al. 2006; Cole et al. 2011). Reduced cardiac efficiency is further 
noted prior to the development of hyperglycemia and LV dysfunction (Buchanan et al. 
2005). Similarly Peterson et al. (2004a) recently reported that BMI predicted 
increased myocardial oxygen consumption and reduced cardiac efficiency (due to 
increased myocardial oxygen consumption) in young obese insulin resistant women. 
Although the oxidation of 1 molecule of palmitate utilizes 46 atoms of oxygen and 
produces 105 ATP molecules, only 12 atoms of oxygen are required to oxidize 1 
molecule of glucose producing 32 ATP molecules. It therefore follows that the 
enhanced FA utilization, as is the case in obesity, will translate into augmented 
myocardial oxygen consumption. Despite this, the increase in work-independent 
myocardial oxygen consumption seen in obesity/diabetes is often more that what can 
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be explained by the elevated consumption of FA as a substrate (How et al. 2006). 
Consequently other factors such as increased uncoupling of mitochondrial respiration 
may further contribute to the enhanced myocardial oxygen consumption evident 
obesity/diabetes (Boudina et al. 2005).   
 
Reduced ATP production and ATP/O ratios could result from mitochondrial 
uncoupling, i.e. disruption of the mitochondrial respiratory chain proton gradient.  
Experimental evidence suggests that FA utilization augments mitochondrial 
uncoupling (via increased UCP3 expression or activity) in both obese insulin resistant 
(Cole et al. 2011) and diabetic animals (Boudina et al. 2007) leading to greater 
myocardial oxygen consumption at the expense of ATP production. FA’s are thought 
to induce mitochondrial uncoupling through enhanced mitochondrial ROS production 
(Boudina et al. 2007; Bugger and Abel et al. 2010). Bugger and Abel (2010) have 
further proposed that LV dysfunction evident in type 2 diabetics may in part result 
from enhanced mitochondrial uncoupling related decreases in myocardial high-
energy reserves. Importantly enhanced mitochondrial uncoupling is evident in heart 
failure (Murray et al. 2004). 
 
2.5.4 Mitochondrial biogenesis 
In the cell, should the need arise to increase substrate oxidation, compensatory 
mitochondrial biogenesis occurs to meet the oxidative requirements induced by the 
increased fuel supply. Recent data however suggest that while mitochondria from 
obese insulin resistant and diabetic animals show signs of dysfunction, the biogenic 
response may additionally be impaired. Myocardial mitochondrial numbers, DNA 
copy and volume density are reported to be elevated in obesity related insulin 
resistance (Duncan et al. 2007) and diabetes (db/db mice) (Boudina et al. 2007). 
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Despite this mitochondrial biogenic response, ADP stimulated respiration and ATP 
synthesis rates are reported to be reduced in these models (Boudina et al. 2007; 
Duncan et al. 2007).  
 
2.5.5 High energy phosphate metabolism 
Insulin resistant or diabetic patients demonstrate abnormal myocardial high-energy 
phosphate ratios. Reduced myocardial PCr/ATP ratios have been observed in 
overweight, obese insulin resistant (pre-diabetic) and diabetic individuals (Diamant et 
al. 2003; Scheuermann-Freestone et al. 2003; Perseghin et al. 2007) and correlate 
with the degree of insulin insensitivity (Perseghin et al. 2007). These alterations in 
energy status precede diabetes related myocardial systolic dysfunction and correlate 
with diastolic dysfunction. Indeed reduced myocardial PCr/ATP ratios have been 
described as a significant predictor of cardiovascular mortality in diabetic patients 
presenting with dilated cardiomyopathy (Neubauer et al. 1997).  Reduced PCr/ATP 
ratios are thought to develop due to the altered substrate metabolism profile 
associated with insulin resistance (Scheuermann-Freestone et al. 2003). Although a 
reduced PCr/ATP ratio may predict mortality in diabetic patients with dilated 
cardiomyopathy, the observations that an altered myocardial energetic status is 
present prior to the development of type II diabetes is a point of concern.  
 
2.5.6 Mitochondrial function and insulin sensitivity 
Mitochondrial respiration rates may be influenced by the degree of insulin sensitivity 
and the extent of visceral obesity and general obesity. Measuring mitochondrial 
respiration in permeablized skeletal muscle fibers, Chanseaume et al. (2010) 
observed that viscerally obese individuals (waist circumference: 88-93cm and 94-
101cm, BMI<30kg/m2) had higher state 2 and 3 respiration rates than lean (waist 
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circumference ≤87cm), and obese insulin resistant individuals (waist circumference 
≥102cm, BMI≥30kg/m2). Despite the higher mitochondrial respiration rates, the 88-
93cm waist circumference group had a similar ATP/O ratio compared to the lean 
group, while the 94-101cm waist circumference group’s ATP/O ratio was significantly 
reduced compared to the lean group. In strong contrast, mitochondrial state 2 and 3 
respiration rates and ATP/O ratios obtained in the obese insulin resistant group 
(waist circumference ≥102cm, BMI≥30kg/m2) were significantly lower compared to 
the lean group. These functional observations were independent of changes in 
oxidative enzyme activity. Thus it appears that skeletal muscle mitochondrial function 
and efficiency (ATP/O ratio) are dependent on the degree of insulin sensitivity, 
visceral adiposity and general adiposity. It further seems as if a clear adaptational 
phase in mitochondrial respiratory function occurs, which is followed by signs of 
mitochondrial dysfunction as obesity and insulin resistance progress.  
Using mice with cardiomyocyte specific insulin receptor deletion (CIRKO), Boudina et 
al. (2009) recently reported enhanced mitochondrial oxidative stress and uncoupling 
accompanied by reduced Krebs cycle and FA oxidative capacity and reduced ATP 
production. These mice further display reduced LV mechanical function and 
increased mortality following in vivo myocardial infarction (Sena et al. 2009). These 
findings together with those of Chanseaume et al. (2010) suggest an important role 
for impaired insulin signaling in the development of mitochondrial dysfunction. 
 
2.5.7 Mitochondrial function and anoxia/ischaemia 
While reduced respiratory capacity, reduced cardiac efficiency and increased 
mitochondrial uncoupling may not pose an immediate threat to LV mechanical 
function in obese insulin resistant pre-diabetic individuals, these factors could well 
leave the myocardium vulnerable to ischaemic events as myocardial ischaemia  per 
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se further impairs mitochondrial respiratory capacity. This mitochondrial dysfunction 
would further impact negatively on myocardial ischaemia/reperfusion injury 
(Lesnefsky et al. 2001). As noted by Sena et al. (2009), impaired post-ischaemic 
myocardial insulin signaling can augment post-ischaemic damage. Essop et al. 
(2009) reported reduced post-anoxia state 3 respiration rates in isolated ventricular 
mitochondria from obese insulin resistant rats in the presence of a FA derived 
oxidizable substrate. The authors proposed that the underlying reduced myocardial 
mitochondrial bio-energetic capacity in these obese insulin resistant rats may 
account for the enhanced post-ischaemic damage (increased myocardial infarct 
sizes) identified in isolated heart perfusions (Essop et al. 2009).  
 
2.6 Peroxisome proliferator activated receptor alpha  
 
Peroxisomes are organelles that are present in most eukaryotic cells and are capable 
of metabolizing FA through β-oxidation, although to a much lesser degree than 
mitochondria. Initial studies performed on rodent hepatic tissue documented 
peroxisomal proliferation in response to various substances termed peroxisome 
proliferators (Issemann and Green, 1990; Lock et al. 1989). In 1990 the receptor to 
which peroxisome proliferators bind was isolated and characterized and became 
known as the peroxisome proliferator-activated receptor (PPAR) (Issemann and 
Green, 1990). Interestingly, although the peroxisomal proliferative response to 
peroxisome proliferators was only induced with the alpha subtype in rodents, the 
proliferative response is absent in humans and certain other species (Lock et al. 
1989; Kliewer et al. 2001).  
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PPARs are a family of ligand activated receptors belonging to the orphan nuclear 
receptor super-family. These receptors act as transcription factors regulating gene 
expression in various cell types. PPARs have naturally occurring and synthetic 
ligands, which upon entering the cell bind and activate PPARs residing in the 
cytoplasm. This initial activation leads to subsequent binding of PPAR to another 
transcription factor, the retinoid X receptor/retinoic acid receptor (RXR/RAR) (Gearing 
et al. 1993). The formation of this heterodimeric complex is essential for PPAR 
function and enables 1) translocation of the complex into the nucleus from the 
cytoplasm and 2) binding of the complex to a peroxisome proliferator response 
element in the promoter region of the target gene within the nucleus (Gearing et al. 
1993; Kieć-Wilk et al. 2005). Through these processes PPAR’s are able to regulate 
genes involved in carbohydrate and lipid metabolism.  
 
Presently three distinct PPAR isoforms have been identified namely α, β/δ and γ. 
These isoforms are differentially distributed throughout the body and are encoded by 
different genes (Kliewer et al. 2001). PPARα has traditionally been ascribed a role in 
lipid metabolism, specifically FA oxidation (Kieć-Wilk et al. 2005). It has also become 
evident that PPARα additionally exerts anti-inflammatory actions and plays a role in 
gluconeogenesis (Colville-Nash et al. 2005; Grau et al. 2006). PPARγ activation 
enables lipid storage into adipocytes, adipogenesis and may also perform an anti-
inflammatory role (Berger and Moller, 2002). Lastly, agonists of PPARβ/δ 
demonstrate lipid lowering and insulin sensitizing effects (Oliver et al. 2001) while the 
receptor has also been implicated in cancer and placental development (Jaeckel et 
al. 2001; Nadra et al. 2006). Although PPARγ and PPARβ/δ have important 
physiological roles, reviewing their function is beyond the scope of this dissertation 
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and accordingly, information relevant to PPARα and the cardiovascular system will 
be discussed.  
 
As PPARα plays a fundamental role in lipid metabolism, its activity and ability to 
influence gene expression is tightly regulated at multiple levels, many of which are 
poorly understood. PPARα can be activated by a host of natural and synthetic 
ligands including LCFA’s, certain eicosanoids and hypolipidaemic drugs (e.g. 
ciprofibrate, bezafibrate, fenofibrate and clofibrate) (Forman et al. 1997; Yu et al. 
1995; Brown et al. 1999).  
 
The activity of PPARs is dependent on their interaction with co-activators or co-
repressors (reviewed by Yu and Reddy, 2007). PPARγ co-activator 1α (PGC1α) is a 
transcriptional co-factor capable of interacting with a wide variety of transcription 
factors including PPARα. PGC1α is an important co-activator of PPARα and as such, 
its presence and consequent binding to PPARα greatly enhances the potential of 
PPARα regulated genes being transcribed (Vega et al. 2000). Adipocyte derived 
factors may further influence the level of PPARα activity or expression. Adiponectin is 
thought to stimulate PPARα gene expression via its interaction with PGC1α (You et 
al. 2005), while PPARα expression may be down-regulated by TNFα (Beier et al. 
1997). In addition to the presence of co-activators and co-repressors, Shalev et al. 
(1996) demonstrated that insulin can phosphorylate PPARα leading to an increase in 
its transcriptional activity (Shalev et al. 1996). Unfortunately little is known about 
PPARα function as a phospho-protein. Intriguingly, glucose was recently shown to 
bind PPARα with high affinity inducing a conformational change in PPARα’s 
secondary structure (Hostetler et al. 2008). This study made use of COS-7 cells and 
it was shown that glucose alone reduced the interaction of PPARα with its co-
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activator steroid receptor co-activator-1 (SRC-1). In the presence of the PPARα 
ligands arachidonic acid and clofibric acid, even low concentrations of glucose 
increased PPARα binding to SRC-1. Glucose further enhanced PPARα-RXRα 
binding to DNA, while attenuating LCFA-CoA binding to PPARα (there was no such 
inhibitory effect on LCFA’s), which paradoxically led to augmented transcription of 
genes favouring FA metabolism.  
 
2.6.1 PPARα expression and gene targets of PPARα  
In rats, PPARα is co-expressed in various cell types. In particular, PPARα has been 
identified in hepatocytes, cardiomyocytes, skeletal muscle, enterocytes, the proximal 
tubule cells of the kidney, and endothelial cells (Braissant et al. 1996; Su et al. 1998; 
Marx et al. 1999).  
 
In the heart, varying reports exist regarding the expression of PPARα in the context 
of obesity and type 2 diabetes. Hearts from obese insulin resistant animals have 
been reported to have elevated myocardial PPARα protein expression in the initial 
stages of high caloric feeding (8 weeks) (N Bezuidenhout, MSc dissertation, 2011), 
while longer periods of feeding (16 weeks) are shown to produce comparable levels 
of PPARα mRNA (Aasum et al. 2008) and protein expression compared to hearts 
from lean control animals (N Bezuidenhout, MSc dissertation, 2011). In similar 
fashion, obese Zucker rat hearts have comparable levels of PPARα mRNA 
expression in the fed state, while fasting attenuates PPARα mRNA expression in 
these animals when compared to lean controls (Young et al. 2002). In the previously 
mentioned study (Young et al. 2002), fasting resulted in increased mRNA expression 
in certain (but not all) PPARα target genes in these obese animals. The expression 
levels of myocardial PPARα mRNA however seems to be inconsistent in obese 
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Zucker rats as elevated PPARα mRNA expression levels have been reported 
elsewhere (Pagano et al. 2008). The expression of myocardial PPARα content in the 
context of obesity may further be dependent on dietary influence. While an obesity 
inducing Western diet failed to influence myocardial PPARα mRNA expression during 
a 32-48 week feeding period, an obesity inducing high fat diet resulted in reduced 
myocardial PPARα mRNA expression after 4-8 weeks and 16-24 weeks of feeding 
relative to the control and western diet fed group (Wilson et al. 2007).  
In hearts from diabetic animals, PPARα mRNA expression levels appear to be 
elevated relative to lean controls (Boudina et al. 2007). 
 
Activation of PPARα in a particular tissue may induce the expression of various 
PPARα target genes which encode proteins and enzymes predominantly involved in 
FA metabolism. These PPARα gene products were summarized in a review by 
Barger and Kelly, (2000) and include FA transport protein (FATP) (Motojima et al. 
1998), FA translocase, (CD36/FAT)) (Motojima et al. 1998), FA binding protein 
(FABP) (van Bilsen et al. 1997; Motojima, 2000), fatty acyl-CoA synthase (Van der 
Lee et al. 2000), CPT-1 (Mascaró et al. 1998; Djouadi et al. 1999), malonyl-CoA 
decarboxylase (Campbell et al. 2002) medium, long and very long chain acyl-CoA 
dehydrogenase (Gulick et al. 1994; Aoyama et al; 1998; Djouadi et al. 1999; Van der 
Lee et al. 2000), short chain 3-hydroxyacyl-CoA dehydrogenase (Aoyama et al. 
1998); short chain specific  3-ketoacyl-CoA thiolase (Aoyama et al. 1998); long chain 
acyl-CoA synthetase (Aoyama et al. 1998), malic enzyme (Aoyama et al. 1998) and 
acyl-CoA oxidase (Djouadi et al. 1999). Activation of PPARα can thus be seen to 
increase the expression of proteins implicated in the transport of FA into the cell, 
through the cytosol and into the mitochondria. Additionally proteins involved in 
peroxisomal and mitochondrial β-oxidation are also expressed. In rodent hearts, 
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PPARα further regulates the expression of uncoupling protein 3 (Young et al. 2001). 
It is noteworthy that activation of myocardial PPARα resulting from diet induced 
obesity does not always correspond with the up-regulation of every PPARα related 
gene/protein product, but rather a specific cassette of PPARα related genes (Wilson 
et al. 2007). These observations indicate that additional unknown factors may exist 
which further regulate PPARα’s transcriptional effects. 
 
2.6.2 The impact of PPARα activation 
Examining the phenotypic characteristics of PPARα null mice and mice with cardiac 
specific PPARα over-expression has provided valuable insight regarding the 
physiological role of PPARα. PPARα null mice display lower levels of hepatic FA 
metabolism related enzymes which correspond with reduced hepatic FA β-oxidation 
activity (Aoyama et al. 1998). Furthermore, after 72 hours of fasting, PPARα null 
mice display excessive hepatic lipid accumulation (Lee et al. 2004). These mice (fed) 
also have elevated total serum cholesterol, HDL-C, and apolipoprotein A-I levels 
(Peters et al. 1997) and do not develop insulin resistance when fed a high fat diet 
(Guerre-Millo et al. 2001). Data on PPARα null mice further support an anti-
inflammatory role of PPARα activation by fibrates (Delerive et al. 1999). In addition 
PPARα null mice demonstrate myocardial substrate switching, reflected by a higher 
reliance on glucose oxidation as opposed to FA β-oxidation compared to wild type 
mice (Luptak et al. 2005, Hafstad et al. 2009). This metabolic switching is associated 
with reduced LV performance during normal perfusion conditions and in response to 
elevated workload (Luptak et al. 2005; Loichot et al. 2006). Distinct from their 
metabolic characteristics, PPARα null mice display increased vascular lesion 
formation (Howroyd et al. 2004). Lastly, the lack of PPARα does not seem to 
influence heart rate or systemic blood pressure (Loichot et al. 2006).  
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Conversely, hearts from mice with cardiac specific PPARα over-expression are 
insulin resistant and exhibit increased expression of genes involved in FA transport 
and oxidation, while the expression of genes related to glucose uptake and transport 
are attenuated (Finck et al. 2002). These genetic modifications corroborate with 
attenuated insulin signaling and elevated FA β-oxidation and reduced glucose uptake 
and oxidation rates in the heart (Park et al. 2005; Sambandam et al. 2006), thus 
representing a phenotype similar to the diabetic heart (Finck et al. 2002). Hearts from 
these mice are also hypertrophied (Finck et al. 2002), exhibit excess myocardial lipid 
accumulation (Finck et al. 2002; Yang et al. 2007) and reduced in vivo myocardial 
systolic function (Finck et al. 2002; Yang et al. 2007), while being more susceptible to 
ischaemia/reperfusion induced injury (Sambandam et al. 2006).     
 
2.6.3 The effect of PPARα agonists/activation on lipid metabolism 
In humans, fibrate treatment has been shown to lower circulating Trig’s and elevate 
HDL-C levels (Robins et al. 2001). Certain authors have also reported reductions in 
circulating LDL-C levels following PPARα agonist treatment (Malmendier and 
Delcroix, 1985). The mechanisms whereby PPARα agonists (fenofibrate) improve the 
lipid profile may involve increasing the synthesis of both apolipoprotein A-I 
(Malmendier and Delcroix, 1985) and A-II (Vu-Dac et al. 1995) thereby assisting in 
elevating the levels of HDL-C, while reducing the amount of apolipoprotein B, the 
major lipoprotein constituent of LDL-C. PPARα agonists further increase transcription 
of the hepatic LPL gene (Schoonjans et al. 1996), while reducing ApoC-III (ApoC-III 
may inhibit LPL mediated Trig hydrolysis) levels (Minnich et al. 2001). This results in 
increased Trig hydrolysis which aids in reducing circulating Trig levels. Elevated 
levels of hepatic mitochondrial β-oxidation in response to PPARα agonism (Minnich 
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et al. 2001) further reduce the level of FFA, an essential component of VLDL and 
LDL-C formation.  
 
2.6.4 The effect of PPARα agonists on systemic insulin sensitivity 
PPARα agonists have repeatedly been demonstrated to have both systemic and 
tissue specific insulin sensitizing effects (Guerre-Millo et al. 2000; Ide et al. 2004; 
Bergeron et al. 2006; Tsunoda et al. 2008) and consequently have tremendous 
potential in the treatment of diabetes. 
 
The mechanisms whereby PPARα agonists achieve enhanced insulin sensitivity 
have been widely investigated. Administration of the selective PPARα agonist Wy-
14,643 significantly increases hepatic and skeletal muscle IR and IRS-tyrosine 
phosphorylation, while increasing IRS-associated PI3K activity in ob/ob mice (Ide et 
al. 2004). These beneficial effects of Wy-14,643 on the insulin signaling pathway 
were accompanied by reduced hepatic and skeletal muscle Trig and fatty acyl-CoA 
levels. In the previously mentioned study it was interesting to note that these 
beneficial effects afforded by PPARα agonism were absent in the lean treated group. 
Nevertheless, similar reductions in myocardial Trig levels in response to PPARα 
agonism have been reported elsewhere (Forcheron et al. 2009). Due to the 
association between intramuscular lipid accumulation and insulin resistance (Boden 
et al. 2001), PPARα agonists may alleviate insulin resistance secondary to their 
systemic and tissue specific lipid lowering effects. 
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2.6.5 Additional cardiovascular effects of PPARα activation 
The impact of PPARα activation on myocardial susceptibility to ischemia/reperfusion 
injury is controversial. Administration of the highly selective and potent PPARα 
agonist GW-7647 to healthy mice, 3 days prior to in vivo CAL induced a dose 
dependent decrease in myocardial infarct size, accompanied by a significant 
improvement in LV contractile function. These cardioprotective effects of GW-7647 
were absent in PPARα null mice (Yue et al. 2003). The cardioprotection afforded by 
GW-7647 was associated with reduced circulating FFA’s, increased expression and 
activity of cardiac FA oxidation enzymes and increased in vivo FA oxidation relative 
to vehicle treated controls after 24 hours reperfusion (Yue et al. 2003). Additional 
studies describing the cardioprotective effects of PPARα agonism following 
ischaemia/reperfusion have been reported in healthy (Bulhak et al. 2006; Tabernero 
et al. 2002, Wayman et al. 2002, Yeh et al. 2006), obese and diabetic (Aasum et al. 
2008; Bulhak et al. 2009) animals. These studies have highlighted metabolic and 
anti-inflammatory effects (Yue et al. 2003), inhibiting various apoptotic pathways 
(Yeh et al. 2006) and stimulating signaling via the PI3K/Akt pathway coupled with the 
production of nitric oxide (Bulhak et al. 2006; Bulhak et al. 2009) as possible 
mechanisms contributing to the protection elicited by PPARα agonism/activation 
following ischaemia/reperfusion episodes. Moreover, PPARα agonists have also 
been reported to reduce myocardial fibrosis in deoxycorticosterone acetate salt 
hypertensive rats and Zucker diabetic rats (Ogata et al. 2004; Forcheron et al. 2009). 
 
In contrast to the reported cardioprotective effects ascribed to PPARα agonist 
treatment, certain studies have observed no effect (Aasum et al. 2003b; Xu et al. 
2006) or have shown PPARα activation to be detrimental to the ischaemia/reperfused 
heart (Hafstad et al. 2009). The later report (Hafstad et al. 2009) concurs with post-
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ischaemic observations made in cardiac specific PPARα over-expressed mouse 
hearts, while hearts from PPARα null mice recover to a similar degree as wild-type 
mice after ischaemia/reperfusion induced injury (Sambandam et al. 2006). 
Remarkably, PPARα agonist treatment (tetradecylthioacetic acid) has been shown to 
increase the rate of myocardial necrosis (Pruimboom-Brees et al. 2006). Clearly the 
issue of whether PPARα agonists are detrimental or beneficial during 
ischaemia/reperfusion needs further investigation.  
 
2.6.6 The need to develop new lipid lowering and insulin sensitizing drugs 
Dislipidaemic patients at risk for cardiovascular disease are generally placed on 
statin therapy (Hydroxymethyl-glutamyl-coenzyme A reductase inhibitors). Although 
statins significantly reduce cardiovascular disease risk (Baigent et al. 2005), primarily 
accomplished by a reduction in LDL-cholesterol (Baigent et al. 2005), a degree of 
atherogenic/cardiovascular disease risk still remains in high risk patients due to 
elevated circulating Trigs and lowered HDL-C levels (Cziraky et al. 2008; Alagona, 
2009). As niacin and fibrates positively influence Trig and HDL-C levels, combination 
therapy involving niacin/statin or fibrate/statin therapy, is advised for the treatment of 
cardiovascular disease (Cziraky et al. 2008; Alagona, 2009).  
 
Although most fibrates are classified as “safe drugs”, the high dosages required 
(Berger and Moller, 2002) and some of the reported side effects (reviewed by 
Rubenstrunk et al. 2007), warrant the development of new, more potent and specific 
PPARα agonists. 
 
Stellenbosch University http://scholar.sun.ac.za
55 
 
For the purposes of this dissertation, information will be provided on K-111, a novel 
PPARα agonist which has shown potential in alleviating the metabolic manifestations 
associated with obesity and type II diabetes. 
 
2.6.7 K-111/BM 17.0744 
 
 
 
 
 Figure 2.6: The chemical structure of K-111 
 
K-111 ((2,2-dichloro-12-(p-chlorophenyl)-dodecanoic acid)), formally known as BM 
17.0744, is a ω-substituted alkyl carboxylic acid developed by Kozva Co Ltd, under 
the licensing of Roche Holding AG, as a oral PPARα agonist. K-111 has a high 
specificity for PPARα, stronger than other fibrates such as Wy-14.643, while it does 
not interact with PPARγ (Meyer et al. 1999). K-111 was reported to be undergoing 
phase II clinical trials (Drew and Calkin, 2007). To date, only a handful of scientific 
papers in accredited journals have been published regarding K-111. The reports 
published concur that K-111 has potent insulin sensitizing and lipid lowering 
properties attributed to its specific interaction with PPARα. K-111 treatment has also 
been shown to exert various biometric effects such as reducing body weight gain, 
and increasing liver and kidney weights (an effect common in rodents exposed to 
PPARα agonists) (Meyer et al. 1999).  
 
 
 
(CH2)10 CCl2 COOHCl 
Stellenbosch University http://scholar.sun.ac.za
56 
 
2.6.7.1 Murine and rodent studies 
The insulin sensitizing capabilities of K-111 have been well documented. For 
example, in cultured 3T3-L1 adipocytes, the use of K-111 enhanced insulin 
stimulated glucose uptake (Pill and Kϋhnle, 1999). K-111 administration was further 
shown to improve systemic insulin sensitivity in 4 different rodent models of insulin 
resistance (Yellow KK mice, ob/ob mice, db/db mice and obese fa/fa Zucker rat) (Pill 
and Kϋhnle, 1999). The insulin sensitizing/glucose lowering effects of K-111 have 
subsequently been confirmed in diabetic db/db mice by various other authors (Aasum 
et al. 2002, 2005; Bratkovsky et al. 2006).  
 
Similarly to the fibrate class of PPARα agonists, K-111 has a potent effect on lipid 
metabolism, reducing circulating Trigs and total cholesterol (Meyer et al. 1999) in 
healthy rats. K-111 has also been shown to reduce circulating Trig and FFA levels in 
diabetic mice (Aasum et al, 2002). 
 
In dose response studies, male Sprague-Dawley rats were administered a range of 
K-111 doses (0, 1.5, 3, 6 and 12.5 mg/kg/day) in an attempt to detect quantifiable 
serum concentrations of the drug. On day 22 of drug administration, K-111 was 
detectable in the serum, but only at the highest investigated dosage (12.5mg/kg/day) 
yielding the following pharmokinetics: cmaxss 0.44mg/l, tmaxss 1hr, t1/2ss 2hrs and 
AUC0>24ss 0.6mg/hr/l (Meyer et al. 1999). Although no further rodent data are 
currently available on K-111’s effects at dosages between 6 and 12.5mg/kg/day, it 
could be speculated that K-111 doses below 6mg/kg/day, would mainly elicit hepatic 
effects as these doses did not result in detectable drug levels in the blood (Meyer et 
al. 1999). Indeed, at the K-111 doses investigated a significant dose dependent 
increase in hepatic FA oxidation enzymes was found (Meyer et al. 1999). In rodents, 
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cardiac PPARα regulated target genes may theoretically only be up-regulated in 
response to chronic K-111 treatment at dosages of 12.5mg/kg/day and above. 
Unfortunately no other studies have investigated K-111’s in vivo transcriptional 
effects on cardiac target genes in rats. However, while cultured rodent 
cardiomyocytes are responsive to K-111 treatment, hearts from db/db mice receiving 
K-111 at 24.5-37.9mg/kg/day for 4-5 (Aasum et al. 2002) or 8-9 weeks (Aasum et al. 
2005) displayed no myocardial transcriptional response to PPARα agonism. A similar 
cardiac unresponsiveness to K-111 was seen in normal mouse hearts at similar 
doses (Aasum et al. 2005). These data suggests that K-111 at sufficiently high 
concentrations is either unable to up-regulate cardiac PPARα target gene expression 
in vivo, or that the myocardial responsiveness to K-111 may differ between mice and 
other species.  
 
2.6.7.2 Studies in non-human primates 
Besides smaller mammals, K-111 administration has also yielded beneficial effects in 
non-human primates. Obese hypertriglyceridaemic hyperinsulinaemic pre-diabetic 
rhesus monkeys treated with K-111 at various doses displayed a marked 
improvement in systemic insulin sensitivity, while body weight and circulating Trig’s 
were reduced in a dose dependent manner. K-111 also improved HDL-C levels in 
these animals, without influencing blood pressure, plasma fibrinogen or total 
cholesterol levels. An insignificant effect on liver weight, adipogenesis, blood 
chemistry and hematological profile was observed following chronic K-111 treatment 
(Bodkin et al. 2003; Schäfer et al. 2004). K-111 further elicited augmented skeletal 
muscle glycogen synthase activity in these animals, which has been proposed as a 
contributory mechanism of K-111’s insulin sensitizing capabilities (Ortmeyer et al. 
2005).  
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2.6.7.3 Species differences 
The effectiveness of K-111 may be species dependent (Meyer et al. 1999). While 
rats develop enlarged livers and kidneys together with significant increases in hepatic 
enzyme activity ((carnitine acetyl transferase activity (CAT): 200 fold increase; acetyl 
CoA oxidase (ACO): 20 fold increase) in response to K-111 treatment, treated dogs 
have normal kidney and liver weights. They also have more modest increases in 
hepatic enzyme activity (CAT: 6-fold; ACO: 2-fold) of PPARα related target genes. 
Furthermore, although doses of up to 12.5mg/kg/day K-111 are well tolerated in rats, 
4 and 6mg/kg/day K-111 appear to be toxic in dogs. In strong contrast to dogs, K-111 
at a dose of 12.5mg/kg/day has no influence on serum Trig’s or total cholesterol in 
guinea-pigs, while hepatic enzyme activity of CAT and ACO are elevated and liver 
and kidney weights remain unchanged (Meyer et al. 1999). Thus clear species 
differences exist in their response to K-111 treatment. Rodents may display a more 
exaggerated response following PPARα treatment due to the high density of hepatic 
PPARα receptors in comparison to other species (Tugwood et al. 1998).      
 
2.6.7.4 Myocardial substrate metabolism 
K-111 has a profound and paradoxical effect on cardiac substrate metabolism. In 
response to chronic K-111 treatment, db/db mice displayed increased ex vivo 
myocardial glycolysis and glucose oxidation rates while FA oxidation rates  were 
reduced (Aasum et al. 2002, 2005), despite increased FA oxidation rates being 
observed in cardiomyocytes cultured with K-111 (Aasum et al. 2005). The inability of 
K-111 to increase myocardial FA oxidation in vivo may be due to an inhibitory effect 
of K-111 on cardiac heparin-releasable LPL activity (Carroll and Severson, 2001; 
Aasum et al. 2005). Reduced cardiac LPL activity could result in the in vivo 
myocardium being transcriptionally conditioned to a lower myocardial FFA supply. 
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Indeed Aasum et al. (2005) have proposed that the decrease in FA oxidation rates in 
response to K-111 treatment may reflect an in vivo adaptation to reduced myocardial 
FFA supply resulting from increased hepatic FFA clearance. 
 
2.6.7.5 Additional effects of K-111 
Similar to other PPARα agonists, K-111 was shown to elicit an anti-inflammatory 
effect. K-111 added to adipocytes (3T3-L1 cells) co-cultured with a 
lipopolysaccharide stimulated macrophage cell line (RAW 263.7 cells) indirectly, 
suppressed adipocyte TNFα secretion by attenuating macrophage interleukin-6 
release (Murakami et al. 2007). K-111 could thus also improve systemic insulin 
sensitivity by reducing the systemic inflammatory response evident in 
obesity/diabetes. 
 
Collectively, these beneficial effects of K-111 agonism allude to its potential use in 
the management of obesity and diabetes. The strong affinity of K-111 for PPARα 
coupled with the low doses required to effectively attenuate lipid levels and improve 
insulin sensitivity make K-111 an even more attractive drug. By reducing body weight 
gain, exerting anti-inflammatory actions, reducing Trig levels and increasing HDL-C 
levels, K-111 can afford added anti-atherogenic benefits. Although elevated liver and 
kidney weights are observed in so-called “high responders” (rodents), the minimal 
effect on liver and kidney mass in non-human primates underscores the potential for 
its future use in humans. 
 
Although potent new insulin sensitizing and lipid lowering drugs are required, the 
importance of investigating these substances outside the scope of their normal 
insulin sensitizing and lipid lowering abilities is critical. As these drugs are 
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administered to patients at risk for developing various cardiovascular diseases, their 
ability to not antagonize endpoints of normal cardiovascular functioning or 
cardiovascular disease is vital. Thus far K-111 has shown promise in the alleviation 
of insulin resistance and dyslipidaemia, but more information is required on its 
specific cardiac effects, and the impact on ischaemia/reperfusion injury.    
 
2.7 Myocardial ischaemia/reperfusion injury 
 
Ischaemia is derived from the Greek words “isch” meaning restriction and “haema” 
meaning blood and thus refers to a condition where a tissue or an organ is partially or 
completely deprived of blood flow. Depending on the severity of the myocardial 
coronary flow restriction, ischaemia may be classified as either moderate or severe. 
Ischaemia may also ensue when insufficient blood reaches the heart muscle in 
response to a stimulus requiring increased myocardial contractility (demand-induced 
ischaemia) (reviewed by Stanley et al. 1997).   
 
Depending on the severity of the ischaemic insult, various metabolic alterations occur 
within the cardiomyocyte, and in the case of severe ischaemia, should reperfusion 
not be instituted with immediate effect, necrosis and the development of infarction 
occurs. Although reperfusion therapy is absolutely essential to salvage the ischaemic 
myocardium and prevent the progression to irreversible ischaemic damage, 
reperfusion itself brings about a certain degree of damage or cell death (as reviewed 
by Kharbanda, 2010). The extent of the myocardial damage (cell death, arrhythmia, 
contractile dysfunction and microvascular dysfunction) incurred is largely dependent 
on the duration and severity of ischaemia, effective reperfusion and the 
myocardium’s intrinsic signaling response to ischaemia and reperfusion (as reviewed 
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by Kharbanda, 2010). Myocardial ischaemia/reperfusion injury is a relevant concern 
in clinical practice and is evident in various interventions (thrombolysis, angioplasty 
and coronary bypass surgery) aimed at restoring blood flow to an ischaemic area. 
Ischaemia/reperfusion injury may also be evident during cardioplegic arrest and 
aortic cross clamping. As such, interventions aimed at reducing the extent of 
ischaemia/reperfusion injury are invaluable.  
 
2.7.1 Metabolic and structural consequences of ischaemia and reperfusion 
Various metabolic and ultrastructural changes occur during ischaemia. These include 
ATP and PCr depletion. Structurally, sarcoplasmic reticulum swelling, myofibril 
relaxation and mitochondrial damage are also evident (Puri et al. 1975; Jennings and 
Ganote, 1976). The extent of these abnormalities are however dependent on the 
length of the ischaemic episode, which subsequently influences the recovery of the 
metabolic parameters upon reperfusion (Puri et al. 1975). Other metabolic 
abnormalities ensue as ATP dependent ion pumps are unable to function, 
culminating in the cytosolic accumulation of sodium, hydrogen and calcium ions and 
intracellular acidosis development (Tani and Neely, 1989).  
 
A fundamental feature of myocardial ischaemia is reduced oxygen availability and 
consequently, lower mitochondrial oxidative phosphorylation rates which disturbs the 
tightly coupled ATP breakdown and re-synthesis equilibrium existing during 
normoxia. Consequently cellular ATP levels become depleted, the extent of which is 
again dependent on the duration and severity of ischaemia (Puri et al. 1975). 
Whereas oxidative metabolism is reduced following an ischaemic event, 
experimental work has shown that after coronary artery ligation, there is an initial 
increase in glycolytic flux which quickly declines to normal levels (Opie, 1976). 
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Although during aerobic conditions, glycolysis accounts for only a small amount of 
the total ATP production, glycolytically produced ATP during mild myocardial 
ischaemia becomes invaluable in maintaining intracellular ion pump activity (Opie, 
2004). However, glycolytically produced ATP is often insufficient to maintain normal 
contractile function (Opie, 2004). While glycolytically generated ATP may aid in 
maintaining ion homeostasis, in the virtual absence of glucose supply to the 
ischaemic portion of the heart, glycogen stores undergoing glycolysis contributes 
greatly to cytosolic proton accumulation and consequently to the decline in 
intracellular pH (Garlick et al. 1979). Despite this, elevated glycogen levels at the 
onset of myocardial ischaemia have been associated with improved functional 
recovery during reperfusion of the ischaemic myocardium (Van Rooyen et al. 2002). 
The beneficial effects of glycogen in the ischaemic myocardium may however be 
dependent on the severity of the ischaemic insult. 
 
In humans, AMI is associated with elevated catecholamine release, which in turn 
increases circulating FFA levels, reduces pancreatic insulin release and induces 
hyperglycemia (Vetter et al. 1974; Opie, 2008). Oliver et al. (1968) noted that high 
levels of FFA were evident for hours following AMI and that these elevated FFA 
levels were associated with an increased incidence of arrhythmias. In line with this, 
systemic glucose intolerance (Allison et al. 1967) and delayed insulin responsiveness 
ensue (Vetter et al. 1974) in the hours following the onset of AMI. These clinical 
observations coincide with our current understanding of the fatty acid-glucose cycle 
and it follows that a state of myocardial insulin resistance is possible after 
catecholamine induced mobilization and elevations of FFA during and following an 
AMI.  
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2.7.2 Obesity and post-ischaemic outcomes 
As discussed previously, obesity is associated with a higher risk of developing 
cardiovascular disease. In a case-control study consisting of 27098 participants, 
obesity defined by waist-to-hip ratio’s was shown to be associated with a higher risk 
of developing myocardial infarction (Yusuf et al. 2005). Healthy obese pre-diabetic 
individuals may also be at risk for developing ischaemic events. During increased 
myocardial workload, obese normotensive pre-diabetic individuals without 
cardiovascular disease present defects in myocardial perfusion (silent ischaemia) 
which are predominantly observed in subjects with insulin resistance and visceral 
adiposity (Nasr and Sliem, 2010). 
 
Despite their high risk for developing cardiovascular disease, the prognosis of obese 
patients seems far better than that of lean patients following an AMI and/or heart 
failure. This phenomenon is known as the obesity paradox (reviewed by Morse et al. 
2010). Although the obesity paradox is well documented, conflicting post-ischaemic 
outcomes associated with obesity are reported in the literature. Certain clinical 
studies have reported an increased risk of coronary events, or death related to 
obesity following an AMI (Rea et al. 2001; Rana et al. 2004), while others have 
reported reduced or unaltered risk for overall mortality following myocardial infarction 
(Lopez-Jimenez et al. 2004; Nikolsky et al. 2006; Eisenstein et al. 2005; Shiraishi et 
al. 2007). Nigam et al. (2006) demonstrated that obese and overweight individuals 
hospitalized following AMI had significantly lower risk of mortality within the first 6 
months following AMI, while long-term mortality remained similar between the 
groups. Despite this, the risk of recurrent AMI and cardiac-related death remained 
higher in the overweight and obese group (Nigam et al. 2006). Using magnetic 
resonance imaging, obese patients (extreme obese patients were excluded) have 
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been reported to have smaller infarct sizes compared to lean patients (Pingitore et al. 
2007) (This finding must be interpreted with caution as the sample size of the obese 
group was only 14 compared to the 75 patients in the non-obese group). Similarly, 
lean patients presenting with coronary artery disease have significantly higher risk of 
cardiac mortality and one-year mortality following percutaneous coronary intervention 
when compared with obese patients (Gruberg et al. 2002). Considering this, the 
possibility exists that in the obese pre-diabetic hyperinsulinaemic state, elevated 
insulin levels may afford a cardioprotective effect following coronary events which is 
lost in the diabetic state (myocardial unresponsiveness to insulin). Notwithstanding 
this paradox, non-diabetic obese patients with the metabolic syndrome have been 
reported to have worse outcomes following myocardial infarction (Clavijo et al. 2006). 
Nevertheless, the post-ischaemic outcomes associated with obesity remain 
controversial.  
 
Although the existence of the obesity paradox requires further elucidation, Ozeke et 
al. (2011) have hypothesized that obese individuals with obstructive sleep apnea 
may be protected from future cardiovascular events due to chronic intermittent 
hypoxic episodes associated with obstructive sleep apnea. Obstructive sleep apnea 
occurs predominantly in the obese population and these hypoxic episodes are 
thought to elicit a cardioprotective preconditioning stimulus thought to be responsible 
for the improved cardiovascular outcomes seen in these patients.    
 
Myocardial susceptibility to ischaemia/reperfusion injury has been investigated in 
many animal models of obesity/insulin resistance and type II diabetes to try and 
ascertain at what point, if any, in the aetiology of obesity, the myocardium becomes 
more susceptible to ischaemia/reperfusion induced injury. The use of animal models 
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allows for the control of confounding factors such as age from influencing post-
ischaemic outcomes. In response to experimentally induced ischaemia/reperfusion, 
certain studies have reported that diabetic animals have greater infarct sizes and 
poorer LV systolic functional recovery compared to non-diabetic animals (Marfella et 
al. 2002) while other studies have observed smaller infarct sizes but reduced LV 
systolic functional recovery (Kristiansen et al. 2004). Available data generated from 
animal models of obesity and insulin resistance without overt type II diabetes, 
demonstrate that myocardial ischaemia/reperfusion injury is either increased (Sidell 
et al. 2002; Du Toit et al. 2005; Clark et al. 2010; Huisamen et al. 2011; Nduhirabandi 
et al. 2011) or comparable (Thim et al 2006; Aasum et al. 2008; Dixon et al. 2009) to 
that observed in lean control groups. Obesity has additionally been shown to 
increase myocardial vulnerability to repetitive ischaemic episodes (Thakker et al. 
2008), while the offspring of obese animals are also more susceptible to 
ischaemia/reperfusion injury (Calvert et al. 2009).  Animal models of obesity are 
further associated with adverse LV remodelling (LV dilation and cardiac hypertrophy) 
after a myocardial infarction (Thakker et al. 2006). Obesity may also increase the 
resistance of the myocardium to known cardioprotective interventions such as 
ischaemic preconditioning (Kristiansen et al. 2004; Katakam et al. 2007) and post-
conditioning (Bouhidel et al. 2008). The majority of the available animal data 
collectively suggests that obesity either increases or has no effect on the myocardial 
susceptibility to ischaemia/reperfusion injury, while abolishing the effectiveness of 
cardioprotective interventions.  
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2.7.3 Oxidative fuel supply and ischaemia/reperfusion injury 
It is probable that the combination of the increased supply of oxidative fuels and 
abnormal myocardial substrate metabolism characteristic of the obese state may 
influence the myocardiums’ tolerance to ischaemia/reperfusion injury. Indeed in 
obese diabetic mice, post-ischaemic LV mechanical function is positively associated 
with pre-ischaemic myocardial glucose oxidation rates and negatively with pre-
ischaemic myocardial palmitate oxidation rates (Hafstad et al. 2007). In addition, a 
detrimental role for FA on post-ischaemic functional outcomes has been shown in 
hearts from healthy animals (Lopaschuk et al. 1988, 1990; Liu et al. 2002; Gambert 
et al. 2006).  
 
Early studies in dogs indicated that experimentally induced elevations in circulating 
FFA during coronary artery ligation (CAL) were associated with increased left 
ventricular dilatation, thus implicating elevated FFA levels with depressed pump 
function during ischaemia (Kjeksjus and Mjøs, 1972). More recent studies have 
focused on the impact of FA’s on cardiac function during reperfusion. While the rates 
of myocardial glucose oxidation during reperfusion are often similar to the pre-
ischaemic period, FA’s once again constitute the major oxidative fuel predominantly 
oxidized during the reperfusion of the previously ischaemic myocardium, as rates of 
FA β-oxidation remain unchanged or become slightly elevated during this period 
(Lopaschuk et al. 1990; Aasum et al. 2003a).  
Hearts from healthy animals perfused with a combination of 1.2mM FA and 11mM 
glucose have significantly poorer myocardial functional recoveries compared to 
hearts perfused with glucose alone (Lopaschuk et al. 1990). Other studies have 
similarly documented depressed cardiac function during myocardial reperfusion in 
response to elevated FA levels in hearts from healthy animals (in most instances 
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compared to conditions where glucose was the only substrate) (Lopaschuk et al. 
1988; Liu et al. 2002; Folmes et al. 2006; Gambert et al. 2006). It is thought that the 
myocardium becomes stunned during the initiation of reperfusion in the presence of 
FA’s due to their inhibitory effect on myocardial glucose oxidation rates (Lopaschuk 
et al. 1990). Furthermore, during reperfusion elevated FA’s appear to have a more 
potent inhibitory effect on myocardial glucose oxidation rates while glycolytic flux 
rates are minimally affected (Lopaschuk et al. 1993). This dissociation between 
myocardial glycolysis and glucose oxidation upon reperfusion is associated with 
enhanced proton production, a decline in the recovery of intracellular pH and LV 
dysfunction (Liu et al. 2002; Folmes et al. 2006). Of great importance, is the 
observation that stimulation of glucose oxidation and not glycolysis, or reducing FA 
metabolism during reperfusion, is associated with improved myocardial functional 
recovery (Lopaschuk et al. 1990; Lopaschuk et al. 1993; Dyck et al. 2004; Gambert 
et al. 2006). Besides proton accumulation, other authors have linked the use of FA to 
excess ROS production which contributes to post-ischaemic cardiac dysfunction 
(Gambert et al. 2006). It is uncertain whether the post-ischaemic implications of 
elevated FFA supply on myocardial infarct size have been investigated. 
 
Despite the general consensus that the presence of elevated FFA concentrations 
negatively impact on myocardial function in the healthy heart following ischaemia, a 
few studies have reported either no or beneficial effects associated with elevated 
FFA supply after ischaemia. This is evident in studies where supplementation of the 
perfusion medium of isolated perfused hearts with palmitate fails to impact on 
myocardial functional parameters before or after hypoxia/ischaemia (Gmeiner et al. 
1975; King et al. 2001). Similarly, increasing the supply of FFA to the hearts of 
conscious dogs during reperfusion after only 10 minutes regional ischaemia was 
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associated with improved reperfusion function, an effect abolished by oxfenicine 
pretreatment (CPT-1 inhibitor) (Van de Velde et al. 1996). Additionally, isolated 
rodent hearts perfused with 5.5mM glucose and 1.2mM palmitate exhibit improved 
mechanical function when compared to hearts perfused with glucose alone following 
20 minutes global ischaemia (Broderick and Glick, 2004). Strong evidence supporting 
a beneficial role for FFA following ischaemia in diseased animals exists as hearts 
from streptozotocin-induced type I diabetic mice achieved a poorer rate pressure 
product recovery compared to hearts from control animals when perfused with 
glucose as the only substrate. The addition of palmitate in conjunction with glucose to 
the perfusate however enabled hearts from these diabetic animals to achieve 
comparable functional recoveries to the control group (King et al. 2001). 
 
Considering the conflicting data regarding the impact of FA on post ischaemic 
myocardial function, Van der Vusse and van Bilsen, (2006) have cautioned authors 
against extrapolating experimental findings to the clinical setting as experimental 
data can be influenced by a wide range of confounding factors. Significantly the 
length and severity of the ischaemic episode may impact strongly of the findings 
reported. Nevertheless, considering all data currently available, one may speculate 
that obesity could be associated with adverse post-ischaemic effects due to excess 
availability of circulating FFA. 
 
2.7.4 The cardioprotective effects of insulin administration 
Insulin is a hormone produced by the β cells of the islets of Langerhans in the 
pancreas. Upon binding to insulin receptors on insulin sensitive tissues, insulin 
stimulates increased glucose uptake and glycogen formation, while FA utilization by 
the cells is reduced. As previously described, there is considerable literature 
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documenting the detrimental consequences of elevated levels of FA β-oxidation 
specifically during reperfusion on the myocardial functional recovery following an 
ischaemic episode (Lopaschuk et al. 1988, 1990; Liu et al. 2002; Folmes et al. 2006; 
Gambert et al. 2006). By virtue of its enhancement of myocardial glucose utilization 
by the heart, before, during and after the ischaemic episode, insulin may confer 
cardioprotection.  
 
The cardioprotective effects of insulin or glucose-insulin-potassium in the setting of 
ischaemia/reperfusion injury have been extensively documented in the literature 
(Baines et al. 1999; Jonassen et al. 2000a, b; Jonassen et al. 2001; Nawata et al. 
2002; Van Rooyen et al. 2002; LaDisa et al. 2004; Hafstad et al. 2007; Fuglesteg et 
al. 2008; Yu et al. 2008; Oates et al. 2009; Xing et al. 2009; Ji et al. 2010; Wong et 
al. 2011). While there is consensus that insulin is cardioprotective in experimental 
physiology, the majority of insulin’s cardioprotective effects have been reported to 
occur when administered 5 minutes prior to reperfusion of the ischaemic myocardium 
(LaDisa et al. 2004; Jonassen et al. 2000a; Jonassen et al. 2001; Fuglesteg et al. 
2008; Yu et al. 2008; Ji et al. 2010; Wong et al. 2011), with a few articles 
documenting cardioprotective effects when it was administered before, during and 
after ischaemia (Jonassen et al. 2000a; Nawata et al. 2002; Van Rooyen et al. 2002; 
Oates et al. 2009; Xing et al. 2009). Despite this, LaDisa et al. (2004) and Hafstad et 
al. (2007) could not demonstrate a cardioprotective effect of insulin in healthy hearts 
when present throughout the experimental period. Insulin further seems unable to 
evoke cardioprotection when administered prior to and during the ischaemic period 
only (Jonassen et al. 2001). However pre-treating isolated hearts with insulin as a 
pre-conditioning stimulus (Fuglesteg et al. 2009), or merely administering insulin for 5 
minutes followed by a 10 minute washout period prior to regional ischaemia (Baines 
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et al. 1999) significantly reduced myocardial infarct size in response to simulated AMI 
ex vivo. This elaborate body of evidence indicates that insulin exerts its 
cardioprotective effects predominantly during reperfusion. Jonassen et al. (2001) 
further determined that the initial 15 minute reperfusion phase is a pivotal period 
during which insulin exerts its cardioprotective effects.  
 
Some of insulin’s cardioprotective mechanisms have been unraveled and include 
early activation of PKB/AKT and p70s6 kinase during reperfusion (Jonassen et al. 
2001), activation of the KATP channel (established with a non-selective KATP 
antagonist) (LaDisa et al. 2004), improved re-synthesis of myocardial high energy 
phosphates upon reperfusion (Nawata et al. 2002), exerting anti-adrenergic effects in 
response to β-adrenergic stimulation (Yu et al. 2008), inhibiting peroxynitrate 
formation (Ji et al. 2010) and activation of Signal Transducer and Activator of 
Transcription 3 (STAT3) (Fuglesteg et al. 2008). Insulin has been shown to reduce 
neonatal cardiomyocyte apoptosis during hypoxia by attenuating caspase-3 cleavage 
in the absence of glucose (Morisco et al. 2007). Although improved glucose uptake 
and glycolytic flux rates can induce cardioprotection (Malhotra and Brosius, 1999), 
additional signaling mechanisms seem to be important in the overall cardioprotective 
effect. As far as we know, only Nawata et al. (2002) (streptozotocin induced type I 
diabetes) and Hafstad et al. (2007) (in diabetic db/db mice) have demonstrated a 
cardioprotective role for insulin in diseased animal models. A cardioprotective role for 
insulin has yet to be demonstrated in diet-induced obese insulin resistant animals. As 
such additional studies are warranted investigating the cardioprotective role of insulin 
in diseased animal models. 
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2.8 Hypotheses and objectives  
 
In view of the literature and the various controversies regarding the cardiovascular 
effects of obesity that were described in the previous sections, a few research 
questions were identified requiring further investigation.  
 
The general aim of the current dissertation is to determine the impact of obesity on 
cardiac function, myocardial sensitivity to insulin administration, substrate 
metabolism, mitochondrial function and susceptibility to ischaemia/reperfusion injury. 
The impact of an insulin sensitizing/lipid lowering PPARα agonist (K-111) on these 
parameters will also be investigated. 
 
For this study, we have developed the following hypotheses: 
 
1) Protracted obesity is associated with compromised in vivo and ex vivo cardiac 
function.  
 
2) Isolated hearts from obese animals are less responsive to insulin 
administration than hearts from lean control animals. 
 
3) Insulin present at normal physiological concentrations confers cardio-
protection from myocardial ischaemia/reperfusion injury in healthy animals, 
while its protective efficacy is reduced in obese animals. 
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4) Under comparable perfusion/substrate conditions, hearts from obese animals 
exhibit altered myocardial substrate metabolism, mitochondrial respiration and 
increased susceptibility to ischaemia/reperfusion injury.  
 
5) Under comparable perfusion/substrate conditions, hearts from animals 
subjected to chronic PPARα agonist treatment are able to improve myocardial 
substrate metabolism and mitochondrial respiration which is associated with 
reduced myocardial susceptibility to ischaemia/reperfusion injury.  
 
To address these hypotheses, we made use of a pre-diabetic rodent model of diet-
induced obesity which is characterized by general and visceral obesity, systemic 
insulin resistance and dyslipidaemia. 
 
Our objectives were to determine:  
 
1) The impact of protracted obesity on in vivo and ex vivo cardiac mechanical 
function. 
 
2) The responsiveness of hearts isolated from control and obese insulin resistant 
animals to insulin administration and the impact thereof on the myocardial 
susceptibility to ischaemia/reperfusion injury and the role of the substrate 
present. 
 
3) The impact of obesity and chronic PPARα agonist treatment on ex vivo 
cardiac function, substrate metabolism, mitochondrial function and 
susceptibility to ischaemia/reperfusion injury. 
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CHAPTER 3 
GENERAL MATERIALS AND METHODS USED FOR STUDIES 1, 2 and 3 
 
In this chapter details are given regarding the animals and their diet as well as the 
techniques routinely used throughout this study. Further details regarding the various 
study designs, protocols, experimental procedures and results are given in the 
subsequent chapters. 
 
3.1.1 Animals 
All studies were performed according to the guidelines set by the Principles of 
Laboratory Animal Care of the South African Medical Research Council and the 
Guide for the Care and use of Laboratory Animals of the National Academy of 
Sciences (NIH publication no 80-23. revised 1985) and were approved by the 
Committee for Experimental Animal Research of the Faculty of Health Sciences of 
the University of Stellenbosch (P06/10/016). 
 
Male Wistar rats were used in all three studies and housed in the Central Research 
Facility (AAALAC accredited), Faculty of Health Sciences, University of Stellenbosch. 
The holding rooms had a 12-hour artificial day-night cycle, while temperature and 
humidity were constantly maintained at 22°C and 40% respectively. The animals 
were weaned at 4 weeks of age and allowed free access to food and water. 
 
3.1.2 The experimental diet 
A central component to all the studies performed in this thesis was the high caloric 
diet (HCD), which has been reported to facilitate hyperphagia-induced obesity in rats 
(Pickavance et al. 1999). The macronutrient composition of the HCD was reported to 
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consist of 65% carbohydrates, 19% protein and 16% fat, while the standard rat chow 
(SRC) contained 60% carbohydrate, 30% protein and 10% fat (Pickavance et al. 
1999). The HCD consisted of 33% SRC, 33% condensed milk (clover), 7% sucrose 
and 27% water (Pickavance et al. 1999). As the HCD promoted hyperphagia, these 
rats had a higher average daily energy consumption compared to the SRC group (Du 
Toit et al. 2005). 
 
 SRC HCD 
Food consumption:  29 g/day 57 g/day 
Energy content 13.1 kJ/g 10.1 kJ/g 
Energy consumption per day 379.9 kJ 575.7 kJ 
(Food consumption x energy content) 
 
Due to the condensed milk present in the HCD, the experimental group (later referred 
to as the obese or the HCD fed group) received fresh food daily to avoid fermentation 
of the food.  
 
The experimental group was placed on the HCD when age matched rats weighed 
between 180-200g. Details regarding the length of feeding will be provided in the 
upcoming chapters. 
 
3.1.3 Isolated heart perfusions  
Isolated rat heart perfusions formed a fundamental component of all the studies 
presented in this thesis. In all cases, hearts were rapidly excised from anaesthetized 
animals (sodium pentobarbitone 60 mg/kg) and immediately placed in ice-cold Krebs-
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Henseleit buffer. Within 60 seconds of excision, the hearts were mounted on the 
appropriate perfusion apparatus for the respective interventions. 
 
3.1.3.1 Perfusion buffer 
All perfusions were performed with a standard Krebs-Henseleit buffer (118.46mM 
NaCl, 25mM NaHCO3, 4.75mM KCl, 1.19mM KH2PO4, 1.19mM MgSO4.7H2O, 
1.25mM CaCl2.2H2O and 10mM glucose (Merck Pty.Ltd., Darmstadt, Germany)) 
which was at times supplemented with insulin (Eli Lilly and Company, Indianapolis, 
IN 46285, USA) and/or fatty acid (FA) (palmitic acid (Sigma-Aldrich, St.Louis, MO)). 
The perfusion protocols employed used different concentrations of insulin and/or FA 
to simulate the specific in vivo plasma insulin and FA content of each group of 
animals. Based on the in vivo insulin and FA concentration obtained in control and 
obese rats, the following perfusion buffer modifications were utilized (unless 
otherwise stated) – Control animals: 30μIU/ml insulin, 0.7mM FA; Obese animals: 
50μIU/ml insulin, 1.5mM FA (See Table 5.2). Fresh perfusion buffer was prepared 
daily and gassed with a mixture of 95% O2 and 5% CO2 before being filtered through 
a 0.45μm mixed cellulose ester pore filter (Advantec MFS Inc, Pleasanton USA). The 
perfusate was further oxygenated with the same gas mixture within the perfusion 
apparatus for the duration of the experimental protocol. 
 
3.1.3.2 Preparation of the FA perfusion buffer 
The preparation of the FA perfusion buffer was performed according to the guidelines 
set out by Lopaschuk and Barr (1997). 
 
Due to the abundance of palmitic acid in the serum of HCD fed rats (Huisamen et al. 
unpublished data), it was decided to used palmitic acid as the FA in the perfusion 
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buffer. Palmitic acid (which contributed 0.4mM or 1.2mM to the total FA 
concentration) was brought into solution with 0.5mM or 1.5mM sodium carbonate 
respectively, 95% ethanol and heat. After the majority of the ethanol had boiled away 
(as determined by carefully smelling the mixture for the presence of ethanol) the 
palmitate solution was carefully added to a warm solution of Krebs-Henseleit buffer 
containing 3% (final concentration) bovine serum albumin (Bovine serum albumin, 
Fraction V, Roche, Germany). Prior determination with gas chromatography showed 
that the bovine serum albumin contributed an additional 3mM to the total FA 
concentration of the perfusion mixture. The concentrated FA perfusion buffer was 
subsequently dialyzed (Spectra/Por dialysis tubing (MW cut-off 6000-8000) Thomas 
Scientific, USA) overnight in 9.5 volumes of glucose free Krebs-Henseleit buffer to 
saturate the calcium binding sites of albumin and to allow excess ethanol to diffuse 
into the Krebs buffer (Lopaschuk and Barr, 1997). The following day the dialyzed FA 
solution was diluted with Krebs-Henseleit buffer to the final working volume. At this 
point 10mM glucose and insulin were added to the perfusion buffer after which the 
solution was filtered through Whatman #1 (Whatman Ltd, England) filter paper. The 
final FA perfusion buffer therefore consisted of Krebs-Henseleit buffer and 0.7mM or 
1.5mM FA and 30 or 50µIU/ml insulin.  
 
 3.1.3.3 Motivation for the concentrations of insulin and glucose used 
Both the insulin (30 or 50µIU/ml) and the FA (0.7mM or 1.5mM) concentrations used 
in the various perfusion buffers were determined to be relevant to the in vivo 
conditions of the animals used (Table 5.2). In the absence of insulin, many studies 
use 0.8mM or 1.2mM FA in combination with 10/11mM glucose in the perfusion 
buffer. However, when insulin is used together with glucose, the glucose 
concentration is normally reduced to 5mM. It is however worth mentioning that when 
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hearts are perfused with 5mM glucose, insulin and FA, the insulin concentrations are 
at times higher (3-fold higher in certain cases) (Wilson et al. 2007; Zhang et al. 2010) 
than those used in the current study. Despite this a number of authors have 
determined cardiac substrate metabolism in normal and insulin resistant animals in 
the presence of 11mM glucose, insulin (140µIU/ml or 2000 μIU/ml) and FA (0.4mM or 
1mM) (Lopaschuk et al. 1991; Buchanan et al. 2005). Consequently we decided to 
continue with 10mM glucose in the presence of different concentrations of insulin (30 
or 50μIU/ml) and FA (0.7 or 1.5mM) in our experiments as: 1) the insulin 
concentrations used in our study were lower than those used by the previously listed 
authors and 2) to limit the amount of variation between our perfusion protocols 
(Krebs-Henseleit perfusion vs. Krebs-Henseleit + FA + insulin perfusion).  
 
3.1.4 Comparisons between the isolated working rat heart perfusion apparatus 
and the Langendorff perfusion apparatus (balloon model) 
Throughout this thesis, reference will be made to both the isolated working rat heart 
perfusion apparatus and the Langendorff perfusion apparatus. Here the fundamental 
differences between these two perfusion models are highlighted. 
 
Stellenbosch University http://scholar.sun.ac.za
78 
 
 
Figure 3.1: Schematic representation of the direction of perfusion buffer flow in 
the isolated working rat heart perfusion apparatus (a), and the isolated 
Langendorff perfusion apparatus (balloon model) (b).  
LA – left atrium; LV – left ventricle 
 
The isolated working rat heart perfusion apparatus used in our experiments was 
based on the model originally described by Neely et al. (1967) and modified by Opie 
et al. (1971). It allows for perfusion of the isolated heart in a working mode (Figure 
3.1a). The aorta of the heart is mounted on the aortic cannula where it immediately 
receives retrograde perfusion in the Langendorff mode. Excess tissue is trimmed off 
from the heart. The left atrium is subsequently cannulated through one of the 
pulmonary veins via the working heart left atrial cannula.  Using a set of stopcocks, 
the perfusion of the heart can be switched between retrograde/Langendorff and 
working heart perfusion/mode at the appropriate times. During the working mode of 
heart perfusion, buffer enters the left atrium via the left atrial cannula of the working 
heart perfusion apparatus and is subsequently pumped out by the left ventricle 
through the aorta. The preload placed on the heart during working heart mode is 
determined by the height of the overflow of the working heart bubble trap supplying 
A 
100 cm 
afterload 
B 
LV 
LV 
LA LA 
100 cm 
preload 
15 cm 
preload 
Direction of 
flow 
Coronary 
artery   
Coronary 
artery 
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the left atrium. For rat hearts, the preload is normally fixed at 15cm H2O, but may be 
adjusted if required. Increasing the preload would be an attempt to simulate clinical 
situations such as volume overload (as seen in obesity), or increased venous return 
(as evident in exercise).  
 
The isolated Langendorff perfusion apparatus was originally described by Oskar 
Langendorff (Langendorff et al. 1895). Isolated hearts are mounted onto the aortic 
cannula of the Langendorff perfusion apparatus (Figure 3.1b) and retrogradely 
perfused. Once the excess tissue has been removed, a water filled balloon (latex or 
plastic where appropriate) tipped cannula is inserted via the atrium directly into the 
left ventricle via the pulmonary veins. Once positioned correctly, the balloon is filled 
with fluid via a syringe attached to the line connecting the cannula to the pressure 
transducer. The force of contraction and relaxation exerted by the left ventricle on the 
balloon generates a pressure that is converted to an electrical signal by the pressure 
transducer.    
 
An important fundamental difference exists regarding the myocardial workload being 
performed during working heart perfusion and Langendorff mode perfusion of the 
isolated heart. During working heart mode perfusion, perfusate enters the left atrium, 
is expelled by the atrium into the left ventricle, which once it contracts pumps the 
perfusate out via the aorta. In contrast, when the heart is retrogradely perfused, 
perfusate never enters the left atrium or ventricle as the aortic valve remains closed. 
The perfusate merely enters the coronary circulation due to retrograde flow of buffer 
down the aorta thus supplying the heart with essential nutrients and oxygen. The 
workload and the metabolic requirements placed on the heart are therefore greater 
during working heart mode perfusion than during Langendorff mode.  
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Both the isolated working heart and Langendorff perfusion apparatus are well suited 
to provide information regarding LV mechanical function. During the working heart 
mode (isolated working heart apparatus), buffer is expelled through the aorta as 
previously described. The expelled buffer represents the aortic output of the heart. 
The buffer that is ejected against the 100cm H2O afterload is collected in a graded 
measuring cylinder over a period of time allowing the aortic output of the heart to be 
measured in ml/min. Aortic output closely reflects the LV mechanical function of the 
in vivo heart. Coronary flow is also manually measured, and as the name indicates, is 
the volume of fluid that is drained from the coronary circulation. On the working heart 
perfusion system, a side arm from the aortic cannula is connected to a pressure 
transducer, which in turn is connected to a computer. From this device, 
measurements for peak systolic/diastolic aortic pressure, heart rate, work total, and 
aortic dP/dtmax/min are monitored and documented. 
 
When using the Langendorff perfusion apparatus a water filled balloon tipped 
cannula is inserted into the left ventricle. The cannula is connected to a pressure 
transducer which converts the pressure changes to signals that are then displayed 
on the computer monitor, thus allowing myocardial isovolumic contractile function to 
be monitored. In this way, both heart rate and the LV developed pressure can be 
determined, the product of which is termed the rate pressure product, which 
represents the major functional parameter assessed on the Langendorff perfusion 
apparatus. The coronary flow is also measured as described previously. 
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3.1.4.1 Myocardial temperature control during the isolated heart 
perfusions 
Once the heart is mounted and heart perfusion initiated, a small incision is made into 
the coronary sinus through which a temperature probe can be inserted. A water bath 
(Grant instruments, Cambridge, England) maintains the temperature of the perfusate 
by re-circulating warm water through the water-jacketed glassware of the perfusion 
system. A separate water bath (Grant instruments, Cambridge, England) is used to 
maintain the temperature of the water-jacket surrounding the perfused heart.  
  
During the experimental procedures of the current study, the following myocardial 
temperatures were maintained for the various stages of the perfusion protocols: 1) 
Working heart apparatus: Langendorff mode: 34.5°C-35.6°C; Working heart mode: 
36.0°C-37.0°C and regional ischaemia 35.8-36.3°C; 2) Langendorff perfusion 
apparatus: Langendorff mode: 36.5°C-37.0°C; global ischaemia 36.0°C-36.5°C.   
 
Circulation of the buffer through the perfusion system was maintained by a peristaltic 
pump (Watson Marlow Ltd, UK). 
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CHAPTER 4 
METHODS AND RESULTS FOR STUDY 1 
AN IN VIVO AND EX VIVO INVESTIGATION ON THE IMPACT OF PROTRACTED 
OBESITY ON MYOCARDIAL MECHANICAL FUNCTION 
 
4.1 Aim of the study 
 
The aim of this sub-study was to determine the impact of protracted obesity on in 
vivo and ex vivo myocardial function in control and obese animals. The contributory 
role of insulin and FA to LV mechanical function was also investigated. 
 
4.2 Methods 
 
4.2.1 Study design  
To determine the consequences of obesity on in vivo and ex vivo myocardial LV 
mechanical function, the feeding regime of our existing model of diet induced obesity 
(Du Toit et al. 2005; Clark et al. 2011) was extended from 16/18 weeks to 32 weeks 
of feeding to exacerbate any potential myocardial functional consequences related to 
obesity. The feeding period was of a similar duration to the “long term” feeding period 
utilized by Wilson et al. (2007) who documented ex vivo myocardial dysfunction in 
isolated hearts from rats fed a Western diet for 32-48 weeks. 
 
Age and weight matched rats weighing 190±10g, were randomly assigned to control 
or experimental groups and fed either a SRC or a HCD respectively for 32 weeks. 
Upon completion of the feeding period, myocardial mechanical function was 
determined using either standard echocardiography techniques (in vivo) or isolated 
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heart perfusions (ex vivo). A separate series of animals was used for each 
determination (echocardiography, isolated Langendorff perfusions and isolated 
working heart perfusions). The importance of glucose and simulated in vivo 
concentrations of insulin and FA on myocardial LV mechanical function was 
assessed using isolated heart perfusions. Different animals were used for each 
different perfusion condition. Random measurements of body weight, retroperitoneal 
and gonadal fat mass and tibia lengths were measured and following the completion 
of the experimental protocol, heart weights (wet weight) were determined. To 
determine the influence of long term HCD consumption on the blood lipid profile and 
glucose and insulin concentrations following the 32 week feeding period, a separate 
series of animals was fasted overnight (duration of fast not documented) and blood 
was collected. 
 
4.2.2 In vivo assessment of LV mechanical function  
4.2.2.1 Echocardiography 
In vivo LV systolic function was determined by two-dimensional targeted M-mode 
echocardiography using a 7.5 MHz transducer and a Hewlett Packard Sonos 2500 
sector scanner according to the guidelines set by the American Society of 
Echocardiography convention and as previously described by Norton et al. (2002). 
Rats were anaesthetized with a combination of ketamine and xylazine (Norton et al. 
2002) and echocardiography was performed blinded, and in a random order by a 
single observer. Two images were obtained from each rat and mean values for LV 
end-diastolic diameter (LVEDD), end-systolic diameter (LVESD) and posterior wall 
thickness (PWT) were determined. These variables were measured using the leading 
edge technique (Norton et al. 2002). To assess LV functional reserve of the animals, 
0.01 mg/kg isoproterenol HCl (Sigma-Aldrich, St.Louis, MO) was injected 
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intraperitoneally and LV functional measurements were documented at regular 
intervals for 30 minutes. 
 
LV systolic chamber function was determined from the LV endocardial fractional 
shortening (LV FSend) and LV systolic myocardial function from the LV midwall 
fractional shortening (LV FSmid). These parameters were calculated as previously 
described by Norton et al. (2002).   
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Figure 4.1: A typical echocardiograph indicating the dimensions of the rat heart 
that were measured 
 A: The scale given on the original print-out was 3 cm between the markings 
(circles). However since the image had been enlarged, the scale had to be 
adjusted accordingly. 
 B: indicates the ESD 
 C: indicates the EDD 
 D: indicates the PWTsyst 
 E: indicates the PWTdiast 
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The various echocardiographic parameters were calculated as follows: 
 Endocardial fractional shortening (FSend) was calculated from:  
 ((EDD - ESD) / EDD)) x 100. 
 Midwall fractional shortening (FSmid) was calculated from:    
(((EDD + PWTdiast) – (ESD + PWTsyst)) / (EDD + PWTdiast)) x 100 
 Posterior wall thickening was calculated from:      
((PWTsyst - PWTdiast) / (PWTdiast)) x 100 
  
4.2.3 Ex vivo assessment of LV mechanical function 
To assess the importance of simulated in vivo concentrations of insulin and FA, on 
myocardial mechanical function, LV function was assessed ex vivo on both the 
isolated Langendorff perfusion apparatus and the isolated working rat heart perfusion 
apparatus. The Langendorff, isovolumetric, constant coronary flow model allowed for 
the measurement of LV intrinsic myocardial mechanical function independent of 
different loading conditions and possible alterations in obesity related coronary flow 
rate. In contrast, the isolated working heart model was used to assess LV mechanical 
function on a working heart which has a coronary flow rate which is dictated by 
intrinsic vascular tone of the coronary arteries. 
 
4.2.3.1 Isolated Langendorff perfusions (Balloon model) 
Hearts were perfused with standard Krebs-Henseleit perfusion buffer containing 
glucose (10mM) as the only substrate. To determine the impact of insulin on LV 
mechanical performance, a separate series of hearts was used and the perfusate 
supplemented with the relevant in vivo concentrations of insulin (Control: 30μIU/ml; 
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Obese: 50μIU/ml). Only the effect of insulin on LV mechanical function was assessed 
in this model. 
 
Once hearts were mounted, the coronary flow rate was determined volumetrically and 
adjusted to achieve a constant flow rate of 12 ml/min/g heart weight. The hearts were 
paced at 300bpm with platinum wire electrodes attached to the left atrium and the 
apex of the heart with the voltage set at 10% above threshold. A water-filled balloon-
tipped cannula coupled to a pressure transducer was inserted into the LV cavity and 
after an initial 10 minute stabilization period LV developed pressure was determined. 
A thin-walled latex balloon with a zero pressure filling volume beyond maximum LV 
lumen capacities was selected for this study to avoid the stiffness of the balloon wall 
contributing to LV pressure at higher filling volumes. The volume of the balloon was 
assessed with a water-displacement technique, and the same balloon was used for 
each heart. A micromanipulator was used to incrementally increase LV filling volumes 
to values that resulted in no further change in LV developed pressure. LV pressures 
were determined at as many multiple small increments in volume as were practically 
possible to improve the accuracy of curve fitting during later analysis. A range of LV 
pressures and volumes were determined in hearts perfused with glucose, or glucose 
together with the relevant in vivo concentration of insulin. 
Peak LV systolic function was determined in isolated hearts from a separate series of 
animals under similar perfusion conditions as described above. This was achieved by 
the addition of isoproterenol HCL (10-8mM) (Sigma-Aldrich, St.Louis, MO) to the 
perfusate. The load-independent LV systolic chamber performance was then 
determined from the slope of the peak LV systolic pressure-volume curve generated, 
(LV end-systolic elastance (LV Ees)).  
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4.2.3.2 Isolated working heart perfusions  
To further assess the impact of physiological concentrations of insulin and FA on LV 
mechanical function, hearts were either perfused with a standard Krebs-Henseleit 
perfusion buffer (see 3.1.3) containing glucose (10mM) or supplemented with 
different combinations of insulin and or FA. The simulated in vivo concentrations of 
insulin and FA used for the different groups were as follows: Control - 30μIU/ml 
insulin, 0.7mM FA; Obese: 50μIU/ml insulin, 1.5mM FA (see 3.1.3). When FA’s were 
present in the perfusion buffer, the perfusate (200ml) was continuously re-circulated. 
It was not expected that re-circulating the buffer would influence myocardial function 
as hearts perfused under these conditions were able to maintain normal working 
heart function for up to one hour (preliminary investigations). Furthermore, it was 
thought that the 200ml re-circulating volume was sufficient to buffer possible 
contributory effects of substrate metabolic by-products on cardiac function. 
 
Once mounted on the perfusion apparatus, hearts were retrogradely perfused for an 
initial 10 minute stabilization period. The perfusion was then changed to working 
heart mode with the preload set at 15cm H2O. A further 10 minute stabilization period 
was initiated under these conditions. To assess myocardial functional reserve under 
the various perfusion conditions, the preload was incrementally increased from 15cm 
to 17.5cm and then to 20cm H2O at 5 minute intervals. Aortic output was documented 
at the end of each perfusion period of a particular filling pressure. Thus, aortic output 
was measured at various preloads, with different combinations of insulin and FA in 
the perfusate.  
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4.2.4 Biometric measurements 
4.2.4.1 Determination of retroperitoneal and gonadal fat content 
After the heart was removed, abdominal incisions were made to access the 
abdominal fat depots. Both the retroperitoneal and gonadal fat depots were removed 
and weighted. 
 
4.2.4.2 Indices of cardiac hypertrophy 
4.2.4.2.1 Ventricular weight to tibia length ratio 
Yin et al. (1982) demonstrated that the ventricular weight to tibia length ratio was a 
far more accurate index to reliably identifying cardiac hypertrophy than the ventricular 
weight to body weight ratio in models where weight fluctuations (such as due to 
aging) were prevalent. 
Measurements of ventricular weight to tibia length ratio were collected at random. 
The tibia was cleaned off and the length measured with a caliper and expressed as a 
ratio to the heart weight. 
 
4.2.5 Biochemical analysis 
4.2.5.1 Blood sample collection 
Unless otherwise stated, blood samples were collected from the thoracic cavity of 
rats following the excision of their hearts. Blood was transferred directly into a 
specific BD Vaccutainer (Lasec SA, Cape Town, South Africa). For whole blood 
analysis, BD Vaccutainer’s containing anticoagulant was used. When serum was 
required for biochemical determinations, BD Vaccutainer’s specific for serum 
separation were used. In these cases the tubes were centrifuged at 3000rpm at 4ºC 
for 10 minutes according to the manufacturer’s instructions. The separated serum 
was aliquoted into tubes and stored at -80 ºC until required for specific assays. 
Stellenbosch University http://scholar.sun.ac.za
90 
 
4.2.5.2 Blood determinations 
4.2.5.2.1 Blood glucose  
Fasting blood glucose levels provide valuable information regarding steady state 
glucose levels. Raised blood glucose levels during post-prandial conditions allude to 
either a failure of normal or elevated levels of insulin to maintain normal blood 
glucose levels, or insufficient insulin being produced. Elevated blood glucose levels 
are further a characteristic of type II diabetes. 
 
Fasting glucose values were determined by placing a drop of blood onto the provided 
absorbent film of a slip/cassette that was inserted into a glucometer (Gluco PlusTM; 
distributed by Cipla Dibcare, Bellville, South Africa). 
 
4.2.5.2.2 HbA1c  
The measurement of HbA1c is a clinical endpoint used to determine the efficiency of 
blood glucose management of the body over a 3 month period. HbA1c is a specific 
subtype of haemoglobin A.  Once the rat (non-fasted) had been anaesthetized an 
incision was made into the hind limb exposing the femoral vein which was then 
heparinised. A few minutes later, blood was collected and taken to the Department of 
Chemical Pathology of Tygerberg Hospital, for further analysis. 
 
Principle of Determination 
Glucose binds (or glycosylates) haemoglobin in the erythrocyte to form the A1c 
subtype, over a period of time. The decomposition of HbA1c occurs very slowly and 
therefore strongly correlates with the average blood glucose levels over the previous 
3 months. When the percentage glycosylated haemoglobin is under 7 %, one may 
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correctly assume that the animal’s blood glucose levels were normal over the 
previous 3 months.   
 
4.2.5.2.3 Blood lipids 
Similarly to blood glucose determinations, a drop of blood from fasted animals was 
placed onto the absorbent film of a PTS strip/cassette which was inserted into a 
CardioCheck instrument (CardioCheck™, Polymer Technology Systems Inc, 
Indianapolis, USA) which quantified total cholesterol, triglyceride and HDL-C levels. 
 
4.2.5.3 Serum determinations 
4.2.5.3.1 Insulin levels 
Serum samples from fasting animals were stored at -80 ºC and were used to 
determine insulin levels by means of competitive radioimmunoassay (Coat-A-Count ® 
Insulin, Diagnostic Products Corporation, LA, USA).  
 
Kit Principle 
A set amount of radio-labelled (125I) insulin competes with the insulin present in the 
serum sample for antibody binding sites specific for insulin. As the walls of the 
provided polypropylene tubes are coated with antibody, decanting the tubes following 
the incubation period isolates the antibody bound fraction containing radio-labelled 
and sample insulin.  
 
Once the assay was completed, the amount of radioactivity was measured with a 
gamma scintillation counter (Cobra II Auto Gamma, A.D.P, South Africa) and the 
specific insulin concentrations determined using a standard curve obtained from 
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known insulin concentrations. Calculations were performed using the appropriate 
computer software. 
 
4.2.6 Statistical analysis 
 
All data are presented as means ± the standard error of the mean. Means were 
considered to be statistically significant from each other when the p-value was 
smaller or equal to 0.05. Statistical comparisons between control and obese animals 
were determined with an unpaired Students t-test. Comparisons of in vivo functional 
data were assessed with a one-way ANOVA followed by the Bonferroni post-test. For 
multiple comparisons between various groups a two-way ANOVA (repeated 
measures where appropriate) was applied followed by the Bonferroni post-test 
(except for the retrograde perfusions where a Tukey post-test was performed). 
Statistical Analysis was performed on Graph Pad Prism 4 and 5 software. 
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RESULTS: STUDY 1 
 
4.3 Results 
4.3.1 Biometric data 
Table 4.1: Biometric data of control and obese animals 
 Control Obese 
Body weights (g) 550±16 (n=15) 673±19 * (n=15) 
retroperitoneal and 
gonadal fat weight (g) 
27.20±0.89 (n=12) 54.6±2.50 * (n=15) 
VW weights (g) 1.10±0.01 (n=13) 1.27±0.02 * (n= 13) 
VW/TL (mg/mm) 24.90±0.18   (n=13) 28.95±0.50 * (n=13) 
VW – ventricle weight; TL – tibia length 
*p<0.05 control vs. obese group 
 
Consumption of a HCD for 32 weeks induced a 22% increase in body weight 
compared to rats fed a SRC diet (Table 4.1) (p<0.05). Similarly the HCD fed group 
had more retroperitoneal and gonadal fat content. In addition HCD fed rats had 
greater VW’s while their VW/TL ratio’s were also significantly greater than the 
corresponding values observed in the SRC fed group (p<0.05).  
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4.3.2 Metabolic data  
Table 4.2: Metabolic data of control and obese animals that were fasted 
overnight. HbA1c levels were determined from non-fasted animals 
 Control Obese 
Glucose (mmol/l) 7.13±0.37 (n=10) 7.61±0.42 (n= 13) 
Insulin (IU/ml) 33.50±6.07 (n=7) 54.40±7.60 * (n=10) 
HbA1c (%) 4.13±0.16 (n=6) 4.10±0.02 (n=6) 
Triglycerides (mmol/l) 0.62±0.08 (n=6) 1.25±0.09 * (n=6 ) 
Total cholesterol (mmol/l) 1.60±0.26 (n=6) 1.83±0.19 (n=6) 
HDL-C (mmol/l) 0.40±0.06 (n=6 ) 0.50±0.07 (n= 6) 
HbA1c – glycosylated haemoglobin; HDL-C – high density lipoprotein 
cholesterol.  
*p<0.05 vs. control 
After 32 weeks of feeding, blood glucose levels were comparable between the 
control and obese groups, however obese animals had significantly higher serum 
insulin levels compared to the control group (p<0.05) (Table 4.2). As glucose and 
insulin determinations were not obtained in the same animals in all cases the 
homeostasis model assessment index for insulin resistance (HOMA-IR) could not be 
calculated, but by studying the means of these groups and comparing them to similar 
data presented in table 5.2 and 6.2, obese animals in this study could be regarded as 
being insulin resistant. Additionally, as the HbA1c values of the two groups were 
comparable, it can be concluded that 32 weeks of HCD feeding was sufficient to 
induce systemic insulin resistance but not type II diabetes. Furthermore, blood Trig 
levels were significantly elevated in obese animals while there was no difference in 
total cholesterol and HDL-C between the groups. 
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4.3.3 In vivo and ex vivo myocardial functional data 
4.3.3.1 In vivo myocardial LV dimensions and mechanical function 
Table 4.3: LV dimensions determined echocardiographically in control and 
obese animals  
 Control (n=5) Obese (n=5) 
LVEDD (cm) 0.80±0.02 0.81±0.03 
LVESD (cm) 0.52±0.03 0.48±0.03 
LV PWT (cm) 0.67±0.09 0.73±0.07 
LVEDD – left ventricular end diastolic diameter; LVESD – left ventricular end 
systolic diameter; LVPWT – left ventricular posterior wall thickness. 
 
Echocardiograph measurements of the various LV dimensions were comparable 
between control and obese animals (Table 4.3). There was no evidence of LV 
remodelling present in the obese group (LV PWT, p>0.05) despite a greater VW/TL 
ratio, indicative of enhanced cardiac mass, in a similar obese group (Table 4.1). The 
absence of significant differences in LV PWT may be due to the small sample size 
used for the in vivo determinations.  
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Figure 4.2: The effect of isoproterenol administration on in vivo LV chamber (a) 
and intrinsic myocardial (b) function in hearts from control and obese animals. 
FSend – endocardial fractional shortening; FSmid – midwall fractional 
shortening. 
#p<0.001 vs. Baseline for both groups 
n = 5 rats per group 
 
Echocardiography assessments of control and obese animals during resting 
conditions revealed similar LV chamber (Figure 4.2a) and intrinsic myocardial (Figure 
4.2b) function between these groups. In response to β-adrenergic receptor 
stimulation (0.01 mg/kg isoproterenol-HCl intraperitoneal injection) both the control 
and obese animals were able to significantly increase their FSend and FSmid to the 
same degree. Under resting and increased myocardial workload conditions, obese 
animals were thus able to functionally (LV chamber and intrinsic myocardial 
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functional measurements) match their control counterparts suggesting the absence 
of any form of myocardial dysfunction in the obese animals after 32 weeks HCD 
feeding.  
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4.3.3.2 Ex vivo functional determinations 
  4.3.3.2.1 Isolated Langendorff perfusions  
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Figure 4.3a: The impact of simulated in vivo concentrations of insulin (Control: 
30μIU/ml; Obese: 50μIU/ml) on LV systolic chamber function assessed at 
different LV preloads in retrogradely perfused hearts isolated from control and 
obese animals. Ins – insulin.   
n = 8 hearts per group   
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Figure 4.3b: The impact of β-adrenergic receptor stimulation on LV systolic 
chamber function assessed at different LV preloads in retrogradely perfused 
hearts isolated from control and obese animals. Iso – isoproterenol. 
*p<0.05 control vs. control + Iso 
n = 8 hearts per group   
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Figure 4.3c: The impact of β-adrenergic receptor stimulation and simulated in 
vivo concentrations of insulin (Control: 30μIU/ml; Obese: 50μIU/ml) on LV 
systolic chamber function assessed at different LV preloads in retrogradely 
perfused hearts isolated from control and obese animals. Ins – insulin; Iso – 
isoproterenol. 
*p<0.05 control vs. control + Ins +Iso  
@p<0.05 obese vs. obese + Ins + Iso  
n = 8 hearts per group   
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Figure 4.3d: The impact of β-adrenergic receptor stimulation and simulated in 
vivo concentrations of insulin (Control: 30μIU/ml; Obese: 50μIU/ml) on the 
slope of the pressure volume relations (LV Ees) generated in Figure 4.3c in 
hearts isolated from control and obese rats. 
*p<0.05 vs. Control; p<0.05 vs. Obese – Insulin 
n = 8 hearts per group   
 
Isolated retrograde perfused hearts from control and obese animals generated 
comparable pressure volume curves indicative of normal LV systolic chamber 
function in these groups. This finding was comparable to that observed in vivo 
(Figure 4.3a (resting conditions)). Significantly, perfusing hearts with their respective 
in vivo concentrations of insulin did not alter the pressure volume curves generated 
indicating that insulin did not elicit a positive inotropic response in retrogradely 
perfused hearts (Figure 4.3a). Interestingly, when the myocardial metabolic demand 
was increased through the addition of isoproterenol (β-adrenergic receptor 
stimulation) to the perfusate, hearts from the control group were able to significantly 
increase their LV systolic chamber function at the higher filling volumes (p<0.05) 
compared to untreated controls hearts perfused in the absence of isoproterenol. 
These findings mimicked what was observed in vivo following the isoproterenol 
*

Control  Obese 
Insulin 
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injection. In strong contrast to the control group, in the presence of isoproterenol, 
isolated hearts from obese animals were unable to significantly increase their LV 
developed pressures at the higher LV filling volumes beyond that generated in the 
absence of isoproterenol (Figure 4.3b). However, when the respective in vivo 
concentrations of insulin were present in the perfusion buffer together with 
isoproterenol, hearts from the obese group were able to generate significantly greater 
(yet similar to controls) LV developed pressure at the higher LV filling volumes 
compared to hearts from obese animals perfused in the absence of isoproterenol and 
insulin (Figure 4.3c). This is evident when the slope of the pressure volume relations 
(LV Ees) generated in figure 4.3c was assessed (Figure 4.3d). The current finding 
alludes to an important contributory role of elevated in vivo concentrations of insulin 
in the maintenance of normal myocardial LV functional reserve in obese animals.  
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4.3.3.2.2 Isolated working heart perfusions 
The effects of 10mM glucose and different combinations of simulated in vivo 
concentrations of insulin and FA on LV mechanical function. 
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Figure 4.4: The impact of obesity and simulated in vivo concentrations of 
insulin (Control: 30μIU/ml; Obese: 50μIU/ml) and FA (Control: 0.7mM; Obese: 
1.5mM) on LV mechanical function determined in isolated working heart 
perfusions with a 15cm H2O preload. Ins – insulin; FA – fatty acid 
*p<0.05; # p<0.001 
1p<0.001 vs. obese glucose 
2p<0.01 vs. obese glucose + Ins; 3p<0.05 vs. obese glucose + Ins 
n = 6-8 hearts per group 
(Figure 4.4 was analyzed using a repeated measures two-way ANOVA where 
data from control and obese animals at all the preloads were included) 
 
Simulated in vivo concentrations of insulin, FA or the combination thereof, when 
present in the perfusate, had no effect on the aortic output generated by the control 
group in the presence of glucose alone (p<0.05) (Figure 4.4). This indicates effective 
myocardial flexibility in substrate use by the control group in maintaining optimal LV 
mechanical function. In strong contrast, glucose perfused hearts from obese animals 
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achieved significantly poorer aortic outputs compared to the control group (32.58±1.2 
vs. 46.17±0.91 ml/min; p<0.001) under comparable perfusion conditions. Although 
the addition of various factors in the perfusate had no functional impact on hearts 
from the control animals, hearts from obese animals reacted more favourably to 
simulated in vivo concentrations of insulin, FA or the combination thereof.  
 
Hearts isolated from the obese group were unable to significantly augment their 
aortic output in response to in vivo concentrations of insulin compared to obese 
hearts perfused with glucose alone (p>0.05). Of great interest was that the addition of 
FA (p<0.001) or FA and insulin (p<0.01) to the perfusion buffer enabled hearts in the 
obese group to significantly increase their aortic output above that achieved by obese 
rat hearts perfused in the presence of glucose alone or glucose and insulin. More 
importantly, only in the presence of FA or FA and insulin were hearts from the obese 
group able to achieve similar aortic outputs compared the control groups at all the 
different perfusion conditions assessed. Insulin produced no additive effect on LV 
mechanical function in the FA perfused obese group indicating that the presence of 
simulated in vivo concentrations of FA in combination with 10mM glucose, were by 
themselves sufficient to increase LV mechanical function maximally at the normal 
preload. These data demonstrate myocardial dependence (in the obese animal) on 
simulated in vivo concentrations of FA to maintain normal LV mechanical function 
during control perfusion conditions. 
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The LV functional response to increments in preload when perfused with 10mM 
glucose and different combinations of simulated in vivo concentrations of 
insulin and FA. 
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Figure 4.5a: The aortic output generated by isolated working hearts from 
control animals following incremental increases in preload when perfused with 
different combinations of 10mM glucose and simulated in vivo concentrations 
of insulin (30μIU/ml) and FA (0.7mM). Ins – insulin; FA – fatty acid. 
&p<0.001 vs. 15cm with particular substrate; %p<0.001 vs. 17.5cm with 
particular substrate; $p<0.05 vs. 17.5cm with particular substrate. 
n = 6 hearts per group 
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Figure 4.5b: The aortic output generated by isolated working hearts from obese 
animals following incremental increases in preload when perfused with 10mM 
glucose and different combinations of simulated in vivo concentrations of 
insulin (50μIU/ml), and FA (1.5mM). Ins – insulin; FA – fatty acid. 
&p<0.001 vs. 15cm; %p<0.05 vs. 15cm; $p<0.001 vs. 17.5cm; #p<0.01 vs. 17.5cm 
within the particular substrate group. 
1p<0.001 vs. glucose at the particular preload; 2p<0.01 vs. glucose at the 
particular preload; 3p<0.05 vs. glucose at the particular preload. 
4p<0.001 vs. glucose + insulin at the particular preload; 5p<0.01 vs. glucose + 
insulin at the particular preload; 6p<0.05 vs. glucose + insulin at the particular 
preload. 
n = 6-8 hearts per group. 
 
Working hearts from both control and obese animals were able to significantly 
augment aortic output in response to incremental increases in preload with all 
combinations of glucose and simulated in vivo concentrations of insulin and FA 
(Figure 4.5a, b). Hearts from the control animals were able to achieve peak aortic 
outputs (20cm preload) in the presence of all perfusion conditions.  
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In contrast to that seen in the control group, hearts from obese animals were only 
able to achieve peak aortic output at the 20cm preload when FA’s were included in 
the perfusate (in a separately conducted repeated measures two-way ANOVA, only 
the FA perfused obese groups had comparable function to the FA perfused control 
groups). This was further reflected by the significant differences in aortic output 
achieved at the 20cm preload between hearts from obese animals perfused in the 
presence of glucose + FA/FA +Ins compared with those hearts perfused with glucose 
or glucose + insulin. 
 
Technical note 
For the isolated working heart experiments conducted in this study, hearts in the 
glucose and glucose + insulin groups were paced at 280bpm. Due to an unforeseen 
problem with the pacer, subsequent perfusions in the presence of glucose + FA or 
glucose + FA + insulin were performed without pacing. The average heart rates 
during the 3 different preloads used for these groups are provided below (Table 4.4). 
According to the Guide for the care and use of experimental animals released by the 
Canadian Council on Animal Care (Olfert et al. 1993), the heart rate of a rat ranges 
between 250-450 beats per minute. In our laboratory, using the perfused working 
heart system, heart rates varied between 220 and 300bpm. 
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Table 4.4: Average heart rate (bpm) achieved during the functional experiments 
in un-paced hearts from control and obese animals in the presence 10mM 
glucose and different combinations of simulated in vivo concentrations of 
insulin and FA. Heart rates were averaged over the three different workloads 
Control Obese 
Glucose + FA 
Glucose + FA + 
insulin 
Glucose + FA 
Glucose + FA + 
insulin 
282.78±11.13 269.39±6.54 249.44±13.35 241.58±11.31 
n = 6-8 hearts per group 
 
As functional differences between the groups were assessed with a 2-Way Analysis 
of variance, we performed similar statistical analysis on the heart rate data. The heart 
rate of the groups in Table 4.4 did not differ statistically from one another although 
diet played a role in predicting lower heart rates (p=0.01). Despite this, we do not 
believe that changes in heart rate would contribute significantly to the aortic outputs 
observed as the working heart compensates for changes in heart rate by adjusting its 
stroke volume.  
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4.4 Summary of the findings 
 
LV mechanical function assessed echocardiographically was similar between control 
and obese rats at baseline and following β-adrenergic receptor stimulation indicating 
the absence of myocardial dysfunction in the obese group in vivo after long term (32 
weeks) of HCD feeding. The normal in vivo LV mechanical function and functional 
reserve observed in these obese animals occurred in the presence of elevated 
circulating levels of insulin and FFA (FFA levels are already elevated at 16 weeks 
(Table 5.2)). Hearts from the control animals were able to maintain normal LV 
mechanical function in the presence of various combinations of glucose, and 
simulated in vivo concentrations of insulin and FA in the perfusate. In contrast, ex 
vivo assessment of LV mechanical function in the obese group revealed 
compromised LV function when perfused with glucose alone. While addition of insulin 
was able to augment myocardial function in the obese group, under conditions of 
greater myocardial workload only the presence of simulated in vivo concentrations of 
FA were able to normalize baseline function and functional reserve in hearts from 
these animals. This data suggests that in the obese insulin resistant pre-diabetic 
state, the heart may rely more heavily on an elevated FFA levels as seen in vivo, to 
maintain effective LV mechanical function particularly when workload is increased. 
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CHAPTER 5 
METHODS AND RESULTS FOR STUDY 2 
THE IMPACT OF INSULIN ON GLYCOLYLTIC FLUX RATES AND INDICES OF 
ISCHAEMIA/REPERFUSION INJURY IN EX VIVO PERFUSED HEARTS 
 
5.1 Aim of the study 
 
The aim of this sub-study was to determine the responsiveness of hearts isolated 
from control and obese insulin resistant animals to insulin administration and the 
impact thereof on the myocardial susceptibility to ischaemia/reperfusion injury. 
 
5.2 Methods 
 
5.2.1 Study design  
Age matched rats weighing 190±10g were randomly fed either SRC or a HCD for 16 
weeks. After 16 weeks the rats were weighed and used accordingly. To determine 
the extent of insulin’s metabolic impact on obese and control rat hearts, isolated 
Langendorff perfused hearts were perfused with D-[5- 3H (N)]- glucose together with 
different combinations of glucose and insulin to determine the rate of myocardial 
glycolytic flux. The impact of obesity on myocardial susceptibility to 
ischaemia/reperfusion induced injury was assessed in isolated glucose perfused 
working hearts as working heart functional parameters could be monitored in addition 
to performing a standard myocardial infarction induction protocol. To determine 
whether insulin could afford cardioprotection in a model of obesity, a separate series 
of glucose perfused hearts received insulin supplementation prior to and during 
regional ischaemia. In yet another series of experiments, the glucose and insulin 
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perfusate was supplemented with FA to determine whether insulin’s post-ischaemic 
outcomes could be attenuated by the use of FA as a substrate. To assess changes in 
the blood profile induced by the HCD following 16 weeks of feeding, blood was 
collected from fasted rats (duration of fast not documented) for glucose, insulin, 
HbA1c, Trig, total cholesterol, HDL-C and FFA analyses. To assess the impact of 
obesity on cardiac morphology echocardiography analysis was employed. Lastly, 
retroperitoneal and gonadal fat was removed from animals to determine the impact of 
the HCD on retroperitoneal and gonadal fat mass. 
 
5.2.2 Determination of myocardial glycolytic flux rate  
Hearts were mounted on the Langendorff perfusion apparatus to determine the effect 
of obesity and insulin (30 or 50μIU/ml) on myocardial glycolytic flux rates. After a 10 
minute stabilization period, hearts were perfused with D-[5-[3H(N)]-glucose 
(Amersham) in the presence of insulin, and the myocardial glycolytic flux rate was 
determined by measuring the amount of 3H2O released into the coronary effluent 
following the metabolism of the D-[5-[3H(N)]-glucose. The specific buffer (100ml) 
containing D-[5-[3H(N)]-glucose was re-circulated. Coronary effluent samples were 
collected every two minutes over an eight minute period.  
 
To separate the 3H2O from the 5-[3H] glucose in the coronary effluent, collected 
samples were passed through ion exchange resin columns (200-400 mesh Dowex 
1x4 (Sigma-Aldrich, St.Louis, MO)) pre-treated with Na2B4O7. Samples (0.1ml) were 
loaded onto the column and eluted with 0.8ml H2O into scintillation vials for 
determination of radioactivity using a Beckman liquid scintillation counter (Beckman 
Instruments, USA) (for a more complete description of the methodology see section 
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6.2.4).  The glycolytic flux rates (μmol/g ww/min) determined during the eight minute 
perfusion period was averaged to obtain an average glycolytic flux rate. 
 
5.2.3 Isolated working rat heart perfusions 
Perfusion Protocol 
Isolated hearts were perfused with a standard glucose (10mM) containing Krebs-
Henseleit perfusion buffer as described previously (Section 3.1.3). Figure 5.1 
demonstrates the standard perfusion protocol used to simulate an acute myocardial 
infarction which aimed to assess ischaemia/reperfusion injury following a regional 
ischaemic episode. Briefly, hearts were retrogradely perfused in Langendorff mode 
for an initial 10 minute stabilization period after which the perfusion mode was 
changed to working heart mode for 20 minutes. During working heart mode, hearts 
would work at a preload of 15cm H2O against an afterload of 100cm H2O. At the end 
of the 20 minute working heart period functional measurements were taken. The 
perfusion was then switched to the Langendorff mode for 10 minutes prior to the 
induction of regional ischaemia. The total stabilization time prior to ischaemia was 
therefore 40 minutes. To induce an infarct, myocardial regional ischaemia was 
applied by ligating the left anterior descending (LAD) coronary artery, approximately 
3mm from the coronary sinus, with a Ethicon silk suture (black braided silk non-
absorbable suture, 3/0, 26mm ½c Taper, Johnson&Johnson Medical (PTY) LTD, 
South Africa). Occlusion of the LAD coronary artery with the suture was maintained 
for a period of 40min. After 40 minutes, the suture was released in order to reperfuse 
the ischaemic myocardium. The reperfusion phase consisted of a 10 minute 
retrograde perfusion followed by a 20 minute working heart perfusion after which 
functional parameters were again measured. At the end of the perfusion protocol the 
LAD coronary artery was re-occluded by tying the suture (i.e. 30 minutes of 
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reperfusion). The heart was stained with 0.6ml Evans blue (0.5%) injected through 
the aortic cannula, which enabled the visualization of the viable myocardium (now 
stained blue) from the area at risk and the necrotic area. Stained hearts were placed 
in a sealed plastic envelope and stored at -20°C for further analysis. The 
determination of myocardial infarct size was performed on stored hearts within a 
week of experimentation. While many laboratories utilize 2 hours of reperfusion for 
determining myocardial infarct size, in our laboratory, both 30 minutes and 2 hours 
reperfusion have yielded similar infarct sizes in control animals (Fan et al. 2009). We 
therefore used a 30 minute reperfusion period. 
 
To determine whether insulin would afford cardioprotection, the perfusion solution of 
glucose perfused hearts was changed to a glucose and insulin supplemented Krebs-
Henseleit perfusion buffer (30μIU/m or 50μIU/ml) 10 minutes prior to the onset of 
regional ischaemia. Insulin perfusion continued for the duration of the ischaemic 
episode and was not present during the reperfusion period (See Figure 5.1). When 
assessing the impact of FA’s on insulin’s post-ischaemic outcomes, hearts were 
perfused with a glucose, insulin and FA supplemented Krebs-Henseleit perfusion 
buffer (Control: 30μIU/ml insulin and 0.7mM FA; Obese: 50μIU/ml insulin and 1.5mM 
FA) (See details for the FA perfusion buffer in section 3.1.3) for the same duration as 
described for insulin administration. At the end of the ischaemic period, the suture 
was loosened and within 5 seconds, the perfusion solution was changed to the 
standard glucose containing Krebs-Henseleit perfusion buffer for the duration of the 
reperfusion period. Although we used a model of coronary occlusion, a small volume 
(up to 6% of pre-ischaemic coronary flow rate) of the perfusion buffer could be 
expected to reach the occluded zone via collateral flow (Maxwell et al. 1987).  
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During the period of insulin and FA perfusion, a 200ml glucose, insulin and FA 
supplemented Krebs-Henseleit buffer was re-circulated in the heart perfusion system. 
 
 
Figure 5.1: Diagrammatic representation of the perfusion protocol followed to 
determine myocardial infarct size and recovery of function following a period 
of coronary artery ligation in hearts from control and obese animals. LD, 
Langendorff perfusion; WH, working heart perfusion.  
 
5.2.4 Indices of myocardial ischaemia/reperfusion injury 
5.2.4.1 Myocardial infarct size 
Frozen hearts were cut into 6-7 slices, 2-3mm thick. The slices were stained with a 
1% 2,3,5 triphenyltetrazolium chloride phosphate buffer (20mM NaH2PO4.2H2O and 
80mM Na2HPO4) (pH7.4) for 20min at 37ºC. Slices were then left to stand in 34% 
formaldehyde for two hours. The heart slices were blindly traced onto a transparency 
paper. Afterwards, an unbiased researcher not involved with the study blindly 
assessed the 3 identified areas on the traces. The transparency was scanned into a 
20min 10min 40min 20min 10min 10min 
LD Regional Ischaemia WH LD WH LD 
Mechanical 
function 
& 
Infarct size 
Mechanical 
function 
 
± Insulin or insulin + fatty acids 
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computer and the area of the viable tissue, area at risk and infarct size was 
delineated and quantified using computerized planimetry (UTHCSA Image Tool 
program, University of Texas Health Science Center at San Antonio, TX, USA). The 
ventricular area at risk did not differ between experimental groups. Infarct size was 
expressed as a percentage of the area at risk to account for differences in heart size 
between the various groups. 
 
5.2.4.2 Myocardial functional recovery 
To monitor myocardial mechanical function, aortic output was documented during the 
working heart periods before and after regional ischaemia. Myocardial functional 
recovery, an indirect index of ischaemic injury, was then calculated as a percentage 
as follows: 
      Pre-ischaemic AO 
Myocardial functional recovery =   Post-ischaemic AO     x     100 
 
It is important to mention that while both infarct size and functional recovery are well 
recognized indices used to assess ischaemia/reperfusion injury, functional recovery 
is not regarded as an accurate indicator of ischaemic damage in a model of regional 
ischaemia, due to concomitant stunning. In our laboratory larger infarct sizes do not 
always translate in poorer functional recoveries following regional ischaemia. Greater 
significance will therefore be given to infarct size than to functional recovery in 
determining the extent of post-ischaemic damage. Indeed myocardial infarct size is 
regarded to be a better predictor of future clinical outcomes than post-ischaemic LV 
functional performance (Wu et al. 2008). 
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5.2.5 Biometric measurements 
A description of the methodology used to quantify retroperitoneal and gonadal fat 
content has been reported in section 4.2.4.1.    
 
5.2.6 Biochemical analysis 
Blood glucose (4.2.5.2.1), HbA1c (non-fasting) (4.2.5.2.2), Trigs (4.2.5.2.3), total 
cholesterol (4.2.5.2.3), HDL-C (4.2.5.2.3) and serum insulin (4.2.5.3.1) levels were 
determined from fasted animals as previously described. In this series of 
experiments, glucose levels were determined from blood collected from the tail vein. 
The fasting glucose and serum insulin levels presented in this section were taken 
from the MSc of Mr. W Smith to save on the cost of additional biochemical 
determinations. These measurements were performed at a similar time to the infarct 
size experiments presented in this sub-study.  
 
5.2.6.1 Serum determinations 
5.2.6.1.1 Non-esterified free fatty acids  
FFA levels were determined in stored serum samples (-80 ºC), collected from fasting 
animals, by means of a Free Fatty Acid Half-micro Test (Roche Diagnostics, 
Penzberg, Germany).  
 
The test follows an enzymatic colorimetric approach and relies on the addition of 
enzymes to the FFA containing sample yielding a particular breakdown product. A 
catalyst (peroxidase) is added which reacts with the breakdown product and a colour 
reaction is visible which can be measured at 546nm. The concentration of the FFA is 
subsequently determined using a standard curve plotting the absorbancies of known 
amounts of FFA.  
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5.2.6.1.2 Determination of systemic insulin sensitivity 
Systemic insulin sensitivity was determined by the homeostasis model assessment 
(HOMA-IR) index. The HOMA-IR index was determined from the product of blood 
glucose (mM) and the serum insulin (μIU/ml) concentrations determined in the fasting 
state. This value was then divided by 22.5. 
 
5.2.7 Statistical analysis 
The data were presented as described in section 4.2.6. Comparisons between 2 
groups were made with an unpaired Student’s t-test. When different values within a 
particular group were compared a one-way ANOVA was used followed by the 
Bonferroni post-test. Multiple comparisons between various groups were made by 
using a two-way ANOVA followed by the Bonferroni post-test. 
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RESULTS: STUDY 2 
 
5.3 Results 
5.3.1 Biometric Data 
Table 5.1: Biometric data of control and obese animals 
 Control Obese 
Body Weight (g) 463.90±8.38 (n=28) 537.30± 9.91 $ (n=30) 
Retroperitoneal and 
gonadal fat weights 
(g) 
24.21± 2.31 (n=10) 40.70± 2.64 # (n=12) 
$p<0.001; #p=0.002 vs. control  
 
Compared to the SRC fed rats those that received the HCD for 16 weeks developed 
obesity characterised by both general (p<0.001) and visceral adiposity (p=0.002) 
(Table 5.1).  
Although not shown along with the biometric data, 16 week HCD fed rats had greater 
heart weights and larger myocyte size compared to the control group. This data was 
previously reported in the MSc dissertation of Mr W Smith (2005). 
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5.3.2 Metabolic data 
Table 5.2: Metabolic data of control and obese animals that were fasted 
overnight 
 Control Obese 
Glucose (mmol/l) 4.82±0.18 (6) 5.28±0.15 (6) 
Insulin (μIU/ml) 31.40±2.80 (11) 49.50±6.20 * (11) 
HOMA-IR 6.20±0.70 (6) 12.50±2.00 * (6) 
HbA1c (%) (non fasting) 3.97±0.18 (13) 4.36±0.13 (16) 
Trig (mmol/l) 0.72±0.07 (13) 1.91±0.18 * (13) 
Total cholesterol  
(mmol/l) 
1.43±0.05 (13) 1.29±0.06 (13) 
HDL-C (mmol/l) 0.87±0.03 (13) 0.56±0.03 * (13) 
FFA (mmol/l) 0.79±0.10 (8) 1.70±0.31 # (8) 
FFA – free fatty acids; HOMA-IR – homeostasis model assessment for insulin 
resistance; HbA1c – glycosylated haemoglobin; HDL-C – high density 
lipoprotein cholesterol. The group size is indicated by the number is brackets. 
#p<0.02; *p<0.05 vs. control 
 
Obese rats had similar glucose levels compared to the control rats, however their 
insulin levels were significantly elevated (p<0.05) and consequently the degree of 
systemic insulin sensitivity was reduced (HOMA-IR index; p<0.05) (Table 5.2). Obese 
rats were however not diabetic as reflected by the normal HbA1c values. In 
comparison to control rats, obese rats additionally displayed an unfavourable blood 
lipid profile evident by reduced HDL-C (p<0.05) and elevated Trig (p<0.05) and FFA 
(p<0.02) levels.  
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5.3.3 Myocardial glycolytic flux rates  
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Figure 5.2a: Average myocardial glycolytic flux rates obtained from 
Langendorff perfused rat hearts from control and obese rats during normoxic 
conditions. Hearts were perfused in the presence or absence of 30μIU/ml 
insulin. 
@p<0.01; #p<0.001  
n = 6-12 hearts per group  
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Figure 5.2b: Average myocardial glycolytic flux rates obtained from isolated 
Langendorff perfused obese rat hearts during normoxic conditions. Hearts 
were perfused in the presence or absence of insulin (30 or 50μIU/ml). 
#p<0.001  
n = 6-8 hearts per group 
 
In the absence of insulin, myocardial glycolytic flux rates did not differ between the 
control and obese groups. In response to insulin present in the perfusate, hearts 
isolated from both the control and obese animals, were able to significantly increase 
their glycolytic flux rates (Control: 2.16±0.57 vs. 0.55±0.14 μmol/g ww/min, p<0.001; 
Obese: 1.54±0.42 vs. 0.32±0.05 μmol/g ww/min, p<0.001) (Figure 5.2a). Despite this 
increased response in glycolytic flux following insulin stimulation (30μIU/ml), hearts 
from obese animals had lower rates of glycolysis compared to the control group 
(1.54±0.42 vs. 2.16±0.57 μmol/g ww/min, p<0.01). Hearts from obese animals were 
however able to incrementally increase their glycolytic flux rate in response to 
different insulin concentrations (Figure 5.2b). This may suggest a mild form of insulin 
resistance in these hearts. 
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5.3.4 The impact of obesity and insulin treatment prior to and during ischaemia 
on myocardial infarct size and functional recovery 
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Figure 5.3a: Myocardial infarct size expressed as a percentage of the area at 
risk obtained in isolated rat hearts from control and obese animals perfused in 
the presence or absence of insulin (30 or 50μIU/ml). Hearts were subjected to 
40 minutes regional ischaemia followed by 30 minutes reperfusion. Insulin 
administration, when present, occurred 10 minutes prior to the onset of 
regional ischaemia and ended upon the initiation of reperfusion. 
#p<0.001;@p<0.01; *p<0.05 
n = 6-8 hearts per group 
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Figure 5.3b: The percentage aortic output recovery obtained from isolated rat 
hearts from control and obese animals perfused in the presence or absence of 
insulin (30μIU/ml or 50μIU/ml). Hearts were subjected to 40 minutes regional 
ischaemia followed by 30 minutes reperfusion. When insulin was present, 
insulin administration occurred 10 minutes prior to the onset of regional 
ischaemia and ended upon the initiation of reperfusion.  
*p<0.05 
n = 6-8 hearts per group 
 
Glucose perfused hearts from obese animals were more susceptible to 
ischaemia/reperfusion induced injury. This was reflected by the larger infarct sizes 
(41.67±2.09 vs. 22.74±2.72 %; p<0.001) and poorer post-ischaemic functional 
recoveries (0.00±0.00 vs. 28.30±3.56 %, p<0.05) in comparison to the control group 
(Figure 5.3a). Insulin, when present in the perfusate, had a cardioprotective effect by 
attenuating infarct size in all cases (Control with 30μIU/ml insulin: 13.85±1.23 vs. 
22.74±2.72 %, p<0.01; Obese with 30μIU/ml insulin: 21.75±2.64 vs. 41.67±2.09 %, 
p<0.001; Obese with 50μIU/ml insulin: 20.94±1.60 vs. 41.67±2.09 %, p<0.001) 
except for the control 50μIU/ml insulin group. Insulin, irrespective of the concentration 
used, further improved myocardial functional recovery in the obese groups 
(26.26±12.48 and 23.16±7.49 vs. 0.00±0.00 %, p<0.05), while in the control group, 
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only the 50μIU/ml concentration of insulin was able to improve LV functional 
recoveries (53.24±5.45 vs. 28.30±3.56 %, p<0.05) (Figure 5.3b). A dissociation 
between infarct size (no change) and functional recovery (improved recovery) was 
observed in the control + 50μIU/ml insulin which is in agreement with previous 
findings from our laboratory that indicate that functional recovery does not always 
follow the same pattern as infarct size.   
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5.3.5 The impact of obesity and insulin or insulin and FA, administered prior to 
and during ischaemia, on myocardial infarct size and functional recovery  
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Figure 5.4: Myocardial infarct size expressed as a percentage of the area at risk 
obtained from isolated hearts perfused in the presence or absence of 
simulated in vivo concentrations of insulin (Control: 30μIU/ml; Obese: 
50μIU/ml) or insulin+FA (Control: 30μIU/ml insulin + 0.7mM FA; Obese: 50μIU 
/ml insulin + 1.5mM FA). Hearts were subjected to 40 minutes regional 
ischaemia followed by 30 minutes reperfusion. When insulin or insulin and FA 
were present in the perfusate, administration occurred 10 minutes prior to and 
during regional ischaemia and ended upon the initiation of reperfusion.  
#p<0.001;@p<0.01;  
n = 6-8 hearts per group 
 
To determine whether insulin’s post-ischaemic effects would be abolished by FA’s, 
myocardial ischaemic tolerance was investigated in the presence of glucose and 
simulated in vivo concentrations of insulin and FA (Figure 5.4). In the control groups, 
the reduction in infarct size afforded by 30μIU/ml insulin was lost when the FA 
perfused hearts were included in the statistical model. Despite this, the presence of 
FA abolished insulin’s infarct lowering effect as the insulin+FA group had significantly 
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larger infarct sizes compared to the insulin treated group (29.45±5.33 vs. 13.17±1.17 
%, p<0.01). Nevertheless, infarct sizes between the glucose perfused hearts and the 
insulin + FA perfused hearts were similar. 
 
In the obese group, insulin’s infarct sparing effect remained when compared to the 
glucose perfused obese hearts (20.94±1.60 vs. 41.67±2.09 %, p<0.001). Myocardial 
infarct sizes did not differ between the insulin and the insulin + FA group. The data 
suggest that in the obese groups, the protection afforded by insulin was attenuated 
by the combination of insulin + FA in the perfusate as infarct sizes observed between 
the glucose perfused and the glucose, insulin and FA perfused hearts were similar.   
Stellenbosch University http://scholar.sun.ac.za
127 
 
 
Control Obese
0
10
20
30
40
50
Normal
Ins
Ins+FA
@ @
#*
@
A
or
tic
 o
ut
pu
t p
er
ce
nt
ag
e 
re
co
ve
ry
(%
)
 
Figure 5.5: The percentage aortic output recovery obtained from isolated rat 
hearts perfused in the absence or presence of simulated in vivo concentrations 
of insulin (Control: 30μIU/ml; Obese: 50μIU/ml) or insulin+FA (Control: 
30μIU/ml insulin + 0.7mM FA; Obese: 50μIU/ml insulin + 1.5mM FA). Hearts 
were subjected to 40 minutes regional ischaemia followed by 30 minutes 
reperfusion. In the presence of insulin, administration occurred 10 minutes 
prior to and during regional ischaemia.  
#p<0.001; @p<0.01; *p<0.05  
n = 6-8 hearts per group 
 
As previously shown, simulated in vivo concentrations of insulin (30μIU/ml) did not 
improve myocardial functional recovery in the control group. However both the 
normal control and the control + insulin group had significantly greater functional 
recoveries compared to the control + insulin + FA group (28.30±3.56 and 39.01±7.68 
vs. 3.22±2.40 %, p<0.05 and p<0.001 respectively) (Figure 5.5). 
 
In the obese groups, hearts perfused with simulated in vivo concentrations of insulin 
had significantly improved post-ischaemic functional recoveries compared to the 
hearts perfused in the absence of insulin (26.26±12.48 vs. 0.00±0.00 %, p<0.01) 
(Figure 5.4) and those perfused with FA in combination with insulin and glucose 
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(26.26±12.48 vs. 0.00±0.00 %, p<0.01). Glucose perfused hearts had similar 
functional recoveries compared to hearts perfused with glucose, insulin and FA 
present in the perfusate prior to and during regional ischaemia.  
Stellenbosch University http://scholar.sun.ac.za
129 
 
 5.4 Summary of the findings 
 
Hearts from obese animals responded favourably to insulin administration in a dose 
dependent manner as reflected by significant changes in glycolytic flux rates during 
normoxic perfusion. Nevertheless, compared to the control group, hearts from obese 
animals achieved lower rates of glycolysis when perfused with comparable insulin 
concentrations indicating that these hearts were insulin resistant.  
 
Glucose perfused obese rat hearts were more susceptible to ischaemia/reperfusion 
injury (greater infarct sizes and poorer aortic output recoveries) compared to control 
hearts. Apart from its impact on glycolysis, simulated in vivo concentrations of insulin, 
when included in the perfusate 10 minutes prior to and during regional ischaemia, 
reduced infarct size in both the control and obese groups. This cardioprotective effect 
of insulin was attenuated when hearts were additionally perfused with simulated in 
vivo concentrations of FA’s. This suggests that insulin’s cardioprotective effects may 
in part be related to its metabolic actions. 
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CHAPTER 6 
METHODS AND RESULTS FOR STUDY 3: 
THE IMPACT OF OBESITY AND CHRONIC K-111 TREATMENT ON 
MYOCARDIAL FUNCTION, SUBSTRATE METABOLISM AND SUSCEPTIBILITY 
TO ISCHAEMIA/REPERFUSION INDUCED INJURY 
 
6.1 Aim of the study 
The aim of this sub-study was to determine the impact of obesity and chronic PPARα 
agonist treatment on ex vivo cardiac function, substrate metabolism, mitochondrial 
function and susceptibility to ischaemia/reperfusion injury. 
 
6.2 Methods 
 
6.2.1 Study design 
To determine the effects of obesity and chronic PPARα agonist treatment on various 
cardiac and circulating blood parameters, age and weight matched male Wistar rats, 
upon reaching 200 ± 20g, were randomly placed on either a SRC diet or the HCD. 
After 8 weeks on their respective diets the animals were weighed. The SRC group 
was randomly sub-divided and one sub-group received the PPARα agonist K-111 
(10mg/kg/day) administered via their drinking water. The same random sub-division 
was performed with the HCD fed group, with one half of the rats receiving both the 
HCD and K-111 (10mg/kg/day) in their drinking water and the other half remaining on 
the HCD without treatment (Figure 6.1). The rats were maintained on their respective 
feeding and drug administration protocols for an additional 8 to 10 weeks extending 
the experimental period to a total of 16-18 weeks (This group will be referred to as 
the 18 week fed group). To determine the impact of obesity and chronic PPARα 
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agonist treatment on myocardial substrate metabolism, hearts were mounted on a 
modified Langendorff perfusion apparatus. Myocardial glycolytic flux, glucose 
oxidation and palmitate oxidation rates were determined during baseline normoxic 
perfusion and during reperfusion following a period of total global normothermic 
ischaemia. To determine the effects of obesity and chronic PPARα agonist treatment 
on the myocardial susceptibility to ischaemia and reperfusion induced injury, hearts 
from the various groups were perfused in the working rat heart mode and subjected 
to 40 minutes CAL and 1 hour reperfusion. Myocardial function measurements were 
documented at regular intervals before and after ischaemia. Upon completion of the 
perfusion protocol, hearts were stained for the determination of myocardial infarct 
size. 
 
To determine the influence of obesity and chronic PPARα agonist treatment on 
myocardial mitochondrial respiratory capacity, isolated ventricular mitochondrial 
respiration was assessed 1) in the presence of oxidizable substrates (glutamate and 
malate or palmitoyl–L–carnitine) and 2) in the combined presence of these substrates 
and ADP. Mitochondrial recovery of respiration in the presence of the oxidizable 
substrates and ADP was also assessed following 25 minutes of anoxia.  
 
The impact of obesity and chronic PPARα agonist treatment on the expression of 
various myocardial proteins was investigated using standard Western blotting 
techniques with the appropriate antibodies. These proteins included CPT-1, a target 
of PPARα transcriptional upregulation, and phosphorylated and total PKB and the 
p85 subunit of PI3K as indicators of the insulin signaling pathway. 
 
Stellenbosch University http://scholar.sun.ac.za
132 
 
To determine the influence of obesity and chronic PPARα agonist treatment on 
various blood parameters, a separate series of animals were fasted overnight, and 
blood samples were collected for glucose, insulin, Trig, total cholesterol, HDL-C and 
FFA determinations. Blood from non-fasted animals was also collected for HbA1c 
analysis. To determine whether chronic K-111 treatment influenced adipogenesis, 
retroperitoneal and gonadal fat content was quantified. Lastly to determine whether 
obesity and chronic PPARα treatment influenced myocardial intracellular Trig levels, 
hearts isolated, freeze clamped and stored for subsequent analysis of myocardial 
intracellular Trig content.  
 
 
Figure 6.1: Flow diagram depicting the feeding and treatment protocol followed 
for control and obese animals 
 
6.2.2 The PPARα agonist K-111 
The PPARα agonist used in this study is a highly selective compound displaying a 
high affinity for PPARα (Phill and Kühnle, 1999; Meyer et al. 1999). The compound 
was previously named BM 17.0744 but is currently referred to as K-111. K-111 was 
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kindly supplied by KOWA Company, Ltd (Fugi Research Laboratories). At the 
commencement of the study, K-111 was reported to be undergoing phase II clinical 
trials. We were advised by KOWA not to exceed a dosage of 10mg/kg/day per 
animal. In rodents a dosage of 12mg/kg/day was however shown not to be toxic 
(Meyer et al. 1999).  
 
6.2.2.1 Maintenance of the required K-111 dosage 
Rats were administered K-111 in their drinking water at an approximate dosage of 
10mg/kg/day. Five to six rats were housed per cage. One week prior to the 
commencement of K-111 treatment, the average daily water consumption per rat was 
calculated for a particular cage. At the beginning of week 8 before K-111 treatment 
started, the groups that would receive K-111 were weighed. The average water 
consumption per rat and average body weight per rat for a specific cage was then 
used to prepare a K-111 containing solution that would provide an approximate 
dosage of 10mg/kg/day for the specific cage. During the week, the water 
consumption for each cage was monitored along with the new average body weight 
per rat and used to calculate the K-111 dosage to be prepared for the following week. 
Thus, each week a fresh stock of K-111 was prepared based on the previous weeks 
average water consumption per rat and the average body weight per rat. Water 
consumption between concurrent weeks did not differ markedly. Water bottles were 
refilled with fresh drug containing water every second day. 
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6.2.3 Isolated heart perfusions for the determination of myocardial substrate 
metabolism 
To determine the effect of obesity and chronic PPARα agonist treatment on 
myocardial substrate metabolism, hearts were perfused with either D-[5-[3H(N)]-
glucose (Perkin Elmer, USA) and D-[14C(U)]-glucose (Perkin Elmer, USA) or 9,10-
[3H]-palmitic acid (Amersham) to determine the respective rates of myocardial 
glycolytic flux, glucose oxidation and palmitate oxidation before and after 15 minutes 
of global ischaemia. 
  
Initially metabolic determinations were to be performed on isolated working heart 
preparations. Since the metabolism of D-[14C(U)]-glucose yields 14CO2, the perfusion 
apparatus was sealed air tight to prevent the escape of 14CO2 from the perfusion 
system. Trial perfusions using a sealed isolated working rat heart perfusion 
apparatus were however not satisfactory as we were not able to maintain a stable 
myocardial systolic pressure during a one hour working heart perfusion. 
Consequently the aortic output was not stable and at times dropped dramatically. 
The same perfusion apparatus was then modified and the working heart component 
of the perfusion system was sealed and excluded, thus leaving only the Langendorff 
component operational. The Langendorff component was then used for the 
metabolism experiments (a satisfactory rate pressure product was obtained following 
1hr perfusion using the LV balloon to measure pressure). The apparatus was 
designed to allow perfusate to re-circulate through the system once it had passed 
through the heart. A small hole was drilled into the perspex dome of the chamber in 
which the heart was contained to allow a temperature probe access to the heart. 
Temperature could therefore be monitored throughout the experiment. Once the 
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temperature probe had been placed into the coronary sinus of the heart, the hole was 
sealed.  
 
When only 9,10-[3H]-palmitate was incorporated into the perfusate, the perfusion 
system was not required to be sealed. During these conditions a fluid filled balloon 
tipped cannula was inserted into the LV for ventricular function determinations during 
the protocol (as previously described in section 3.1.4). 
 
6.2.3.1 Preparation of the radio-labelled fatty acid perfusion buffer 
The perfusion buffer containing FA was prepared as previously described in section 
3.2.3 (Lopaschuk and Bar, 1997). The various tracers were added at different steps 
during the preparation of the buffer (to be discussed below). 
 
After the FA perfusion buffer was prepared, the final working solution was 
supplemented with D-[14C(U)]-glucose (25μCi per 100ml working solution; specific 
activity 250-360 mCi/mmol) or D-[5-[3H(N)]-glucose (25μCi per 100ml working 
solution; specific activity 10-20 Ci/mmol) and stirred for 20 minutes. When using 9,10-
[3H]-palmitate (20μCi per 100ml working solution; specific activity 30-60 mCi/mmol), 
the tracer was added to the boiling palmitate sodium carbonate solution prior to the 
mixture being added to the concentrated bovine serum albumin solution. As two of 
the radio-labelled substrates had the same isotope (3H) one series of hearts was 
perfused with D-[14C(U)]-glucose and D-[5-[3H(N)]-glucose and the other with 9,10-
[3H]-palmitate.  
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6.2.3.2 Perfusion protocol followed when determining myocardial 
substrate metabolism 
Before experimentation, samples were taken from the radio-labelled perfusion buffer 
prior to being placed into the perfusion system to determine the specific activity of the 
appropriately labelled isotope. The radio-labelled buffer (130ml) was re-circulated 
throughout all the perfusion lines of the perfusion system for 5 minutes prior to 
experimentation. After re-circulating the radio-labelled FA buffer, buffer samples, 
which would later be used as blanks, were taken in duplicate from the various 
injection ports in the system.  
 
Isolated rat hearts were mounted on the perfusion apparatus via the aortic cannula 
and retrogradely perfused with Krebs-Henseleit perfusion buffer entering the system 
via a separate perfusion line (preload 100cm H2O). Once all the excess tissue had 
been trimmed and the blood washed out (5 minute Krebs perfusion) the system was 
sealed and the perfusion medium immediately changed to the radio-labelled FA 
buffer. Two perfusion protocols were used differing only in the levels of insulin and 
FA used. Insulin and FA concentrations simulating the in vivo conditions of the 
control animals will be referred to as normal insulin + FA (30μIU/ml insulin and 
0.7mM FA), whereas insulin and FA concentrations simulating the in vivo  conditions 
of the obese animal will be referred to as high insulin + FA (50μIU/ml insulin and 
1.5mM FA). In each perfusion protocol, 10mM glucose was also present.  
 
Perfusate samples (containing both the tracer and its metabolic by-products) were 
collected from the perfusion system after 30 and 40 minutes of aerobic perfusion. 
Thereafter, hearts were subjected to 15 minutes of normothermic total global 
ischaemia followed by 30 minutes aerobic reperfusion. Additional buffer samples 
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were collected 20 and 30 minutes after the onset of reperfusion in order to determine 
the metabolic rate of the hearts during the reperfusion phase of the protocol.  
 
At the end of the perfusion period, the hearts were carefully removed from the 
perfusion system and the connective tissue and atria were trimmed off. The ventricles 
were cut into three slices, placed in an oven overnight and weighed to obtain dry 
weights. 
 
6.2.3.3 Collection and processing of radio-labelled metabolic end 
products 
Myocardial glycolytic flux, glucose oxidation, and palmitate oxidation rates from the 
various groups were determined by collecting the various metabolic end products 
produced from the metabolism of D-[5-[3H(N)]-glucose, D-[14C(U)]-glucose and 9,10-
[3H]-palmitate. 14CO2 released by the metabolism of [14C]-glucose was present in 
both the gaseous and liquid phases in our experimental conditions. Collection of the 
gaseous 14CO2 was achieved by bubbling gas from the perfusion system directly into 
20N NaOH (20ml). 14CO2 binds to the NaOH effectively trapping the 14C in the NaOH 
solution. It was noted that the 20ml NaOH did not become completely saturated with 
14CO2. An injection port with a plastic tube leading directly into the NaOH solution 
was used to withdraw samples at the appropriate time intervals.  The alternative 
solution to trapping 14CO2 is hyamine hydroxide, but due to the exorbitant cost 
thereof, we chose to use NaOH. NaOH has previously been used in our laboratory to 
successfully trap 14CO2 (McCarthy et al. 2011). Both the liquid phase 14CO2, 
generated from the metabolism of D-[14C(U)]-glucose and 3H2O, produced from the 
metabolism of both D-[5-[3H(N)]-glucose and 9,10-[3H]-palmitate were collected in a 
similar manner. Briefly, perfusate samples (2.5ml) were directly withdrawn with a 
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syringe through a 3-way stop cock that was inserted into the line between the water 
jacket surrounding the heart and the main reservoir containing the radio-labelled FA 
buffer. Glass scintillation vials were prepared with 3ml mineral oil. Perfusate samples 
required for the analysis of liquid phase 14CO2 were injected directly under the layer 
of mineral oil to prevent the release of 14CO2 from the buffer.  
 
6.2.4 Methodology used to determine substrate metabolism 
6.2.4.1 Myocardial glycolytic flux rate (Saddik and Lopaschuk, 1991)  
Principle 
The amount of 3H2O released from the metabolism of D-[5-[3H(N)]-glucose was 
determined by passing samples through Dowex® 1-4X anion exchange columns 
(Sigma-Aldrich, St.Louis, MO). As glucose has a net negative charge, all glucose 
molecules would adhere to the column, while the positively charged 3H2O were 
eluted through the column and collected. 
 
Procedure 
The Dowex resin was conditioned with 2 washes of 1M NaOH, 4 washes of dH2O, 2 
washes of 0.9M boric acid, 2 washes of Na2B4O2 and finally another 4 washes of 
dH2O.The conditioned dowex slurry was stored at 4ºC.  
 
The Dowex slurry was added to a 5ml syringe to form a column. We aimed to 
achieve a consistent 1ml Dowex column for all analyzed samples. Collection tubes 
were placed below each syringe. 200μl samples were slowly added to their 
respective columns and left to stand for 30 minutes. Hereafter, samples were eluted 
with 800μl dH2O. From the volume of eluted 3H2O, 900μl was added to scintillation 
vials containing 5ml scintillation fluid and counted in a β scintillation counter for 2 
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minutes (Beckman LS 6500 Multi Purpose Scintillation Counter, Beckman 
Instruments, USA).  
  
Calculation of the myocardial glycolytic rate 
The following formula was used to determine the amount of glucose metabolized via 
glycolysis at a particular time point: 
 
(Sample counts – blank) x total perfusion volume   x 1   x  1     x DF 
Sample volume (0.2ml)    SA     dw   
 
where SA refers to the specific activity, dw to myocardial dry weight and DF to the 
dilution factor. The SA was determined by counting the 200μl buffer sample and 
dividing the counts by the amount of glucose (counts/μmol) present in the 200μl 
sample.  
 
The final glycolytic flux rate was then calculated by dividing the amount of glucose 
metabolized via glycolysis (μmol/g dw) by the particular time interval at which the 
sample was taken (e.g. 30 minutes) (μmol/g dry weight/min). The glycolytic flux rates 
for the two samples taken during the pre-ischaemic perfusion period were averaged 
to determine the average basal glycolytic flux rate. A similar calculation was then 
used to determine the reperfusion glycolytic flux rate. However to account for 
possible metabolic occurrences during the global ischaemic period, the amount of 
glucose metabolized via glycolysis after 40 minutes perfusion (the sample directly 
before global ischaemia) was subtracted from the 75 and 85 minute sample (i.e. was 
used as the new blank). 
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6.2.4.2 Myocardial glucose oxidation rate (Saddik and Lopaschuk, 1991) 
As mentioned previously, 14CO2 was generated by the metabolism of D-[14C(U)]-
glucose and was present in both the gaseous and liquid phase. Collected gaseous 
phase samples trapped in NaOH were directly placed into scintillation vials 
containing 5ml scintillation fluid and were counted using a β scintillation counter. 
Liquid phase 14CO2 was quantified using sealed metabolic flasks. 
 
Principle 
Liquid phase 14CO2 present in perfusate samples were placed into sealed metabolic 
flasks containing 9N H2SO4. The metabolic flask consisted of an Erlenmeyer flask 
fitted with a rubber stopper. The rubber stopper contained an injection port, for the 
injection of the sample, and a fitting into which a glass tube could be securely 
inserted. The glass tube contained Whatman #1 filter paper which was laced with 3N 
NaOH. H2SO4 would react with the [14C] bicarbonate ions in the perfusate sample 
liberating 14CO2. The 14CO2 passes into the glass tube and is trapped on the filter 
paper.  
 
Procedure 
1ml perfusate samples were injected into the metabolic flasks containing 9N H2SO4, 
and placed on a shaker. After 1 hour, the filter paper was removed, placed in 
scintillation vials containing 5ml scintillation fluid and counted in a β scintillation 
counter. 
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Calculation of the myocardial glucose oxidation rate 
The same formulas and calculations were used to determine the average basal and 
reperfusion glucose oxidation rates as were described for glycolytic flux rate 
determinations. The only difference was that the amount of glucose oxidized in the 
gas and liquid phase samples were combined to determine the overall myocardial 
glucose oxidation rate. In addition, a dilution factor was not required in the 
calculation. 
 
 
Figure 6.2: Diagram depicting the fate of 3H and 14C labelled glucose in the 
heart. (Taken from Lopaschuk and Barr, 1997) 
CAC – citric acid cycle; G-6-P – glucose -6- phosphate; 2-PG – 2-
phosphoglycerate  
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6.2.4.3 Myocardial palmitate oxidation rate (Personal communication 
between A Lochner and GD Lopaschuk) 
Principle 
Myocardial palmitate oxidation rates were calculated by measuring the amount of 
3H2O released from the metabolism of 9,10-[3H]-palmitate. The perfusate samples 
collected during the perfusion protocol contained both 3H2O and 9,10-[3H]-palmitate. 
The evaporation method allowed the separation and collection of evaporated 3H2O 
from the perfusate sample. The volume of evaporated 3H2O collected from the 
perfusion was then counted and the final amount of 3H2O present in the specific 
sample was determined by factoring in the ratio of the processed and unprocessed 
internal standard (to be discussed below).  
When using the evaporation method, the assumption is made that all the 3H2O from 
the perfusate sample, present within the microfuge tube will evaporate and be 
transferred into the scintillation vial during the evaporation process. To account for 
any possible transfer of 3H originating from the un-metabolized 9,10-[3H]-palmitate 
into the scintillation vial together with metabolized 3H2O following the evaporation 
procedure, two precisely identical internal standards were prepared in duplicate (four 
standards in total). The internal standards consisted of a known amount of 9,10-[3H]-
palmitate (1mCi/ml) added to 1ml Krebs-Henseleit buffer. Of these standards, one 
internal standard (in duplicate) was processed via the evaporation method 
(processed internal standard). The other internal standard (in duplicate) 
(unprocessed internal standard) was merely counted with the rest of the samples at 
the end of the procedure. This enabled us to determine the percentage transfer of 
9,10-[3H]-palmitate during a particular experimental run and to compensate for it 
when calculating the final amount of 3H2O present in each sample. The amount of 
9,10-[3H]-palmitate carry over varied form 1-4%. 
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Procedure 
200μl aliquots of the blank, sample and internal standard (to become the processed 
standard) were pipetted in duplicate into capless microfuge tubes (tube volume: 
250μl). The microfuge tubes were carefully placed in a 7ml scintillation vial containing 
500μl dH2O. Capped scintillation vials were kept in an incubator (50ºC) for 24 hours. 
Subsequently, all vials were transferred to the cold room (4ºC) overnight. Microfuge 
tubes were then carefully removed from the scintillation vials by dragging them 
against the side of the vial to remove any 3H2O. The microfuge tubes were discarded 
and the scintillation vials were all filled with 5ml scintillation fluid. The unprocessed 
internal standard (the standard that did not go through the evaporation method) was 
also added to a scintillation vial and filled with scintillation fluid. 
 
The un-metabolized perfusion solution (200μl taken before the addition of perfusate 
to the perfusion system) was placed into a separate scintillation vial and 5ml 
scintillation fluid was added. This vial served to determine the specific activity of the 
tracer used in the perfusate. All the samples were counted in a β-scintillation counter. 
 
Calculation of palmitate oxidation rate 
The following formula was used to determine the amount of palmitate oxidized by the 
heart: 
 
(Sample counts – blank) X volume of buffer in perfusion system X 1   X  1               
Sample volume (0.2ml)       SA      dw 
 
 
where SA refers to the specific activity and dw to myocardial dry weight. The specific 
activity was determined by counting the 200μl SA sample and dividing it by the 
amount (nmol) of palmitate present.  
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The final rate of palmitate oxidation rate was expressed as nmol/g dry weight/min. 
The palmitate oxidation rates for the two samples taken during the pre-ischaemic 
perfusion period were averaged to determine the basal palmitate oxidation rate. A 
similar calculation was used to determine the reperfusion palmitate oxidation rate. 
However to account for possible metabolic occurrences during the 15 minute global 
ischaemic period, the amount of palmitate oxidized at 40 minutes (the sample directly 
before global ischaemia) was subtracted from the 75 and 85 minute (post-ischaemic) 
sample (i.e. the 40 minute sample acted as the blank for the 75 and 85 minute 
samples). 
 
 
Figure 6.3: Diagram depicting the fate of 3H and 14C labelled palmitate in the 
heart. (Taken from Lopaschuk and Bar, 1997) 
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6.2.5 Perfusion protocol used to assess the myocardial susceptibility to 
ischaemia/reperfusion injury  
The impact of obesity and chronic PPARα agonist (K-111) treatment on the 
myocardial susceptibility to ischaemia/reperfusion injury was assessed in isolated 
working rat hearts as it allowed for working heart function to be determined. As with 
the metabolic perfusions, two different perfusion protocols were used differing only in 
the concentration of insulin and FA used. As described in section 6.2.3.2 these two 
different perfusion solutions will again be referred to as the “normal” or “high” insulin 
+ FA concentrations. This approach further enabled us to elucidate the impact of 
altered substrate and insulin supply on post-ischaemic outcomes.  
 
Hearts from each group were subjected to a standard myocardial infarction perfusion 
protocol (Figure 6.4). While being mounted on the perfusion apparatus, all hearts 
were initially perfused with Krebs-Henseleit perfusion buffer for 5 minutes to ensure 
that all the blood was washed out from the hearts. After 5 minutes the perfusion 
buffer was switched to the appropriate glucose containing Krebs-Henseleit perfusion 
buffer supplemented with insulin and FA. This solution (200 ml) was re-circulated for 
the duration of the perfusion protocol. The perfusion protocol consisted of an initial 10 
minute retrograde perfusion which served as a stabilization period. The perfusion 
was then changed to the working heart mode for 20 minutes after which the hearts 
were again retrogradely perfused and the left anterior descending coronary artery 
ligated with a silk suture. Occlusion of the coronary artery induced regional ischaemia 
which was maintained for a period of 40 minutes, and was followed by 60 minutes of 
reperfusion after the suture had been loosened. The reperfusion period consisted of 
10 minutes Langendorff perfusion, 20 minutes working heart perfusion and a further 
30 minutes of Langendorff perfusion. During the working heart perfusion periods, 
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myocardial LV mechanical function was monitored and documented (See section 
3.1.4 for the list of functional measurements documented in isolated working hearts).  
 
Hearts that were unable to pump adequately during the working heart reperfusion 
period were perfused in an assisted working heart mode (a working heart mode with 
the Langendorff perfusion tap slightly opened). This ensured that an adequate 
perfusion pressure was maintained during the working heart period. These hearts 
could therefore not generate data for reperfusion function. The number of hearts that 
were perfused in an assisted mode can be determined by the difference between the 
sample size of the pre-ischaemic function and the sample size of the post-ischaemic 
function. In instances where the reperfused working heart was pumping adequately 
and developing pressure but not able to generate aortic output, the hearts were 
allowed to continue in the working heart mode alone, and a dp/dt value was 
measured and an aortic output value of 0 ml/min recorded. 
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Figure 6.4: Perfusion protocol followed to document the impact of obesity and 
chronic K-111 treatment on the myocardial susceptibility to ischaemia and 
reperfusion injury.  
LD – Langendorff mode; WH – Working heart mode. 
 
6.2.6 Indices used to assess myocardial ischaemia/reperfusion induced injury 
6.2.6.1 Myocardial infarct size  
Myocardial infarct size was assessed as a direct measure of ischaemia/reperfusion 
injury. The protocol for the determination of myocardial infarct size has previously 
been described (Section 5.2.3.1). 
 
6.1.6.2 Myocardial functional recovery 
The aortic output recovery was used as an index of the severity of 
ischaemia/reperfusion damage and has already been described (section 5.2.3.2). 
The total work and cardiac output (aortic output + coronary flow) recoveries were 
calculated using the formula previously described (Section 5.2.4.2). 
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As previously mentioned, while both infarct size and functional recovery are well 
recognized indices of the severity of ischaemia/reperfusion injury, functional recovery 
is not regarded as an accurate indicator of ischaemic damage in a model of regional 
ischaemia. 
 
6.2.7 Isolated mitochondria experiments 
To determine the influence of obesity and chronic K-111 treatment on mitochondrial 
respiratory capacity, ventricular mitochondria from the various groups were isolated 
and mitochondrial respiration measured in the presence of different oxidizable 
substrates (glutamate or palmitoyl – L – carnitine). The choice of glutamate and 
palmitoyl – L – carnitine as substrate was merely to assess respiratory capacity and 
not the effect of the substrate per se.  The ability of these mitochondria to regain their 
normal respiratory capacity was also assessed following a 25 minute period of 
anoxia. Mitochondrial oxygen consumption (nAtoms O2/ml/min) was monitored by 
means of Clarke electrode (Oxygraph, Hansatech Instruments Bannan, UK). For the 
purpose of this study we only wished to determine the impact of obesity and K-111 
agonist treatment on total mitochondrial respiratory capacity. Consequently we did 
not perform complex analysis of the electron transport chain.  
 
6.2.7.1 Preparation of ventricular mitochondria 
After rats were anaesthetized, their hearts were removed and all excess tissue and 
atria removed. The ventricles were placed in a Sorvall tube containing ice cold 
potassium chloride ethylenediaminetetraacetic acid (KE) (0.18M KCl, 0.01M 
ethylenediaminetetraacetic acid, pH set at 7.4 with 2M Tris) isolation medium and cut 
into small fine pieces with a scissor. The pieces of ventricle were washed 4-5 times in 
ice cold KE isolation medium to remove all traces of blood. Mitochondria were 
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prepared according to the method of Sordahl et al. (1971). Ventricles were 
homogenized (on ice) with a Polytron (PT10) homogenizer for 2 cycles of 4 seconds 
at setting 4. The homogenate was centrifuged at 2500 rpm (755 x g) for 10 minutes 
in a Sorvall centrifuge (rotor SS34). The supernatant was then transferred into a 
clean Sorvall tube and centrifuged again at 12500 rpm (18 800 x g) for 10 minutes. 
The supernatant was discarded and the remaining pellet, which represented the 
ventricular mitochondria population (subsarcolemmal fraction), was re-suspended in 
0.5ml KE isolation medium with the help of a pre-cooled glass Teflon Potter Elvehjem 
homogenizer. 
 
6.2.7.2 Determination of mitochondrial protein content 
From the 0.5ml re-suspended pellet containing the mitochondria, 50μl was placed 
into a tube containing 1ml trichloroacetic acid (TCA) (10%) overnight to precipitate 
the mitochondrial protein. The mitochondrial protein content was assessed using the 
Lowry method (Lowry et al. 1951). Briefly, the precipitated protein was isolated by 
centrifuging the mitochondrial TCA suspension at 2500 rpm for 15 minutes. The 
supernatant was discarded and the pellet re-suspended in 500μl 1N NaOH. These 
samples were subsequently placed in a water-bath at 70°C for 10 minutes. Once the 
samples were clear (or after the 10 minute incubation) an additional 500μl dH2O was 
added to each tube and the samples mixed with a vortex.  
 
For the assay, a 0.5N NaOH solution was used as the blank, while 3 different 
concentrations of an albumin standard were used to generate a standard curve. 50μl 
of mitochondrial samples, standards or blank were aliquoted in triplicate into lucham-
tubes. A 1ml solution of 2% NaK-Tartrate, 1% CuSO4.5H2O, 2% Na2CO3 was added 
to each tube at 10 second intervals and vortexed. After 10 minutes, 100μl Folin 
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Ciocalteu’s (33%) was added to each tube, at 10 second intervals and vortexed.  A 
colour reaction developed and after 30 minutes the optical density was measured at 
750nm in a spectrophotometer. The absorbancies of the 3 different known 
concentrations of albumin were plotted to generate a standard curve, which was 
used for the determination of the protein content of the unknown samples. 
 
6.2.7.3 Determination of ventricular mitochondrial respiration and the 
post-anoxic recovery of respiration 
Mitochondrial oxidative phosphorylation was determined using an oxygraph 
(Oxygraph, Hansatech Instruments Bannan, UK). During all calibrations and 
experimental conditions a small magnet was placed in the chamber and set to stir to 
ensure that a homogeneous solution was maintained at all times. At the start of each 
experimental day, the oxygraph was calibrated as follows: Incubation medium (see 
the next paragraph for details) was placed in the chamber. Upon reaching the 
experimental temperature of 26°C (previous authors have used temperatures of 
either 25ºC (Boudina et al. 2005; Duncan et al. 2007) or 37º (Khalid et al. 2011)), the 
oxygen concentration was set at 100%. Sodium dithionite, which acts as an oxygen 
scavenger, was added and the 0% oxygen concentration was set once the decline in 
oxygen concentration reached a steady state. The chamber surrounding the 
electrode containing the incubation medium and sodium dithionite was then sealed 
for 20 minutes to determine whether the chamber’s o-rings sealed air tight (in the 
event of a leak, the oxygen concentration in the chamber would rise within 20 
minutes). Hereafter the chamber was repeatedly washed to remove all traces of 
sodium dithionite. 
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The incubation solution used for the experiments consisted of 250mM sucrose, 
10mM Tris HCL, 8.5mM K2HPO4, 2mM malate and either 5mM glutamate or 0.45mM 
palmitoyl-L-Carnitine as oxidative substrates. The pH of the incubation solution was 
set at 7.4. All experiments were performed at 26ºC. Isolated mitochondria were kept 
on ice during the entire procedure until they were ready to be placed into the 
chamber. 
 
At the start of each experiment, incubation solution containing either glutamate or 
palmitoyl-L-Carnitine as oxidizable substrates was added to the oxygraph chamber. 
The solution was allowed to reach 26ºC before experimentation commenced. Once a 
stable oxygen concentration trace was maintained in the chamber, the recording was 
started. Isolated mitochondria were then added to the chamber and state 2 
respiration was recorded (See figure 6.5). Thereafter, 50μl of a 7.48mM ADP (in total 
374nmol ADP) solution was added and the chamber sealed. This event induced 
mitochondrial state 3 respiration during which oxygen was consumed at a rapid rate 
due to the production of ATP from ADP. Once all the ADP had been phosphorylated, 
state 4 respiration ensued.  After a measurable period of state 4 respiration, the seal 
of the chamber was removed and an oversupply of ADP (100μl of a 10X solution) 
was added to the mitochondrial suspension. The chamber was then resealed. This 
“oversupply” of ADP allowed the mitochondria to utilize all oxygen present in the 
chamber, effectively inducing anoxia in the chamber with excess ADP remaining in 
the medium. Following 25 minutes of anoxia, the seal was removed and the chamber 
re-oxygenated using a plastic Pasteur pipette, restoring the oxygen concentration too 
approximately half of that present in the chamber prior to the addition of the 
mitochondria. A re-oxygenation state 3 respiration rate ensued due to the presence 
of excess ADP previously added. Mitochondrial susceptibility to anoxia re-
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oxygenation was then calculated by expressing the post-anoxia state 3 respiration as 
a percentage of the pre-anoxia state 3 respiration rate. 
 
6.2.7.4 Mitochondrial parameters measured and investigated   
The various measurements obtained during the experimental protocol are depicted in 
figure 6.5. In this figure (A) represents state 2 respiration (the slope of the curve), 
representing mitochondrial respiration in the presence of the specific substrates in 
the incubation solution in the absence of ADP. (B) Represents state 3 respiration (the 
slope of the curve), which corresponds with the rate at which the substrates were 
oxidized in the presence of ADP. During this period oxidative phosphorylation occurs 
where ADP is converted to ATP. State 4 respiration (the slope of the curve), 
represented by (C), illustrates mitochondrial respiration in the absence of ADP (all 
the ADP was converted to ATP). The value of the state 4 respiration is often similar 
to that of state 2 respiration. The value of state 4 respiration may vary slightly due to 
the presence of various breakdown products in the incubation solution following 
oxidative phosphorylation.  
 
The slope of the curves for A, B and C, was determined by software provided with 
the oxygraph to effectively quantify State 2, 3 and 4 respiration (nmolO2/min/ml). The 
final respiration rate was expressed as natomsO2/min/mg protein. Mitochondrial 
protein content of the various groups was determined using the Lowry method for 
protein determination (Lowry et al. 1951) as previously described (6.2.7.2). 
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Figure 6.5: Diagrammatic representation of the respiration curves obtained on 
the oxygraph. A, represents state 2 respiration; B, represents state 3 
respiration; and C, represents state 4 respiration 
 
From the graph presented in Figure 6.5, both the ADP/O ratio and the respiratory 
control index (RCI) index could be calculated. The ADP/O ratio represents the 
relationship between ATP synthesis and oxygen consumption. In the presence of 
glutamate as a substrate the theoretical ADP/O ratio is calculated to be 3, whereas in 
the presence of palmitoyl-L-carnitine the theoretical value should be 2.6. The ADP/O 
ratio is determined by dividing the total amount of ADP added by the amount of 
oxygen consumed during state 3 respiration. For all experiments, aliquots of a stock 
solution of ADP were made and the absorbance of the stock solution was measured 
at 259nm with a spectrophotometer. Using the absorbance of the ADP solution, and 
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the molar extinction coefficient of ADP at 259 nm (15.4) the exact ADP concentration 
used could be determined. Once the ADP/O ratio had been calculated, the oxidative 
phosphorylation rate (nmol ADP/min/mg protein) was calculated from the product of 
the ADP/O ratio (nmol ADP/nAtom O2) and state 3 respiration (nAtoms O2/min/mg 
protein). 
 
The RCI is the ratio of state 3:state 4 respiration and is an indication of the tightness 
of the coupling between respiration and phosphorylation.  
 
6.2.8 Biometric measurements 
Retroperitoneal and gonadal fat mass was determined as previously described 
(4.2.4.1). 
 
 6.2.8.1 Determination of pericardial fat mass 
Hearts were carefully removed from anaesthetized rats. Once mounted on a 
perfusion apparatus, the fat surrounding the heart was removed and weighed. 
 
6.2.9 Biochemical analysis 
 6.2.9.1 Determination of intramyocardial triglyceride content 
Hearts isolated from animals were immediately placed in ice cold Krebs-Henseleit 
buffer. The atria and connective tissue were removed and the heart cut in half. The 
two halves were placed in a new container of ice cold Krebs-Henseleit buffer to wash 
away the remaining blood from the ventricles. These pieces of ventricular tissue were 
then freeze clamped with pre-cooled Wollenberger tongs and placed into liquid 
nitrogen, where they were stored until required for further analysis. 
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Analysis of the intramyocardial Trig content was performed by the Lipid Clinic at the 
Cape Heart Center, University of Cape Town (South Africa). Briefly, lipids were 
extracted using the Folch extraction (Folch et al. 1957) and the quantity of Trig 
present in each sample determined spectrophotometrically using the KAT enzymatic, 
spectrophotometric kit (KAT Laboratory and Medical (PTY) Ltd , Gauteng, South 
Africa, catalogue number KAT801T). The protein concentration of each sample was 
determined by the Markwell spectrophotometric method (a modification of the Lowry 
protein determination method) (Markwell et al. 1978). The amount of Trig present in 
each sample was then expressed in terms of the protein concentration of the sample. 
 
6.2.9.2 Blood and serum determinations 
Blood glucose (4.2.5.2.1), lipid (Trig’s, total cholesterol and HDL-C) (4.2.5.2.3), and 
serum insulin (4.2.5.3.1), FFA (5.2.6.1.1) and HbA1c (4.2.5.2.2) levels were 
determined in non-fasting animals as previously described. Lastly, systemic insulin 
sensitivity was determined from the HOMA-IR index as previously described in 
section 5.2.6.1.2. 
 
6.2.10 Western blot analysis 
To determine whether obesity and chronic K-111 treatment influenced the expression 
of various proteins involved in carbohydrate and FA metabolism, Western blot 
analysis was performed. Hearts were isolated and stored as described in section 
6.2.9.1. 
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6.2.10.1 Preparation of Western blot lysates 
Approximately 200mg of frozen ventricular tissue was crushed using a mortar and 
pestle which had been pre-cooled in liquid nitrogen. The crushed tissue was quickly 
placed into Sorvall tubes containing 900μl lysis buffer (20mM Tris-HCl pH 7.4, 1mM 
EGTA, 25mM NaCl, 1mM Na3VO2, 10mM NaF, 1% (v/v) triton X-100, 10μg/ml 
leupeptin, 10μg/ml aprotinin, 1mM benzamidine. 1mM Phenylmethyl-sulphonyl 
fluoride was only added before usage) for the extraction of the myocardial proteins. 
The same lysis buffer was used to prepare lysates for all the proteins investigated in 
this study. 
 
The tubes containing the lysis buffer and ventricular tissue were homogenized with a 
Polytron (PT10) (2 cycles of 5 seconds each at setting 5). Following the 
homogenization step, the tubes were kept on ice for 30 minutes to ensure adequate 
protein extraction. The samples were then centrifuged at 14000rpm for 14 minutes to 
remove particulate matter. From each sample, an aliquot was used to determine the 
protein concentration of the supernatant using the Bradford protein determination 
technique (Bradford, 1976). Once the exact amount of protein present in each 
sample was known, aliquots of each sample were made and diluted with Laemmli 
sample buffer (3:1). The aliquots were boiled for 5 minutes and stored at -20ºC. 
Western blot analysis was performed within 2 weeks of lysate preparation. 
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6.2.10.2 The Bradford protein determination method 
Principle 
A standard curve is generated plotting the absorbancies and concentrations of 
different known amounts of albumin. The absorption of each of the unknown protein 
samples can then be determined at 595nm and their concentration determined by 
using the linear equation of the standard curve. 
 
Procedure 
The Bradford assay was preformed in duplicate. A standard curve was prepared by 
performing serial dilutions from a stock of albumin to create a standard curve with 
protein concentrations ranging from 1-20μg protein. Protein samples from the 
experimental group were diluted 1:10 with dH2O. From this dilution 5μl was aliquoted 
into a new tube and further diluted with 95μl dH2O. These dilutions ensured that the 
protein content of the diluted sample would be less than 20μg thus allowing the 
unknown samples to fit on the standard curve. 0.9ml Bradford reagent (Coomassie 
Brilliant Blue G-250 0.01% (w/v), ethanol 4.7% (v/v), and phosphoric acid 8.5% (v/v)) 
was added to each tube (standards and unknown proteins) and vortexed. Between 
15 and 30 minutes following the addition of the Bradford reagent, the absorption of 
each sample was spectrophometrically determined at 595nm. The unknown protein 
concentrations could then be determined from the standard curve as was described 
above.  
 
6.2.10.3 Separation of the proteins 
Prior to use, each lysate was boiled for 5 minutes followed by centrifugation at 
14000rpm for 5 minutes. The proteins from each sample were then separated on a 
SDS-polyacrylamide gel using the Bio-Rad Mini-PROTEAN III system (Bio-Rad, Life 
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Science Group, USA) (140V, 140mA for 80 minutes). The samples were loaded onto 
a 4% stacking gel and electrophoretically separated onto a 10% running gel. After 
this, the separated proteins were transferred to a polyvinylidene fluoride membrane 
(Millipore Corporation, Immobilon Transfer Membranes, USA) by electro-blotting. 
Thereafter, the membranes were washed with Tris-buffered saline mixed with 0.1% 
Tween-20 (TBS-T). The wash step was repeated for 2 hours with 5% fat-free milk 
powder in TBS-T solution in order to block all non-specific binding sites on the 
membrane. 
 
Following the TBS-T milk powder incubation, membranes were washed (TBS-T) and 
incubated on a shaker with the appropriate primary antibody overnight at 4ºC (see 
specific dilution details below). Following the incubation procedure, membranes were 
once again washed (TBS-T) and incubated with a horseradish peroxidase-labelled 
secondary antibody (1:4000 in 5% fat-free milk powder in TBS-T, unless otherwise 
stated) for 1 hour at room temperature. The membranes were again washed (TBS-T) 
after which they were ready to be developed. Membranes were subsequently 
incubated with electro-chemiluminescence detection agents (ECL Solution Detection 
Reagents 1 and 2, GE Healthcare, UK) for 1 minute. The membranes were then 
briefly exposed to high performance chemiluminescence film (Hyperfilm ECL) 
allowing for a light emission to portray the protein band on the film. The protein bands 
were then quantified by laser scanning densitometry and analyzed with the relevant 
software (UN-SCAN-IT, Silkscience, USA). 
 
Relevant information relating to each protein analyzed will be discussed below. 
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PI3-kinase p85 subunit 
60μg protein fractions were loaded onto a 10% SDS-polyacrylamide gel. Membranes 
were incubated with total PI3K p85 or the phospho-PI3K p85 (Tyr 458) (Cell 
Signalling Technology, Inc) primary antibody overnight. The primary antibodies were 
diluted 1:1000 in TBS-T. 
 
PKB 
30μg protein fractions were loaded onto a 10% SDS-polyacrylamide gel. Membranes 
were incubated with total PKB or the phospho-PKB (Ser 473) (Cell Signalling 
Technology, Inc) primary antibody overnight. The primary antibodies were diluted 
1:1000 in TBS-T. 
 
CPT-1 
60μg protein fractions were loaded onto a 10% SDS-polyacrylamide gel. Membranes 
were incubated with CPT-1 – M(H-120): sc-20670  (Santa Cruz Biotechnology, Inc) 
primary antibody overnight. The primary antibodies were diluted 1:1000 in TBS-T.  
 
β-Tubulin 
A membrane that had been used for PI3K determination was stripped (3 x dH2O, 1 x 
1N NaOH, 3 x dH2O) and probed for B-tubulin. Membranes were incubated with B-
Tubulin (Cell Signalling Technology, Inc) primary antibody overnight. The primary 
antibodies were diluted 1:1000 in TBS-T.  
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6.1.10.4 Calculation of the amount of protein in each sample 
A total of 6 hearts were used per group. On each gel only 3 samples were loaded per 
group as only 12 sample wells were available per gel. To enable comparisons 
between 2 different gels for a specific protein investigated, an internal standard was 
loaded onto each gel. The internal standard used was proteins from a heart isolated 
from a healthy 250g rat. After completing the densitometry of each protein band, the 
number of pixels for each band was expressed as a ratio of the internal standard. 
Using this approach the amount of pixels obtained for a specific protein in a specific 
group spread over two gels could simply be combined.  
 
6.2.11 Statistical analysis 
Statistical comparisons were made as previously described in section 5.2.7. In 
addition, the comparison between pre- and post-ischaemic rates of myocardial 
substrate metabolism within a particular group were assessed by means of a paired 
Students t-test.  
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RESULTS: STUDY 3 
 
6.3 Results 
 
6.3.1 Biometric and metabolic data after 8 weeks of feeding 
Table 6.1: Body weight of control and obese animals after 8 weeks of feeding 
prior to receiving the K-111 treatment. 
 Control Obese 
Body Weight (g) 333.50±5.57 (n=58) 375.60±5.35* (n=59) 
*p<0.001 
 
After 8 weeks of feeding and prior to rats receiving chronic K-111 treatment, HCD fed 
rats were already significantly heavier than the control group (Table 6.1). Although 
we did not determine any metabolic parameters after 8 weeks of HCD feeding (to 
reduce the number of animals required for this study), it is important to mention our 
research group has previously shown that such rats have increased retroperitoneal 
and gonadal fat mass, are euglycaemic and have elevated fasting insulin levels 
compared to control animals (Huisamen et al. unpublished data). Thus the 8 week 
HCD fed rats in this study may be considered to be obese (both general and visceral) 
and have systemic insulin resistance when compared to the lean control animals. 
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6.3.2 Biometric and biochemical data after 18 weeks 
Table 6.2: Biometric and biochemical data of non-fasted control and obese 
animals with and without chronic K-111 treatment. 
 Control Obese Control        
+ K-111 
Obese       
+ K-111 
BW (g) 428.50±17.23 506.14±10.61@ 403.13±17.08 410.42±11.78*
Retroperitoneal 
and gonadal fat 
weights (g) 
15.15±1.18 30.45±1.99# 12.29±0.86 17.53±1.70%,$ 
Retroperitoneal 
and gonadal fat 
as % BW (%) 
3.53±0.19 5.99±0.30# 3.06±0.20 4.27±0.38&,^ 
Pericardial fat (g) 0.11±0.02 0.28±0.06@ 0.13±0.01 0.14±0.02* 
Intramyocardial 
Trig (μg/mg 
protein) 
852.81±69.85 895.36±108.62 1017.09±121.41 847.37±63.83 
Glucose (mmol/l) 12.08±0.70 12.78±0.83 9.75±0.28* 10.29±0.64* 
Insulin (μIU/ml) 30.24±4.55 60.18±7.25# 21.70±2.56 37.99±3.76* 
HOMA-IR (AU) 16.19±2.85 35.66±6.26@ 9.86±1.25 17.31±2.32^ 
HbA1c (%) 2.62±0.07 2.78±0.04 2.78±0.05^ 2.77±0.05 
Trig (mmol/l) 0.97±0.19 2.53±0.24# 0.57±0.00 0.57±0.00$
HDL-C (mmol/l) 0.98±0.12 0.85±0.08 0.56±0.14* 0.48±0.07* 
FFA (mmol/l) 0.26±0.02 0.47±0.05# 0.23±0.02 0.23±0.02$
BW – body weight; HbA1c – glycosylated haemoglobin; HDL-C – high density 
lipoprotein cholesterol; HOMA-IR – homeostasis model assessment for insulin 
resistance; FFA – free fatty acid; Trig – Triglyceride.  
#p<0.001, @p<0.01 vs. control; &p<0.001, %p<0.05 vs. control treated; $p<0.001, 
^p<0.01 *p<0.05 vs. corresponding untreated group 
n = 6-8 rats per group; intramyocardial triglyceride content: n = 3-5 hearts per 
group 
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After 18 weeks, HCD fed rats were significantly heavier and had more retroperitoneal 
and gonadal fat (absolute mass and expressed as a percentage of body weight) and 
pericardial fat compared to their control littermates (Table 6.2). Chronic K-111 
treatment had a beneficial effect on adiposity and prevented the increase in body 
weight, retroperitoneal and gonadal fat and pericardial fat mass associated with HCD 
feeding. HCD fed K-111 treated rats did however have more retroperitoneal and 
gonadal fat in comparison to control K-111 treated animals. Furthermore, although 
chronic K-111 treatment did not influence the body weight, retroperitoneal and 
gonadal fat or pericardial fat mass in this specific group of control rats (compared to 
the untreated controls), certain series of K-111 treated control animals did indeed 
have lower body weights compared to their untreated littermates (data not shown). 
Similar observations were made between the HCD K-111 treated and control K-111 
treated groups where in certain series of animals, the body weight of the HCD K-111 
treated group was greater than the control K-111 treated group (yet still less than the 
HCD untreated group). 
 
Neither the HCD nor chronic K-111 treatment influenced the intramyocardial 
triglyceride content, suggesting the absence of lipotoxicity in the model after 18 
weeks of feeding.   
 
After the 18 week feeding period, HCD fed rats developed hyperinsulinaemia, while 
normoglycaemia was maintained and consequently these animals displayed 
systemic insulin resistance (reflected by a raised HOMA-IR index) (Table 6.2). This 
was accompanied by raised blood Trig’s and FFA levels compared to the control 
group. The HCD did not change the percentage glycosylated haemoglobin or HDL-C 
levels. 
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Chronic K-111 treatment attenuated many of the metabolic abnormalities associated 
with obesity. This included reducing blood glucose, insulin, Trig and FFA levels, while 
whole body insulin sensitivity was markedly improved (treated vs. untreated HCD fed 
rats). The metabolic influence of K-111 was less pronounced in the control group 
where only a reduction in blood glucose was noted. Although the control K-111 
treated group had raised glycosylated haemoglobin levels compared to the control 
untreated group, these values remained within the normal range. Surprisingly chronic 
K-111 treatment reduced HDL-C levels within both dietary groups. Lastly, no 
standard error of the means were included for blood Trig levels in the K-111 treated 
groups as the Trig levels obtained were lower than the detectable limit of the Cardio-
check instrument. Thus the value reported was the lower detection limit of the 
Cardio-check instrument. 
 
Although the HCD K-111 treated animals in Table 6.2 were not heavier than the 
control or control treated animals, they will also be referred to as the obese or HCD 
fed K-111 treated group as at the time of K-111 administration, these animals were 
significantly heavier compared to their control littermates (Table 6.1). 
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6.3.3 Ex vivo myocardial function and substrate metabolism obtained on the 
Langendorff perfusion apparatus 
 6.3.3.1 Normal insulin and FA concentrations in the perfusate 
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Figure 6.6: Rate pressure product obtained from isolated rat hearts perfused 
with glucose (10mM) and normal insulin (30μIU/ml) and FA (0.7mM) 
concentrations. Hearts were subjected to 15 minutes normothermic total global 
ischaemia followed by 30 minutes reperfusion.  
n=4-8 hearts per group 
 
Neither obesity nor chronic PPARα agonist treatment influenced myocardial RPP 
before and during reperfusion (Figure 6.6). Similarly, there was no difference in the 
RPP percentage recovery between the four groups (data not shown). 
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Table 6.3: Average normoxic baseline and reperfusion myocardial substrate 
metabolism obtained from isolated rat hearts perfused with glucose (10mM) 
and normal insulin (30μIU/ml) and FA (0.7mM) concentrations. Hearts were 
subjected to 15 minutes normothermic total global ischaemia. Baseline 
samples were collected after 30 and 40 minutes of normoxic perfusion. 
Reperfusion samples were collected after 20 and 30 minutes post-ischaemic 
perfusion. 
 Baseline 
 Control Obese Control     
+ K-111 
Obese       
+ K-111 
Glycolysis                  
(μmol/g dw/min) 
0.62±0.11 0.80±0.18 0.79±0.20 1.24±0.26 
Glucose oxidation 
(μmol/g dw/min) 
0.11±0.03 0.07±0.02 0.13±0.03 0.09±0.03 
Palmitate oxidation 
(nmol/g dw/min) 
5.69±1.84 6.32±1.70 5.64±1.80 2.37±0.69 
 Reperfusion 
 Control Obese Control     
+ K-111 
Obese       
+ K-111 
Glycolysis 
(μmol/g dw/min) 
1.48±0.24b 1.27±0.12a 1.84±0.21c 1.65±0.21a
Glucose oxidation 
(μmol/g dw/min) 
0.15±0.05 0.16±0.05 0.18±0.04 0.28±0.10 
Palmitate oxidation 
(nmol/g dw/min) 
7.95±2.15 12.71±3.78a 9.32±1.55 8.25±1.51a
dw – dry weight 
ap<0.05; bp<0.01; cp<0.001 vs. baseline value 
Glycolytic flux rate: n = 5-7 hearts per group 
Glucose Oxidation: n = 4-6 hearts per group 
Palmitate oxidation n = 4-8 hearts per group 
 
In the presence of normal levels of insulin and FA neither obesity nor chronic K-111 
treatment influenced myocardial glycolytic flux, glucose oxidation or palmitate 
oxidation rates (Table 6.3) prior to and following global ischaemia. Notably, glycolytic 
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flux rates of all the groups and palmitate oxidation rates of the obese and the obese 
treated groups were elevated from baseline during the reperfusion phase.  
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6.3.3.2 High insulin and FA concentrations in the perfusate 
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Figure 6.7: Rate pressure product obtained from isolated rat hearts perfused 
with glucose (10mM) and high insulin (50μIU/ml) and FA (1.5mM) 
concentrations. Hearts were subjected to 15 minutes global ischaemia followed 
by 30 minutes reperfusion. 
N= 4-8 hearts per group 
 
Neither obesity nor chronic PPARα agonist treatment influenced the myocardial rate 
pressure product during baseline and reperfusion (Figure 6.7). In addition there was 
no difference in the percentage RPP recovery between the four groups (data not 
shown). 
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Table 6.4: Average normoxic baseline and reperfusion myocardial substrate 
metabolism obtained from isolated rat hearts perfused with glucose (10mM) 
and high insulin (50μIU/ml) and FA (1.5mM) concentrations. Hearts were 
subjected to 15 minutes normothermic total global ischaemia. Baseline 
samples were collected after 30 and 40 minutes of normoxic perfusion. 
Reperfusion samples were collected after 20 and 30 minutes post-ischaemic 
perfusion. 
 Baseline 
 Control Obese Control        
+ K-111 
Obese        
+ K-111 
Glycolysis              
(μmol/g dw/min) 
0.29±0.04 0.38±0.06 0.32±0.06 0.56±0.11
Glucose 
oxidation 
(μmol/g dw/min) 
0.07±0.01 0.05±0.01 0.07±0.01 0.10±0.02 
Palmitate 
oxidation 
(nmol/g dw/min) 
25.01±5.31 35.49±2.92 38.01±6.41 20.07±2.90* #
 Reperfusion 
 Control Obese Control        
+ K-111 
Obese        
+ K-111 
Glycolysis 
(μmol/g dw/min) 
0.86±0.14a 0.91±0.13a 1.90±0.34*b 1.38±0.20b
Glucose 
oxidation 
(μmol/g dw/min) 
0.15±0.05 0.12±0.03a 0.09±0.02 0.15±0.04 
Palmitate 
oxidation 
(nmol/g dw/min) 
104.32±12.96b 81.59±18.86d 100.09±10.43c 83.33±4.03c
dw – dry weight; HCD – high caloric diet 
*p<0.05 vs. similar dietary untreated group; #p<0.05 vs. control treated group;  
ap<0.05; bp<0.01; cp<0.001; dp =0.05 vs. baseline value 
Glycolytic flux rate: n = 6- 8 hearts per group 
Glucose Oxidation: n = 5 hearts per group 
Palmitate oxidation n = 4-7 hearts per group 
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The HCD had no impact on the rate of myocardial substrate metabolism. This was 
reflected by similar myocardial glycolytic flux, glucose oxidation and palmitate 
oxidation rates compared to the control group when hearts were perfused with 
elevated levels of insulin and FA (Table 6.4). The impact of K-111 treatment on 
myocardial substrate metabolism was dependent on the presence or absence of 
HCD feeding. While HCD fed K-111 treated rats had lower pre-ischaemic palmitate 
oxidation rates compared to the HCD fed untreated animals, similar differences were 
found when being compared to the control K-111 treated group. During reperfusion, 
comparable rates of substrate metabolism were observed between the various 
groups. The only exception was with the control K-111 treated group that achieved 
significantly higher glycolytic flux rates compared to the untreated control group.  
 
Reperfusion had a marked effect on the pattern of substrate metabolism with the 
rates of glycolytic flux, and palmitate oxidation for the various groups being higher 
during reperfusion compared to baseline values. Similarly glucose oxidation rates 
were higher during reperfusion compared to baseline values in the obese group, 
while a similar non-significant trend was observed in the other experimental groups. 
 
 
Stellenbosch University http://scholar.sun.ac.za
171 
 
6.3.3.3 Comparisons of myocardial function and substrate metabolism 
between control and obese animals perfused with both 10mM glucose 
and normal or high concentrations of insulin and FA  
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Figure 6.8: Pre-ischaemic rate pressure product obtained from isolated rat 
hearts perfused with glucose (10mM) and normal (30μIU/ml insulin and 0.7mM 
FA) or high (50μIU/ml insulin and 1.5mmol/l FA) insulin and FA concentrations. 
Measurements were taken after 40 minutes normoxic perfusion.  
@p<0.01 
n = 4-8 
 
Hearts from control animals perfused with elevated insulin and FA concentrations 
had significantly greater baseline RPP’s compared to hearts from control animals 
perfused with the low insulin and FA concentrations (38984.25±1281.63 vs. 
32558.50±1162.01 mmHg.beats.min-1, p<0.01) (Figure 6.8). In contrast, the presence 
of elevated insulin and FA in the perfusate did not cause the baseline RRP values to 
differ from those obtained when these hearts were perfused with normal insulin and 
FA concentrations. 
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Figure 6.9a: Post-ischaemic rate pressure product percentage recovery 
obtained from isolated rat hearts perfused with glucose (10mM) and normal 
(30μIU/ml insulin and 0.7mM FA) or high (50μIU/ml insulin and 1.5mmol/l FA) 
insulin and FA concentrations. Hearts were subjected to 15 minutes global 
ischaemia followed by 30 minutes reperfusion. Functional values were taken at 
the end of the pre- and post-ischaemic periods.  
*p<0.01 
n = 4-8 
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Figure 6.9b: Post-ischaemic rate pressure product percentage recovery 
obtained from isolated rat hearts perfused with glucose (10mM) and normal 
(30μIU/ml insulin and 0.7mM FA) or high (50μIU/ml insulin and 1.5mmol/l FA) 
insulin and FA concentrations after 20 minutes reperfusion. Hearts were 
subjected to 15 minutes global ischaemia followed by a reperfusion period. 
Functional values were taken at the end of the pre-ischaemic and after 15 
minutes of reperfusion. 
n = 4-8 
 
In the control hearts the recovery in RPP was not influenced by the concentration of 
insulin and FA (Figure 6.9a) present in the perfusate. However in the obese group, 
high insulin and FA levels enabled these hearts to achieve a significantly better RPP 
percentage recovery compared to hearts from the same group perfused with low 
insulin and FA concentrations (102.00±2.64 vs. 73.12±9.71 %, p<0.05). While this 
may suggest that hearts from obese animals respond better to ischaemia in the 
presence of elevated insulin and FA concentrations, the improvement in functional 
recovery observed in the obese group has to be interpreted with caution. The raw 
RPP percentage recovery data for the low insulin + FA obese group was as follows: 
58.46, 85.02, 31.87, 52.01, 98.01, 89.33, 97.16. Three of these hearts obtained 
significantly lower RPP’s recoveries primarily due to unstable sinus rhythm 
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(ventricular arrhythmia’s) during the last 10 minutes of reperfusion which contributed 
to a lower RPP values. Figure 6.9b demonstrates that after 20 minutes reperfusion, 
prior to the development of these rhythm disturbances in some of the hearts, the 
RPP recovery was comparable between the obese groups.    
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Figure 6.10: Average a) baseline and b) reperfusion myocardial glycolytic flux 
rates obtained from isolated rat hearts perfused with glucose (10mM) and 
either normal (30μIU/ml insulin and 0.7mM FA) or high (50μIU/ml insulin and 
1.5mmol/l FA) insulin and FA concentrations. Hearts were subjected to 15 
minutes global ischaemia followed by 30 minutes reperfusion. Baseline 
samples were collected after 30 and 40 minutes of normoxic perfusion. 
Reperfusion samples were collected after 20 and 30 minutes post-ischaemic 
perfusion. 
*p<0.05 
n = 5-7 hearts per group   
 
Although there was a tendency for baseline glycolytic flux rates in the control groups 
to be influenced by the different insulin and FA concentrations present in the 
Stellenbosch University http://scholar.sun.ac.za
176 
 
perfusate, this proved to be insignificant (Figure 6.10a). However during the 
reperfusion phase, elevated insulin and FA present in the perfusate resulted in these 
hearts generating lower glycolytic flux rates compared to similar hearts perfused in 
the presence of normal insulin and FA concentrations (0.86±0.14 vs. 1.48±0.24 
μmol/g dw/min; p<0.05) (Figure 6.10b). 
 
In the presence of high insulin and FA levels, hearts from the obese group had 
significantly lower baseline myocardial glycolytic flux rates compared to those hearts 
perfused with normal insulin and FA concentrations (0.38±0.06 vs. 0.80±0.18 μmol/g 
dw/min, p<0.05) (Figure 6.10a). During reperfusion, the presence of high insulin and 
FA levels in the perfusate did not significantly affect myocardial glycolytic flux rates in 
either of the obese groups (Figure 6.10b). 
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Figure 6.11: Average a) baseline and b) reperfusion myocardial glucose 
oxidation rates obtained from isolated rat hearts perfused with glucose (10mM) 
and either normal (30μIU/ml insulin and 0.7mM FA) or high (50μIU/ml insulin 
and 1.5mmol/l FA) insulin and FA concentrations. Hearts were subjected to 15 
minutes global ischaemia followed by 30 minutes reperfusion. Baseline 
samples were collected after 30 and 40 minutes of normoxic perfusion. 
Reperfusion samples were collected after 20 and 30 minutes post-ischaemic 
perfusion. 
n = 4-5 hearts per group  
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Increasing the concentration of insulin and FA in the perfusate of hearts from control 
and obese animals did not influence their glucose oxidation rates either prior to 
(Figure 6.11a) or during reperfusion following global ischaemia (Figure 6.11b).  
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Figure 6.12: Average a) baseline and b) reperfusion myocardial palmitate 
oxidation rates obtained from isolated rat hearts perfused with glucose (10mM) 
and either normal (30μIU/ml insulin and 0.7mM FA) or high (50μIU/ml insulin 
and 1.5mmol/l FA) insulin and FA concentrations. Hearts were subjected to 15 
minutes global ischaemia followed by 30 minutes reperfusion. Baseline 
samples were collected after 30 and 40 minutes of normoxic perfusion. 
Reperfusion samples were collected after 20 and 30 minutes post-ischaemic 
perfusion. 
#p<0.001 
n = 4-8 
 
High insulin and FA levels present in the perfusate had an substantial impact on 
myocardial palmitate oxidation rates by significantly increasing these values during 
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baseline and reperfusion in both the control (Baseline: 3.25±1.01 vs. 20.01±4.24 
nmol/g dw/min, p<0.0001; Reperfusion: 4.55±1.23 vs. 83.46±10.37 nmol/g dw/min, 
p<0.0001) and obese groups (Baseline: 3.61±0.97 vs. 28.39±2.34 nmol/g dw/min, 
p<0.001; Reperfusion: 7.26±2.16 vs. 65.28±15.09 nmol/g dw/min, p<0.001) (Figure 
6.12a, b). 
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6.3.4 Ex vivo pre- and post-ischaemic myocardial functional parameters  
 6.3.4.1 Normal insulin and FA concentrations in the perfusate 
Table 6.5: The effect of obesity and chronic K-111 treatment on myocardial 
functional parameters assessed prior to and following 40 minutes of regional 
ischaemia when perfused with glucose (10mM) and normal insulin (30μIU/ml) 
and FA (0.7mM) concentrations 
 
Baseline data 
 Control 
 
n = 11 
Obese 
 
n = 11 
Control  
K-111 
n= 11 
Obese  
K-111 
n = 11 
Aortic output 
(ml/min) 
49.3±1.3 46.4±1.8 48.9±1.0 43.8±2.0 
Coronary flow 
(ml/min) 
19.9±1.0 19.3±1.4 17.6±0.7 17.7±0.4 
Cardiac output 
(ml/min) 
69.1±1.3 65.7±2.7 66.6±1.3 61.5±2.3 
SP (mmHg) 99.1±1.0 96.0±1.0 98.4±1.0 95.4±1.4 
DP (mmHg) 61.4±1.4 61.6±1.8 59.6±1.2 62.2±1.1 
Heart rate (bpm) 282±5 295±6 275±6 287±5 
Work total (W) 15.3±0.3 14.1±0.6 14.6±0.3 13.1±0.6 
dP/dtmax 
(mmHg/s) 
28.4±1.9 26.8±1.8 25.0±0.9 27.1±1.4 
dP/dtmin 
(mmHg/s) 
-21.1±1.0 -24.30±0.8* -22.5±1.0 -21.2±0.9& 
Reperfusion data 
 Control 
 
n = 7/8 
Obese 
 
n = 10 
Control  
K-111 
n = 10 
Obese  
K-111 
n = 9 
Aortic output 
(ml/min) 
3.4±1.6 0.0±0.0 4.9±2.0 1.6±1.3 
Coronary flow 
(ml/min) 
19.7±2.0 19.7±3.2 23.1±2.2 19.0±2.2 
Cardiac output 
(ml/min) 
23.1±3.0 19.7±3.2 28.0±3.6 20.6±2.6 
SP (mmHg) 76.3±5.5 68.1±4.1 82.2±2.4 73.7±4.2 
DP (mmHg) 56.4±5.7 53.9±3.8 64.8±2.3 58.2±3.4 
Heart rate (bpm) 294±16 285±13 299±12 296±18 
Work total (W) 3.9±0.8 3.8±1.0 5.2±0.7 3.6±0.6 
dP/dtmax 
(mmHg/s) 
13.1±2.0 9.3±0.8 15.3±1.0 11.1±0.9$ 
dP/dtmin 
(mmHg/s) 
-7.7±0.9 -8.3±0.5 -9.6±0.8 -8.0±0.7 
DP – aortic diastolic pressure; dP/dt – delta aortic pressure over delta time; SP 
– aortic systolic pressure 
*p<0.05 vs. control; $p<0.05 vs. control + K-111; &p<0.05 vs. obese  
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Neither the HCD nor chronic K-111 treatment had any effect on either of the 
functional parameters assessed prior to and following myocardial regional ischaemia, 
when isolated working hearts were perfused with normal insulin and FA 
concentrations (Table 6.5). The exception was aortic dP/dtmax/min. As the aortic 
outputs between all these groups were comparable, this finding has no immediate 
functional implication. 
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6.3.4.2 High insulin and FA concentrations in the perfusate 
Table 6.6: The effect of obesity and chronic K-111 treatment on myocardial 
functional parameters assessed prior to and following 40 minutes of regional 
ischaemia when perfused with glucose (10mM) and high insulin (50μIU/ml) and 
FA (1.5mM) concentrations 
 
Baseline data 
 Control 
 
n = 10 
Obese 
 
n = 12 
Control 
K-111 
n = 11 
Obese 
K-111 
n = 10 
Aortic output 
(ml/min) 
48.3±1.9 45.7±2.3 47.0±1.5 47.5±1.3 
Coronary flow 
(ml/min) 
19.3±1.1 20.3±1.1 18.9±0.7 20.1±1.0 
Cardiac output 
(ml/min) 
67.6±2.6 66.0±3.1 65.9±1.8 67.6±2.0 
SP (mmHg) 99.7±1.4 99.8±1.0 97.8±1.3 98.8±1.2 
DP (mmHg) 61.8±0.9 60.1±1.2 60.7±1.4 59.9±1.7 
Heart rate (bpm) 279±6 269±8 284±7 283±8 
Work total (W) 15.1±0.6 14.8±0.8 14.4±0.5 14.9±0.5 
dP/dtmax 
(mmHg/s) 
30.6±1.5 30.5±1.8 28.6±1.7 26.5±1.1 
dP/dtmin 
(mmHg/s) 
-18.3±1.0 -22.0±0.95* -22.6±0.9* -22.8±1.3 
Reperfusion data 
 Control 
 
n = 8 
Obese 
 
n = 11 
Control  
K-111 
n = 9 
Obese  
K-111 
n = 9 
Aortic output 
(ml/min) 
10.7±3.8 8.0±1.9 7.2±1.8 9.9±3.3 
Coronary flow 
(ml/min) 
21.8±1.1 24.5±2.0 21.8±2.7 22.8±3.0 
Cardiac output 
(ml/min) 
32.4±4.5 32.5±3.4 29.0±3.9 32.7±5.9 
SP (mmHg) 89.0±1.5 88.8±0.8 81.4±6.7 81.6±4.6 
DP (mmHg) 67.4±1.8 65.7±1.4 59.9±5.3 60.8±4.2 
Heart rate (bpm) 284±10 282±10 272±20 279±18 
Work total (W) 6.5±0.9 6.5±0.7 5.7±0.9 6.2±1.2 
dP/dtmax 
(mmHg/s) 
18.3±1.7 16.6±1.7 16.6±2.0 15.9±1.7 
dP/dtmin 
(mmHg/s) 
-9.2±0.6 -11.3±1.1 -9.8±0.9 -9.6±1.4 
DP – aortic diastolic pressure; dP/dt – delta aortic pressure over delta time; SP 
– aortic systolic pressure 
*p<0.05 vs. control 
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When hearts were perfused with elevated levels of insulin and FA, a similar 
myocardial functional profile was noted amongst the various groups as was 
previously observed in the presence of normal insulin and FA levels. Again no 
differences between any of the functional parameters existed among the various 
groups, with the exception of the aortic dP/dtmin values (Table 6.6). Although 
differences in aortic dP/dtmin exist, these findings have no immediate functional 
implications.  
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6.3.5 Myocardial susceptibility to ischaemia/reperfusion injury 
6.3.5.1 Normal insulin and FA concentrations in the perfusate 
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Figure 6.13: a) Myocardial infarct size expressed as a percentage of the area at 
risk and b) the area at risk expressed as a percentage of the LV area. Hearts 
perfused with glucose (10mM) and normal insulin (30μIU/ml) and FA (0.7mM) 
concentrations were subjected to 40 minutes regional ischaemia followed by 
60 minutes reperfusion.  
n = 11 hearts per group   
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Table 6.7: Post-ischaemic functional recovery assessed in working hearts in 
the presence of 10mM glucose and normal insulin and FA concentrations 
 
 Control 
 
n = 8 
Obese 
 
n = 10 
Control        
+ K-111 
n = 10 
Obese       
+ K-111 
n = 9 
AO (%) 7.23±3.39 0.00±0.00 9.64±3.85 3.30±2.80 
CO (%) 34.07±4.64 27.00±4.35 41.66±4.54 33.05±3.60 
Total work (%) 25.97±5.06 26.88±6.65 35.48±4.24 26.76±3.78 
CO – cardiac output; AO – Aortic output 
 
Obesity and chronic K-111 treatment had no impact of the measured indices of 
ischaemia/reperfusion injury when hearts from these groups were perfused with 
normal insulin and FA concentrations. This was reflected by comparable infarct sizes 
(with similar at risk areas) (Figure 6.13 a, b) and similar functional recoveries (aortic 
output, cardiac output, total work) (Table 6.7) between the various groups. 
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6.3.5.2 High insulin and FA concentrations in the perfusate 
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Figure 6.14: a) Myocardial infarct size expressed as a percentage of the area at 
risk and b) The area at risk expressed as a percentage of left ventricular area. 
Hearts perfused with glucose (10mM) and high insulin (50μIU/ml) and FA 
(1.5mM) concentrations were subjected to 40 minutes regional ischaemia 
followed by 60 minutes reperfusion.  
n = 10-12 hearts per group   
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Table 6.8: Post-ischaemic functional recovery assessed in working hearts in 
the presence of 10mM glucose and high insulin and FA concentrations 
 
 Control 
 
n = 8 
Obese 
 
n = 11 
Control        
+ K-111 
n = 9 
Obese       
+ K-111 
n = 9 
AO (%) 21.47±6.92 17.28±4.12 15.89±3.80 19.91±5.93 
CO (%) 47.17±5.51 37.43±2.35 37.18±7.53 47.40±7.26 
Total work (%) 42.52±5.30 43.99±3.92 37.53±6.29 41.05±6.93 
CO – cardiac output; AO – Aortic output 
 
Neither obesity nor chronic K-111 treatment influenced post-ischaemic outcomes 
when hearts from each group were perfused with elevated insulin and FA levels. 
Both myocardial infarct size, the area at risk (Figure 6.14a,b) and functional 
recoveries (Aortic output, cardiac output and total work) (Table 6.8) were comparable 
between the various groups.  
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6.3.5.3 Comparisons of indices of ischaemia/reperfusion injury in the 
control and obese groups perfused with both 10mM glucose and normal 
and high insulin and FA concentrations  
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Figure 6.15: Myocardial infarct size expressed as a percentage of the area at 
risk. Hearts perfused with either glucose and normal (30μIU/ml insulin and 
0.7mM FA) or high (50μIU/ml insulin and 1.5mmol/l FA) insulin and FA 
concentrations were subjected to 40 minutes regional ischaemia followed by 
60 minutes reperfusion. 
n = 10-12 hearts per group   
The size of the myocardial infarction did not differ within groups when comparisons 
were made between control and obese hearts perfused with normal and high insulin 
and FA concentrations (Figure 6.15).  
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Table 6.9: Comparison of the post-ischaemic percentage functional recovery 
attained in the presence of 10mM glucose and normal and high insulin and FA 
concentrations, assessed in working hearts from control and obese animals  
 
 Control Obese 
 Normal 
n = 8 
High 
n = 10 
Normal 
n = 8 
High 
n = 11 
AO (%) 7.23±3.39 21.47±6.92 0.00±0.00 17.28±4.12@
CO (%) 34.07±4.64 47.17±5.51 27.00±4.35 37.43±2.35 
Total work 
(%) 
25.97±5.06 42.52±5.30 26.88±6.65 43.99±3.92* 
CO – cardiac output; AO – aortic output 
@p<0.01, *p<0.05 vs. obese normal 
 
When comparing the effect of the different perfusion conditions on the myocardial 
functional recovery, it was intriguing to observe how well hearts from obese animals 
responded to elevated concentrations of insulin and FA in the perfusion medium. In 
the presence of elevated insulin and FA concentrations, hearts from obese animals 
achieved significantly greater aortic output and total work recoveries compared to 
similar hearts perfused with normal insulin and FA concentrations (Table 6.9). 
Although a similar trend was seen in the control groups, these effects were not 
significant.  
 
 
 
Stellenbosch University http://scholar.sun.ac.za
191 
 
6.3.6 Comparisons of myocardial substrate metabolism and infarct size 
between hearts from control and obese animals when simulating the group 
specific relevant in vivo conditions 
 
Table 6.10: Comparison of myocardial glycolytic flux, glucose oxidation and 
palmitate oxidation rates in isolated hearts from control and obese animals in 
the presence of 10mM glucose and simulated in vivo concentrations of insulin 
and FA  
 Baseline 
 Control Obese 
Glycolysis                      
(μmol glucose/g dw/min) 0.62±0.11 0.38±0.06 
Glucose oxidation 
(μmol glucose/g dw/min) 0.11±0.03 0.05±0.01* 
Palmitate oxidation 
(nmol palmitate/g dw/min) 
3.25±1.05 28.39±2.34# 
 Reperfusion 
 Control Obese 
Glycolysis 
(μmol glucose/g dw/min) 1.48±0.24 0.91±0.13 
Glucose oxidation 
(μmol glucose/g dw/min) 0.15±0.05 0.12±0.03 
Palmitate oxidation 
(nmol palmitate/g dw/min) 
4.55±1.23 65.28±15.09# 
dw – dry weight  
#p<0.001, *p=0.057 
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Figure 6.16: Myocardial infarct size expressed as a percentage of the area at 
risk obtained from hearts isolated from control rats perfused with glucose 
(10mM) and normal insulin and FA concentrations (insulin (30μIU/ml) and FA 
(0.7mM)) and hearts from obese animals perfused with glucose (10mM) and 
high insulin and FA concentrations (insulin (50μIU/ml) and FA (1.5mmol/l)). 
Hearts were subjected to 40 minutes regional ischaemia followed by 60 
minutes reperfusion. Administration of substrate and insulin was done 
throughout the perfusion protocol 
*p<0.05 
n = 10-12 hearts per group 
 
When comparisons between the control and obese groups were made simulating the 
specific in vivo environment that the heart would be expected to be exposed to, 
significant observations were made. In the presence of simulated in vivo insulin and 
FA concentrations, baseline myocardial glucose oxidation rates were reduced 
(0.05±0.01 vs. 0.11±0.03 μmol/g dw/min, p<0.057) whereas palmitate oxidation rates 
were increased (28.39±2.34 vs. 3.25±1.01 nmol/g dw/min, p<0.001) in the obese 
group compared to the control group (Table 6.10). Baseline glycolytic flux rates were 
comparable between the two groups. While no significant differences existed 
between the myocardial reperfusion glycolytic flux and glucose oxidation rates 
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between the control and obese groups, reperfusion palmitate oxidation rates were 
significantly elevated in the obese group (65.28±15.09 vs. 4.55±1.23 nmol/g 
dw/min) relative to the control group.  
 
Of particular interest was the increase in the size of infarction observed in the obese 
group compared to the control group (47.44±3.13 vs. 37.17±2.63 %, p<0.05) (Figure 
6.16). It is worth mentioning that comparisons of myocardial infarct size specifically 
assessed with the unpaired Students t-test were not significant between the control 
and obese group when perfused with comparable perfusion conditions (i.e. unpaired 
Students t-test performed on the control and obese groups in Figures 6.13 a and 
6.14 a). 
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6.3.7 Measurements of mitochondrial function  
 6.3.7.1 Substrate: glutamate 
 
Table 6.11: The effect of obesity and chronic K-111 treatment on measurements 
of mitochondrial respiration and susceptibility to anoxia induced mitochondrial 
dysfunction in the presence of glutamate. Following state 3 and 4 respiration, 
mitochondria were made anoxic for 25 minutes and reoxygenated for the 
measurement of state 3 respiration.  
 Control 
 
n = 11 
Obese 
 
n = 9 
Control  
+ K-111 
n = 10 
Obese  
+ K-111 
n = 12 
ADP/O (nmol 
ADP/nAtoms 
oxygen) 
2.65±0.19 2.67±0.17 2.56±0.12 2.80±0.15 
RCI 
(State3/State4) 
7.17±0.73 7.39±0.43 6.55±0.65 6.88±0.44 
State 2 Resp. 
(nAtoms 
oxygen/min/mg) 
21.50±1.94 17.91±0.96 19.67±1.28 19.31±1.48 
State 3 Resp. 
(nAtoms 
oxygen/min/mg) 
145.10±11.22 146.67±9.087 138.27±12.65 147.39±11.46
State 4 Resp. 
(nAtoms 
oxygen/min/mg) 
21.41±2.16 19.93±0.86 21.98±1.95 21.93±1.68 
Oxphos rate 
(nmol 
ADP/min/mg) 
390.87±42.62 388.78±32.42 362.39±46.55 410.34±44.85
State 3 % 
recovery during 
reoxygenation 
after anoxia (%)   
54.52±5.87 53.62±5.35 47.24±5.77 53.79±4.13 
ADP/O – adenosine diphosphate phosphorylation/oxygen uptake; Oxphos – 
oxidative phosphorylation rate; Resp – respiration 
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In the presence of glutamate as substrate, indices of mitochondrial respiration in 
control and obese untreated and treated animals were similar (Table 6.11). Neither 
obesity nor chronic K-111 treatment impacted on the amount of ADP utilized per 
atom of oxygen, or the coupling of the mitochondria during oxidative respiration. 
Lastly, neither obesity nor chronic K-111 treatment affected ventricular mitochondrial 
susceptibility to anoxia/reoxygenation.  
 
Stellenbosch University http://scholar.sun.ac.za
196 
 
6.3.7.2 Palmitoyl – L – carnitine as the oxidative substrate 
Table 6.12. The effect of obesity and chronic K-111 treatment on measurements 
of mitochondrial respiration and susceptibility to anoxia induced mitochondrial 
dysfunction in the presence of palmitoyl – L – carnitine. Following baseline 
state 3 and 4 respiration mitochondria were made anoxic for 25 minutes and 
reoxygenated for the measurement of state 3 respiration. 
 Control 
 
n = 8 
Obese 
 
n = 10 
Control  
+ K-111 
n = 9 
Obese  
+ K-111 
n = 11 
ADP/O (nmol 
ADP/nAtoms 
oxygen) 
2.44±0.22 2.49±0.20 2.30±0.14 2.61±0.93 
RCI 
(State3/State4) 
5.67±0.32 6.27±0.27 5.75±0.51 6.68±0.46
State 2 Resp. 
(nAtoms 
oxygen/min/mg) 
30.94±3.90 29.56±2.38 28.84±3.24 28.33±3.76 
State 3 Resp. 
(nAtoms 
oxygen/min/mg) 
204.12±17.95 211.30±13.37 201.07±25.89 204.69±18.01
State 4 Resp. 
(nAtoms 
oxygen/min/mg) 
36.50±3.48 33.91±2.05 35.15±2.70 30.99±2.16 
Oxphos rate 
(nmol 
ADP/min/mg) 
491.34±57.43 523.67±50.52 464.17±67.59 551.06±79.04
State 3 % 
recovery during 
reoxygenation 
after anoxia (%)   
21.69±6.41 25.52±4.05 26.49±5.67 27.97±4.74 
ADP/O – adenosine diphosphate phosphorylation/oxygen uptake; Oxphos – 
oxidative phosphorylation rate;  Reox – reoxygenation; Resp – respiration. 
@p<0.01 vs. control+K-111 
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Ventricular mitochondrial respiration parameters were unchanged by the HCD and 
chronic K-111 treatment in the presence of palmitoyl – L – carnitine as substrate 
(Table 6.12). Mitochondrial ADP/O ratios, RCI values and susceptibility to 
anoxia/reoxygenation were comparable between the groups.  
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6.3.7.3 Comparisons between glutamate and palmitoyl – L – carnitine on 
mitochondrial respiration and anoxic injury susceptibility 
Table 6.13: Comparison of the effects of glutamate and palmitoyl – L – carnitine 
on measurements of respiration and anoxia injury susceptibility in ventricular 
mitochondria isolated from control and obese animals. Following baseline 
state 3 and 4 respiration mitochondria were made anoxic for 25 minutes and 
reoxygenated for the measurement of state 3 respiration 
 Glutamate Palmitoyl-L-carnitine 
 Control 
n = 11 
Obese 
n = 9 
Control 
n = 8 
Obese 
n = 10 
ADP/O (nmol 
ADP/nAtoms 
oxygen) 
2.65±0.19 2.67±0.17 2.44±0.22 2.49±0.20 
RCI 
(State3/State4) 
7.17±0.73 7.39±0.42 5.67±0.32 6.27±0.27 
State 2 Resp. 
(nAtoms 
oxygen/min/mg) 
21.50±1.94 17.91±0.96 30.94±3.90* 29.56±2.38@ 
State 3 Resp. 
(nAtoms 
oxygen/min/mg) 
145.10±11.22 146.67±9.09 214.12±17.95@ 211.30±13.37@ 
State 4 Resp. 
(nAtoms 
oxygen/min/mg) 
21.41±2.16 19.93±0.86 36.50±3.48# 33.91±2.05# 
Oxphos rate 
(nmol 
ADP/min/mg) 
390.87±42.62 388.78±32.42 491.34±57.43 523.67±50.52 
State 3 % 
recovery during 
reoxygenation 
after anoxia (%)   
54.52±5.88 53.62±5.35 21.69±6.41# 25.52±4.05@ 
ADP/O – adenosine diphosphate phosphorylation/oxygen uptake; Oxphos – 
oxidative phosphorylation rate; Reox – reoxygenation; Resp – respiration. 
*p<0.05, @p<0.01, #p<0.001 vs. glutamate. 
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Interesting observations were made when comparing the use of glutamate and 
palmitoyl – L – carnitine as oxidizable substrates (Table 6.13). Although the ADP/O 
(Control: 2.72±0.26 vs. 2.42±0.26; Obese: 2.75±0.17 vs. 2.47±0.21) and RCI 
(Control: 7.43±0.81 vs. 5.77±0.35; Obese: 7.57±0.43 vs. 6.35±0.29) values within the 
control and obese groups were similar irrespective of the substrate present, state 2, 3 
and 4 respiration values were higher in both these groups when palmitoyl – L – 
carnitine was being oxidized. Furthermore, the presence of palmitoyl – L – carnitine 
significantly reduced the mitochondria’s ability to function effectively during 
reoxygenation following a period of anoxia when compared to experiments where 
only glutamate was used. 
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6.3.8 Western blot analysis 
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Figure 6.17: The impact of obesity and chronic K-111 treatment on 
phosphorylated PKB (a) and total PKB (b) expression in ventricular tissue. 
Hearts were freeze clamped after being removed from the animals. 
n = 6 hearts per group 
 
Phosphorylated PKB (Figure 6.17a) and total PKB (Figure 6.17b) expression were 
similar in hearts from control and obese animals. In addition, K-111 treatment did not 
influence total PKB expression or phosphorylation in the ventricular tissue. 
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Figure 6.18: The impact of obesity and chronic K-111 treatment on 
phosphorylated p85 subunit of PI3K (a) and total PI3K (b) expression in left 
ventricular tissue. Hearts were freeze clamped after being removed from the 
animals. 
n = 6 hearts per group 
 
The expression of both the phosphorylated p85 subunit of PI3K (Figure 6.18a) and 
total PI3K (Figure 6.18b) was unaltered between the groups, with neither obesity nor 
K-111 treatment affecting the levels of protein expression. 
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Figure 6.19: The impact of obesity and chronic K-111 treatment on CPT-1 
expression in left ventricular tissue. Hearts were freeze clamped after being 
removed from the animals. 
n = 6 hearts per group 
 
Although the 2-way analysis of variance determined that the HCD contributed 
significantly to the variance seen in CPT-1 expression (p=0.03), post test analysis 
indicated no significant differences between the four groups (Figure 6.19). (When 
assessed with an unpaired Students t-test, the expression of CPT-1 was greater in 
the obese group compared to the control group). K-111 treatment did not influence 
myocardial CPT-1 expression in the LV. 
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Figure 6.20: The impact of obesity and chronic K-111 treatment on -Tubulin 
expression in left ventricular tissue. Hearts were freeze clamped after being 
removed from the animals.  
n = 6 hearts per group 
 
There was no difference in β-tubulin between the groups (Figure 6.20) indicating that 
equal amounts of protein from the various groups were loaded onto the membranes 
prior to being separated by electrophoresis. 
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6.4 Summary of findings 
 
When perfused with glucose and comparable concentrations of insulin and FA, 
hearts from obese animals had comparable LV mechanical function, rates of 
substrate metabolism and tolerance to ischaemia/reperfusion injury relative to the 
control hearts. The infarct sizes obtained in the hearts from control and obese 
animals perfused in the presence of their respective simulated in vivo insulin and FA 
condition were compared and it emerged the in vivo environment associated with 
obesity contributed significantly to increased infarct sizes in hearts from obese rats. 
These perfusion conditions were associated with the most dramatic shifts in 
myocardial substrate metabolism between the control and obese untreated groups.    
 
K-111 treatment attenuated many of the systemic metabolic abnormalities associated 
with obesity, while it did not impact on LV or mitochondrial oxidative phosphorylation 
function. K-111 treated obese hearts maintained lower palmitate oxidation rates 
compared to the untreated obese group (when perfused in the presence of high 
insulin and FA concentrations in the perfusate), however this occurred without any 
significant change in the expression of the PPARα regulated enzyme CPT-1.  
Despite K-111’s beneficial systemic and metabolic effects, it did not induce 
cardioprotection following an episode of ischaemia/reperfusion. Nevertheless, 
considering some of the adverse effects associated with myocardial PPARα 
activation, the fact that K-111 did not detrimentally affect post-ischaemic outcomes in 
our study is of great clinical importance regarding the usefulness of PPARα agonists 
in the treatment of patients at high risk for developing myocardial ischaemic 
disorders. 
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The rates of myocardial substrate metabolism should however be interpreted with 
caution (See Discussion section 7.3).  
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CHAPTER 7 
DISCUSSION 
 
Using a pre-diabetic rodent model of diet induced obesity and insulin resistance, the 
aims of the present studies were to determine the impact of protracted obesity on 
myocardial mechanical function, the responsiveness of isolated hearts from obese 
insulin resistant animals to insulin treatment prior to and during a simulated acute 
myocardial infarction. The effects of obesity on myocardial substrate metabolism, 
ventricular mitochondrial function and susceptibility to ischaemia/reperfusion injury 
were also investigated. The same rodent model of obesity was further used to 
investigate the impact of chronic PPARα agonist treatment (K-111) on myocardial 
mechanical function, substrate metabolism, ventricular mitochondrial function and 
susceptibility to ischaemia/reperfusion injury.  
 
The main findings of the present study were as follows: 1) Protracted obesity, in the 
present model, was associated with normal in vivo myocardial LV mechanical 
function and functional reserve. The study unmasked an inability of hearts from 
obese animals to utilize glucose effectively as a fuel source (myocardial substrate 
inflexibility) in the maintenance of normal LV mechanical function ex vivo. The 
importance of simulated in vivo concentrations of FFA’s in the maintenance of both 
normal in vivo LV mechanical function and functional reserve in the obese state was 
further highlighted; 2) While glucose perfused hearts from obese animals were 
metabolically responsive to insulin present in the perfusate, this response was not to 
the same degree as observed in hearts isolated from the control animals, indicating 
some degree of myocardial insulin resistance in these animals. Isolated hearts from 
obese insulin resistant animals further showed increased susceptibility to 
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ischaemia/reperfusion injury when perfused with glucose alone, while insulin 
administration prior to and during ischaemia conferred significant cardioprotection in 
the obese group and to a lesser extent in the control group; 3) In the presence of 
similar concentrations of glucose, insulin and FA in the perfusate, hearts from obese 
animals had similar ex vivo myocardial mechanical function, substrate metabolism 
and post-ischaemic outcomes compared to the control group. In addition, 
mitochondrial function and tolerance to anoxia were also comparable between the 
obese and control groups in the presence of glutamate or palmitoyl-L-carnitine as 
substrate; 4) The current data further suggest that the specific metabolic environment 
associated with obesity (elevated circulating insulin and FA levels)  may contribute to 
detrimental post-ischaemic outcomes in the obese state; 5) Lastly, although chronic 
K-111 treatment improved the systemic metabolic profile associated with obesity, it 
had a limited impact on cardiac substrate metabolism (reduced palmitate oxidation 
rates in the presence of high insulin and FA levels in the perfusate), while it did not 
influence myocardial function or myocardial ischaemic tolerance irrespective of the 
different perfusion conditions implemented. Similarly chronic K-111 treatment did not 
influence ventricular mitochondrial function or their tolerance to anoxia in the 
presence of either glutamate or palmitoyl-L-carnitine as substrates in either the 
obese or control treated groups.  
 
7.1 The model of diet induced obesity 
 
Obesity seldom exists in isolation from various other co-morbidities such as 
dyslipidaemia, hyperinsulinaemia, insulin resistance, diabetes and hypertension, 
each of which constitutes a risk for cardiovascular disease (Stamler et al. 1978; 
Kannel et al. 1979; Kannel and McGee, 1979; Van Itallie et al. 1985; Barbir et al. 
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1988; Colditz et al. 1995; O’Donnell et al. 1997; Abassi et al. 2002; Rewers et al. 
2004). Not surprisingly, it was found that 16, 18 and 32 weeks of HCD feeding 
significantly increased rodent body weight and visceral (retroperitoneal and gonadal) 
fat content (Table 4.1, 5.1, 6.2). Obese rats further displayed a metabolic profile 
similar to pre-diabetic metabolic syndrome seen in humans, evident by the co-
occurrence of normoglycaemia, hyperinsulinaemia, insulin resistance (HOMA-IR), 
and hypertriglyceridaemia, while in certain groups of animals HDL-C levels were 
significantly reduced compared to the lean animals (Table 4.2, 5.2, 6.2). Additional 
biochemical determinations only performed after 16 or 18 weeks of feeding revealed 
an increase in circulating FFA levels in response to HCD feeding (Table 5.2, 6.2). 
Despite this increased supply of FFA, intramyocardial Trig levels of control and obese 
animals did not differ (Table 6.2). Normal levels of glycosylated haemoglobin further 
confirmed the absence of diabetes and effective blood glucose management in our 
model of obesity (Table 5.2, 6.2).  
Comparisons between 32 week and 16 week control and HCD fed animals (data not 
shown) revealed that 32 week HCD fed rats had a 25% and 34% increase in body 
weight and visceral fat mass relative to the 16 week fed rats (p<0.001). Similarly, the 
body weight of the 32 week fed control rats was 19% more than the 16 weeks control 
group (p<0.001), while no differences in visceral fat mass were seen (comparisons 
not shown). Comparisons of metabolic parameters between 32 and 16 week rats 
were not possible due to differences in the overnight fasting periods between these 
two groups. 
 
Other rodent models of diet induced obesity likewise displayed similar biometric and 
metabolic profiles to that observed in the current study (Wilson et al. 2007), while in 
certain models, raised glucose levels may also develop following high caloric feeding 
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(Ouwens et al. 2007; Ussher et al. 2010). Although the caloric composition of the 
HCD utilized in the present study differed slightly from that used by other groups 
(Ouwens et al. 2007; Wilson et al. 2007; Ussher et al. 2010), it was beyond the scope 
of this study to determine whether alterations in the macronutrient content of the diet 
influenced the various cardiovascular outcomes associated with obesity. Such a 
study has previously been conducted by Wilson et al. (2007) who documented 
differences in LV mechanical function in response to altered dietary macronutrient 
content.  
 
In the present study, the impact of HCD feeding on myocardial ventricular 
remodelling appeared to be mild at most. Our research group has previously shown 
greater echocardiographically determined LV posterior wall thickening with significant 
cardiomyocyte hypertrophy (W Smith, MSc. Dissertation, 2005) and greater heart 
weight to body weight ratios (indicative of ventricular remodelling) in 16 week HCD 
fed animals (Du Toit et al. 2005). Although 16 week HCD fed rats had greater LV 
posterior wall thickening than control rats, these remodelling differences were absent 
after 32 weeks of HCD feeding (Table 4.3). This finding could however be due to the 
small sample size used for these echocardiography determinations in the 32 week 
HCD fed group. Indeed, while a non-significant tendency was evident for greater LV 
posterior wall thickening to be present in these animals, a larger group of 32 week 
HCD fed rats was shown to have significantly greater ventricular weight to tibia length 
ratios (indicative of ventricular remodelling) (Table 4.1). These discrepant findings 
could suggest that the ventricular remodelling observed in our model of diet induced 
obesity may not be of a pathological nature. In support of this, mice fed a HCD 
similar to that used in the present study had normal heart weights and heart to body 
weight ratio’s (Aasum et al. 2008). 
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Format of the discussion 
 
Although this thesis consists of 3 interrelated studies, the overlapping nature of the 
work justifies the discussion to follow the major overlapping outcomes investigated, 
i.e. cardiac function, substrate metabolism, mitochondrial function and susceptibility 
to ischaemia/reperfusion injury. The impact of chronic K-111 treatment on these 
parameters will be discussed separately. 
 
7.2 The impact of obesity on cardiac mechanical function 
 
Obesity has traditionally been associated with normal or augmented cardiac systolic 
function whereas diastolic function is usually compromised (Berkalp et al. 1995; 
Iacobellis et al. 2002, 2004; Pascual et al. 2003; Otto et al. 2004; Dorbala et al. 
2006). Recent data have however identified the presence of sub-clinical myocardial 
systolic dysfunction in obese (Ferraro et al. 1996; Peterson et al. 2004b; Wong et al. 
2004; Di Bello et al. 2006; Tumuklu et al. 2007, Kosmala et al. 2008a) and 
overweight (Wong et al. 2004) individuals occurring at times independently of 
ventricular loading conditions. As obesity is an independent risk factor for the 
development of heart failure (Kenchaiah et al. 2002), it is plausible that protracted 
obesity may be associated with sub-clinical alterations in cardiac function.  
 
A few studies have documented the impact of altered ex vivo myocardial substrate 
supply (glucose alone or glucose + FA in the perfusate) on LV function both during 
baseline perfusion conditions and in response to augmented workload (Lopaschuk et 
al. 1999; Liu et al. 2002; Boudina et al. 2005) in isolated hearts from healthy animals. 
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In addition, only Boudina et al. (2005) has reported on the effects of glucose alone or 
in combination with FA present in the perfusate on LV mechanical function and 
functional reserve in hearts from obese animals. Neither of these studies has 
investigated the contributory role of insulin on LV mechanical function (Lopaschuk et 
al. 1999; Liu et al. 2002; Boudina et al. 2005). This is important as obesity is normally 
associated with a state of hyperinsulinaemia. Furthermore, Boudina et al. (2005) 
made use of retrogradely perfused hearts from leptin deficient ob/ob mice. While this 
model is a well recognized animal model of obesity, it is important to note that while 
leptin may not always influence LV mechanical function in normal healthy hearts, it 
still impacts on myocardial FA metabolism (Atkinson et al. 2002). Furthermore, the 
contractile dysfunction identified in isolated cardiomyocytes from obese ob/ob mice, 
has been show to be abolished by the presence of leptin administered in vitro (Dong 
et al. 2006). Interestingly, the previous study found that these contractile 
abnormalities were not present in cardiomyocytes isolated from diet-induced obese 
mice. These findings suggest that ex vivo LV functional data generated from hearts 
from ob/ob mice may have to be interpreted with caution due to the influence of leptin 
on cardiac metabolism and the impact of in vitro leptin administration on 
cardiomyocyte contractile performance. Although these effects of leptin on the 
various cardiovascular parameters were documented upon ex vivo administration, it 
is possible that hearts not being conditioned by leptin in vivo may respond differently 
in ex vivo preparations. Lastly, although certain aspects regarding the impact of 
altered substrate supply on LV mechanical function at baseline and in response to 
increased workload have been investigated, the present study is the first to combine 
data from both in vivo and ex vivo (retrograde perfused heart to assess LV 
contractility and working heart to assess LV function in a working heart) models to 
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develop a sound conclusion regarding the impact of altered cardiac substrate and 
insulin supply on normal and peak LV function in obese animals. 
 
7.2.1 In vivo data 
In the present study, pre-diabetic obese insulin resistant animals following 32 weeks 
of HCD feeding displayed comparable in vivo mechanical function (FSend, FSmid) 
relative to control animals. Moreover, myocardial functional reserve (FSend, FSmid), 
in response to β-adrenergic receptor stimulation, was also similar between the 
experimental groups (Figure 4.2a, b). The data indicate that protracted obesity 
associated with euglycaemia, hyperinsulinaemia and elevated circulating FFA levels, 
in the absence of overt type II diabetes and hypertension (blood pressure data not 
shown), is associated with normal in vivo cardiac function under both basal and 
augmented workloads. Unfortunately the in vivo measurements of LV function used 
in the present study were not independent of LV loading conditions. However, LV 
end-systolic elastance (a load independent measure of LV systolic function) was 
comparable between the control and obese groups in the presence of isoproterenol, 
glucose and insulin (Figure 4.3d), suggesting that the normal LV function observed in 
vivo could be independent of LV loading conditions. Nevertheless, our in vivo 
observations are in agreement with other models of diet induced obesity which 
similarly report normal in vivo LV myocardial function (Carroll et al. 2006; Yan et al. 
2009; Zhang et al. 2010). As Wilson et al. (2007) documented obesity related ex vivo 
cardiac dysfunction only after 32-48 weeks of western diet feeding, it is unclear 
whether the absence of cardiac dysfunction in these previously mentioned studies 
(Carroll et al. 2006, Yan et al. 2009, Zhang et al. 2010) was due to the shorter 
feeding periods employed (12, 20 and 10 weeks respectively). Our data however 
indicate that diet induced obesity (32 weeks of feeding) that developed over a similar 
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feeding period as used by Wilson et al. (2007), was not associated with in vivo 
cardiac dysfunction. Although not investigated in the current study, it is plausible that 
subtle changes in the fat and carbohydrate composition of the diets used may impact 
on these findings. Whereas a diet consisting of 60% of the calories derived from fat 
was unable to elicit cardiac dysfunction after 32-48 weeks of feeding (Wilson et al. 
2007), a HFD in which 50.4% of the calories derived from fat led to cardiac 
dysfunction after only 8 weeks of feeding (Owens et al. 2007), thus illustrating the 
possible impact of dietary composition on various cardiovascular outcomes. In the 
previously mentioned study cardiac dysfunction ensued after a relatively short period 
of feeding in the absence of obesity, but with evidence of advanced ventricular 
remodelling (Owens et al. 2007), which was absent in the present study and those of 
others (Carroll et al. 2006; Yan et al. 2009; Zhang et al. 2010). Thus results from the 
previously mentioned studies emphasize the importance of strict dietary control in 
studies assessing the cardiovascular outcomes associated with diet induced obesity.  
 
7.2.2 Ex vivo data 
While the majority of cardiac energy is derived from the oxidation of circulating FFA 
(Zierler, 1976; Opie, 1998), healthy hearts are thought to be capable of adapting to 
an altered substrate supply enabling them to maintain normal LV mechanical function 
(Yan et al. 2009). In agreement with previous studies (Lopaschuk et al. 1999; Liu et 
al. 2002; Boudina et al. 2005), the present study using isolated working and 
retrogradely perfused hearts from control animals found that these hearts exhibited 
effective metabolic substrate flexibility in the presence of different combinations of 
simulated in vivo substrate and hormone concentrations enabling them to achieve 
normal LV mechanical function irrespective of the substrate/hormone supply 
perfusion conditions (Figures 4.3a, 4.4). Despite obese animals having comparable 
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in vivo LV mechanical function relative to the control group, ex vivo function differed 
markedly from that observed in vivo. Isolated working hearts from obese animals 
were unable to achieve similar LV mechanical function compared to the control 
groups in the presence of glucose and at times in the presence of glucose + insulin 
(Figure 4.4). The reduced LV end-systolic elastance (a load-independent measure of 
LV systolic chamber performance) observed in paced retrograde glucose perfused 
hearts from obese animals (Figure 4.3d) suggests that the ex vivo cardiac 
dysfunction seen in working hearts in the presence of glucose was related to intrinsic 
contractile abnormalities independent of changes in LV loading conditions. 
Significantly, when working hearts from obese animals were perfused with simulated 
in vivo concentrations of glucose + FA or glucose + insulin + FA that were 
physiologically relevant to the obese animal, LV myocardial mechanical function was 
normalized relative to the control group (Figure 4.4). Our data suggest that hearts 
from obese animals depend on elevated  (physiologically relevant to the obese state) 
FA concentrations for the maintenance of normal LV function, while exhibiting an 
inability to maintain normal LV function when provided with carbohydrate as its sole 
substrate supply. Supporting this notion is the observation that the reduced LV 
mechanical function (aortic output and cardiac output) generated by obese insulin 
resistant ob/ob mouse hearts when perfused with glucose, 0.4mM palmitate and 
1nmol/l insulin,  was reversed when the palmitate concentration in the perfusate was 
elevated to 1.2mM (Mazumder et al. 2004). Although it appears that the heart from 
the obese animal has a preference for an elevated FA supply to maintain normal LV 
function, this adaptation may come at the expense of increased oxygen utilization 
(How et al. 2005; 2006). Furthermore this substrate preference could render these 
hearts vulnerable to enhanced injury during an ischaemic event (To be discussed in 
Section 7.6). 
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Despite working hearts from obese animals displaying ex vivo LV mechanical 
dysfunction in the presence of glucose or glucose + insulin, this finding was 
contradicted by the normal (relative to the control group) pressure-volume relations 
generated by retrogradely perfused hearts from the obese group using a similar 
perfusate (Figure 4.4 vs. 4.3a). Boudina et al. (2005) similarly reported comparable 
LV function between control and ob/ob retrogradely perfused mouse hearts in the 
presence of glucose alone. The discrepancy between the data may be explained by 
the different workloads placed on the heart by the two different perfusion modes (i.e. 
working vs. non-working retrograde) used. Consequently we believe that the higher 
myocardial workload, and therefore energy demand, placed on the working heart had 
unmasked functional abnormalities between the control and obese groups not seen 
in the retrogradely perfused hearts. This argument is supported by the presence of 
functional differences between retrogradely perfused hearts from control and obese 
animals when perfused in the presence of glucose and the β-adrenergic receptor 
agonist, isoproterenol (Figure 4.3 b), which would impose an increase in workload. A 
second reason may relate to the balloon inserted into the left ventricle in the 
retrogradely perfused heart. Whereas the balloon may assist diastolic relaxation by 
the elastic recoil of the compressed water inside the balloon, this assistance is 
absent in the working heart, which itself is dependent on normal diastolic relaxation 
to maintain aortic output.        
 
7.2.3 The effect of substrate on peak LV function 
In response to increased β-adrenergic receptor stimulation (increasing myocardial 
workload), the healthy heart reacts by increasing glucose oxidation rates, while FA 
oxidation rates have been reported to become slightly elevated, remain constant or 
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even become reduced (Collins-Nakai et al. 1994; Wilson et al. 2007; Yan et al. 2009). 
During these events the contribution of glucose to myocardial ATP production 
increases greatly (Collins-Nakai et al. 1994). In the present study, it was 
demonstrated that control and obese animals were able to increase their LV 
mechanical function equally in response to increased workload (β adrenergic 
stimulation) in vivo (Figure 4.2). Assessment of ex vivo myocardial functional reserve 
showed that both groups were able to augment LV mechanical function in response 
to increments in preload regardless of the substrate and hormonal conditions 
employed (Figure 4.5a, b). Whereas hearts from the lean group were able to achieve 
peak aortic output with all substrate and insulin perfusion conditions, it emerged that 
hearts from obese animals were only able to achieve peak aortic output values (as 
defined by the aortic output values achieved by the lean FA perfused groups at the 
20cm preload) in the presence of simulated in vivo concentrations of FA (FA alone or 
together with insulin). These ex vivo observations concur with the ex vivo 
observations of Wilson et al. (2007) and Yan et al. (2009) who similarly found 
comparable functional reserve between control and obese animals when glucose, 
insulin and FA were present in the perfusate. In contrast hearts from obese ob/ob 
mice were not able to achieve comparable LV function at high workloads compared 
to hearts from the lean group in the presence of glucose and palmitate (Boudina et 
al. 2005). The reason for this discrepancy may be due to a more advanced form of 
mitochondrial dysfunction in these hearts (Boudina et al. 2005). 
 
Although the healthy heart’s response to increased workload is to increase glucose 
oxidation rates, while FA oxidation rates are slightly elevated, maintained or even 
reduced (Collins-Nakai et al.1994; Wilson et al.  2007; Yan et al. 2009), Pagliaro et 
al. (2002) noted that retrogradely glucose perfused hearts from normal animals rely 
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on energy derived from the oxidation of endogenous myocardial lipids to maintain 
effective LV contractile function in response to incremental increases in LV filling 
(Frank-Starling mechanism). Although our study did not assess the functional impact 
of endogenous lipid stores, we concede that endogenous lipids would have 
contributed to the substrate supply in glucose perfused hearts from the current study. 
Although not different between the control and obese groups, these endogenous 
Trig’s may have aided LV mechanical function. Nevertheless, the present study 
demonstrated that with the use of the more physiological working heart model, 
glucose metabolism in addition to the contribution of endogenous lipid stores was not 
sufficient to induce effective LV mechanical function in response to incremental 
increases in LV preload and hence filling conditions in the obese state (Figure 4.5a, 
b). Consequently a physiologically relevant exogenous supply of FA is essential to 
achieve normal Frank-Starling responses in the obese state.  
 
Although not investigated, it can be speculated why working hearts from obese 
animals did not achieve normal LV mechanical function in the presence of glucose or 
glucose + insulin. Firstly, it is well known that cardiomyocyte glucose transport is 
regulated by the glucose transporters, GLUT 1 and GLUT4, with the sarcolemmal 
translocation of the latter being regulated by insulin (Zaninetti et al. 1988; Kraegen et 
al. 1993). Wright et al. (2009) reported on HFD fed mice having reduced myocardial 
glucose uptake, glycolysis and glucose oxidation rates coupled with reduced 
myocardial GLUT 4 content and attenuated insulin stimulated GLUT4 sarcolemmal 
translocation after short term feeding. Obese animals in the present study similarly 
display reduced insulin stimulated myocardial rates of glycolytic flux (Figure 5.2a), 
while our research group has previously identified attenuated rates of insulin 
stimulated glucose uptake in cardiomyocytes isolated from these obese animals 
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(Huisamen, unpublished data). Secondly pre-diabetic obesity is associated with 
reduced myocardial PDH activity (reduced activity of the active fraction of PDH) 
(Boudina et al. 2005). It is well known that elevated myocardial FA supply may inhibit 
PDH activity through the up-regulation of the PDH inhibitor, PDK4 (Denton et al. 
1975; Hansford and Cohen, 1978; Huang et al. 2002; Holness and Sugden, 2003). 
Consequently high rates of FA supply in the context of high caloric feeding or obesity 
could reduce myocardial glucose oxidation by reducing the activity of PDH. As 
circulating FFA are elevated in our model of obesity after 16 weeks of feeding, it is 
plausible that following long-term obesity (32 weeks of HCD feeding), myocardial 
PDH activity would be reduced in these obese rats. Although the current study made 
use of isolated perfused hearts it is possible that the inhibition of the PDH complex by 
PDK4 may persist in these hearts when perfused. Taken together, abnormalities in 
myocardial glucose transporter content, insulin stimulated GLUT4 translocation and 
reduced PDH activity associated with obesity would aid to diminish myocardial 
glucose uptake and utilization, thus compromising myocardial energetics in the 
absence of FA as a fuel source which would in turn result in cardiac dysfunction in 
the glucose or glucose + insulin perfused heart. Consequently energy derived from 
FA metabolism may be vital for the maintenance of effective contractile function in 
the obese insulin resistant state. 
 
In the current study, the improvement in ex vivo LV mechanical function attributed to 
the presence of simulated in vivo FA concentrations in the obese group help explain 
our previous published findings and those of others. We have previously reported 
reduced ex vivo cardiac mechanical function in hearts from 16 week HCD fed 
animals perfused with glucose alone (Du Toit et al. 2005; Nduhirabandi et al. 2011), 
while cultured cardiomyocytes isolated from non-obese insulin resistant rats 
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demonstrate functional abnormalities in media containing glucose as the only 
oxidative substrate (Schwanke et al. 2006). These findings could therefore be 
influenced by the lack of FA as a fuel source.  
 
7.2.4 FA supply and cardiac function 
The relationship between altered cardiac substrate supply, metabolism and 
contractile function is complex, delicate and not fully understood, and has received 
much attention over recent years where the focus has been on the metabolic effects 
associated with chronically increased myocardial substrate delivery as seen in 
obese, insulin resistant and diabetic conditions.  
 
Defective or insufficient FA oxidative metabolism in response to high FA supply 
coupled with the activation of alternative glucose metabolic pathways resulting from 
an enhanced myocardial oxidative fuel supply (both glucose and FA) may explain the 
relationship between altered cardiac substrate supply, metabolism and LV 
dysfunction associated with models of obesity (Young et al. 2002; Wilson et al. 2007; 
Yan et al. 2009; Ballal et al. 2010). This form of cardiac dysfunction is thought to 
stem from myocardial FA overload (due to reduced FA metabolism) and in certain 
cases a combination of FA and glucose overload (lipo- and glucotoxicity) leading to 
the activation of lipotoxic pathways or the generation of reactive oxygen species, 
which could induce cardiomyocyte apoptosis and attenuate cardiac function (Zhou et 
al. 2000; Young et al. 2002; Yan et al. 2009; Ballal et al. 2010). 
The present study provides additional insight into the complex interplay between 
substrate supply and cardiac function. Although enhanced FA supply to the heart 
plays a major role in the development of myocardial insulin resistance, this 
oversupply of oxidative fuel is inevitable in the progression of obesity. Consequently 
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the heart adapts metabolically to an elevated FA supply possibly by up-regulating 
PPARα response genes which culminates in enhanced FA metabolism (outlined by 
Barger and Kelly, 2000). It may be that during the initial developmental phases of 
obesity related myocardial insulin resistance, elevated levels of FA become more 
important in the maintenance of normal LV mechanical function and functional 
reserve, especially in light of attenuated glucose metabolism. However, unless body 
weight/caloric intake is controlled, the enhanced supply of FA and/or carbohydrates 
coupled with a reduced expression of PPARα response gene products (Wilson et al. 
2007), may eventually become a burden (or become disrupted) to the point where 
the heart is unable to effectively utilize the elevated substrate supply and metabolic 
and mechanical cardiac dysfunction ensue (Young et al. 2002; Wilson et al. 2007; 
Yan et al. 2009).  
 
7.2.5 Study limitations 
A limitation to this study was the failure to determine fasting FFA levels present in the 
32 week animals. This was due to insufficient serum being collected from fasted 
animals. Consequently fasting FFA levels determined from 16 week control and HCD 
fed rats (Table 5.2) were used as a reference for the FFA levels in the present study. 
Although these values may not be a true reflection of 32 week fed condition, it did 
ensure that the FFA levels used in the ex vivo perfusions were in the range that 
hearts from these animals may have been exposed to. A further possible limitation to 
this study was that we did not determine whether normal insulin and FA levels (as 
seen in the control animal) present in the perfusate, would be sufficient to sustain 
cardiac function after 32 weeks of HCD feeding. Although 16 week HCD fed animals 
have reduced LV mechanical function in the presence of glucose alone (Du Toit et al. 
2005), it is interesting to note that obese animals, following 18 weeks of HCD feeding 
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in the present study have normal LV mechanical function when perfused with 
concentrations of insulin and FA seen in the control animals (Table 6.5). Although 
this may suggest myocardial dependency on FA’s independent of their concentration, 
it is uncertain whether this observation will remain following 32 weeks of HCD 
feeding where the adverse myocardial effects of obesity may be more advanced.  
 
The data of the present study suggest that protracted obesity in the absence of overt 
type II diabetes is not associated with cardiac dysfunction in a rodent model 
characterised by normoglycaemia, hyperinsulinaemia, hypertriglyceridaemia, raised 
FFA levels and normotension (blood pressure data not shown). Our study proposes 
that during the initial adaptational phase of obesity related myocardial insulin 
resistance, energy derived from FFA metabolism plays a much more important role in 
maintaining normal LV mechanical function and functional reserve than in the healthy 
heart. This is possibly due to the heart’s loss of flexibility in utilizing glucose 
effectively as an energy source for the maintenance of normal LV mechanical 
function.  
 
7.2.6 Future directions 
Future work investigating the relationship between FA levels and LV mechanical 
function in obese insulin resistant rats should do so using different doses of CPT-1 
inhibitors, such as oxfenicine, in either the perfusate or administered chronically. In 
this way, the extent to which obese insulin resistant animals rely on FA as a fuel 
source for the maintenance of LV mechanical function can further be investigated. It 
was recently shown 8 weeks of oxfenicine treatment in rats fed either a high 
saturated, high unsaturated or medium chain FA diet had no effect on in vivo cardiac 
mechanical function. It should however be noted that this feeding period was not 
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associated with significant changes in body weight (Okere et al. 2007). Consequently 
the myocardial response to the elevated FA load may not have been long enough to 
determine the significance of CPT-1 inhibition on LV mechanical function in the 
obese insulin resistant condition. 
 
7.3 The impact of obesity on myocardial substrate metabolism  
 
Insulin resistant hearts are characterized by an insensitivity to insulin administration, 
either in terms of glucose uptake, glycolysis or glucose oxidation, (Atkinson et al. 
2003; Mazumder et al. 2004; Ouwens et al. 2007; Zhang et al. 2010). 
 
In the present study, hearts from 16 week HCD fed obese insulin resistant animals 
responded surprisingly well to insulin treatment by exhibiting a dose dependent 
increase in myocardial glycolytic flux rates (Figure 5.2b). In spite of this, myocardial 
glycolytic flux rates remained lower in the obese group compared to the control group 
in the presence of comparable insulin concentrations (Figure 5.2a), a finding which is 
indicative of an insulin resistant myocardium. This is in agreement with reduced 
myocardial glycolytic fluxes observed in other models of insulin resistance and 
diabetes (Atkinson et al. 2003). Hafstad et al. (2006) similarly noted that despite 
isolated hearts from diabetic db/db mice showing attenuated glucose metabolism, 
they responded remarkably well to insulin stimulation, since changes in substrate 
oxidation rates elicited by insulin stimulation seemed more pronounced in the db/db 
mouse hearts compared to the control group during certain experimental conditions. 
Thus, despite hearts from obese insulin resistant rats (present study) and diabetic 
mice (Hafstad et al. 2006) being insulin resistant, it appears that these hearts are 
indeed able to respond to insulin stimulation. 
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Systemic insulin resistance is a predictor of myocardial FA uptake, utilization and 
oxidation in obese insulin resistant humans (Peterson et al. 2004a). Following 18 
weeks of HCD feeding it was aimed to obtain a more complete picture of the 
myocardial substrate metabolism profile of these obese animals. Surprisingly, under 
comparable perfusion conditions, no changes in myocardial glycolytic flux, glucose 
oxidation, or palmitate oxidation rates were observed between hearts from the control 
and obese animals, either before or after myocardial global ischaemia (Table 6.3, 
6.4). This is in contrast to many studies describing marked alterations in myocardial 
substrate metabolism in diet induced obese and/or insulin resistant animals (Wilson 
et al. 2007; Aasum et al. 2008; Wright et al. 2009; Zhang et al. 2010). As expected 
(How et al. 2005; 2006), palmitate oxidation was significantly increased in hearts 
from both groups perfused with high levels of insulin and FA compared to hearts 
perfused with normal insulin and FA levels (Figure 6.12). The last mentioned 
perfusion conditions coincided with a non-significant tendency for glucose 
metabolism to be attenuated (Figure 6.10; 6.11). In addition, myocardial rates of 
palmitate oxidation were elevated from baseline values during the reperfusion phase 
(especially in the presence of high insulin and FA in the perfusate) (Table 6.3, 6.4) 
which is in accordance with previous findings in isolated working mouse hearts 
(Aasum et al. 2003a). 
 
The absolute values obtained for the different metabolic parameters in the present 
study appeared rather low. An extensive search of the literature showed that most of 
the recent studies on myocardial substrate metabolism were done on isolated 
working mouse hearts (Muzumder et al. 2004, Kuang et al. 2004, Buchanan et al. 
2005; Aasum et al. 2008; Wright et al. 2009; Zhang et al. 2010), which may 
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profoundly influence the values obtained. One study also using Langendorff perfused 
rat hearts yielded different FA oxidation values to those seen in the present study, 
but differences in the FA/albumin ratio used and the absence of insulin in the 
perfusion buffer (Heather et al. 2007) complicate any comparisons with our own work 
(Evans et al. 1963). Similarly, comparisons of the present findings with that of Shipp 
and co-workers (1961), using a similar model could not be done due to differences in 
substrate composition (5mM glucose, 0.4mM palmitate, 0.5% albumin vs. 10mM 
glucose, 30 or 50μIU/ml insulin and 0.4 or 1.2mM palmitate, 3% albumin (containing 
an additional 0.3mM FA)). 
 
In the current study, Western blot analysis for the assessment of the expression of 
metabolically related proteins involved in insulin signalling did not provide additional 
insight regarding the insulin sensitivity of the myocardium from the obese animals as 
no differences in the total or phosphorylated PKB or the p85-subunit of PI3K were 
observed between the two groups (Figure 6.17, 6.18). This is in contrast to studies 
which show that reduced glucose uptake may be associated with attenuated PKB 
and p85-subunit of PI3K phosphorylation (Summer et al. 1998; Florian et al. 2010). 
However myocardial CPT-1 levels were significantly elevated in the obese group 
(Figure 6.19 (assessed with a t-test)), which together with elevated circulating levels 
of FFA suggest increased FFA flux into the mitochondria.  
It is however important to consider methodological differences between the present 
study and a recent study published from our research group (Huisamen et al. 2011). 
While hearts in the current study were snap frozen upon removal from the body (i.e. 
without perfusion) for Western blotting analysis, Huisamen et al. (2011) perfused 
isolated hearts from 16 week HCD fed rats with insulin prior to being frozen. Under 
these conditions Huisamen et al. (2011) observed reduced insulin stimulated PKB 
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and eNOS (endothelial derived nitric oxide synthase) phosphorylation, reduced IRS-1 
expression and increased ser612 IRS-1 phosphorylation (an inhibitory action) in the 
hearts from obese animals compared to hearts from control animals. Our research 
group has further observed reduced insulin stimulated glucose uptake in 
cardiomyocytes isolated from obese rat hearts (16 weeks of HCD feeding) 
(Huisamen, unpublished data) while another research group using a similar HCD 
have reported reduced myocardial glucose oxidation and increased palmitate 
oxidation rates in isolated hearts from HCD fed mice (Aasum et al. 2008). Taken 
together these findings indicate that HCD feeding induces an insulin resistant 
myocardium, as was also indicated by the reduced effect of insulin on the myocardial 
glycolytic flux rate of obese animals (Figure 5.2a).  
 
Studies have documented an association between intramyocardial Trig accumulation 
and myocardial insulin resistance (Atkinson et al. 2003; Yan et al. 2009). The present 
study has however shown myocardial insulin resistance in the absence of elevated 
intramyocardial Trig levels in the hearts from obese animals. This finding is 
corroborated by a few other studies (Wilson et al. 2007; Aasum et al. 2008). 
Together, these observations question the relevance of intramyocardial Trig 
accumulation as a contributor to myocardial insulin resistance. More specific lipid 
intermediates such as diacylglycerol may be a better mediator of myocardial insulin 
resistance (Zhang et al. 2010). 
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7.4 Ventricular mitochondrial function 
 
Ventricular mitochondrial dysfunction (impaired respiratory capacity leading to 
reduced ATP production), evident in diabetic animals (Boudina et al. 2007; Khalid et 
al. 2011) is speculated to contribute to the LV functional abnormalities associated 
with the diabetic cardiomyopathy and metabolic syndrome (Ren et al. 2010; Bugger 
and Abel, 2010). While obesity is an independent risk factor for the development of 
heart failure (Kenchaiah et al. 2002), the observations of myocardial mitochondrial 
dysfunction in obese insulin resistant humans (Niemann et al. 2011) and animals 
(Boudina et al. 2005; Essop et al. 2009) are disconcerting. Indeed, it has been 
suggested that reduced mitochondrial bioenergetic capacity evident in obese insulin 
resistant animals may account for reduced LV mechanical function and the 
worsening of post-ischaemic outcomes reported in these animals (Essop et al. 2009). 
 
7.4.1 The impact of obesity on ventricular mitochondrial function 
In contrast to previous findings (Boudina et al. 2005; Essop et al. 2009), the present 
study found the oxidative phosphorylation function to be normal in mitochondria 
isolated from obese insulin resistant animals (Table 6.11, 6.12). This was evident 
from coupled oxidative phosphorylation (ADP/O and RCI ratio’s), and comparable 
rates of oxygen consumption during ADP stimulated respiration (State 3 respiration) 
between the control and obese groups. Additionally states 2 and 4 respiration and 
oxidative phosphorylation rates were similar in the two groups. These respiration 
rates were similar, regardless of the oxidative substrates used.  
 
Essop et al. (2009), using the same rodent model as that used in the present study, 
reported reduced ADP phosphorylation rates in mitochondria isolated from obese rat 
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hearts in the presence of palmitoyl-L-carnitine. While this observation is in contrast to 
the findings of the present study, it is noteworthy that obese rats in the latter study 
had more visceral fat than obese rats in the present study (49.5g vs. 30.45g). While 
intra-abdominal mass has been shown to correlate with systemic insulin sensitivity 
(Park et al. 1991), which in turn correlates with the degree of mitochondrial 
morphological and functional abnormalities (Kelley et al. 2002), it is possible that the 
differences noted between the current study and those of Essop et al. (2009) and 
Boudina et al. (2005) may be due to differences in the degree of systemic insulin 
resistance present in the respective models of obesity. Based on the data obtained, 
this would suggest that during the early stages of obesity related insulin resistance, 
ventricular mitochondria have normal function in the presence of glutamate and 
palmitoyl – L – carnitine as substrates. The respiratory capacity of these 
mitochondria isolated from obese rats may however deteriorate as the degree of 
systemic insulin resistance increases. It is important to mention that while the current 
study measured mitochondrial respiration by challenging the tricarboxylic acid cycle, 
β-oxidation and the electron transport chain, it failed to investigate the impact of flux 
through PDH on mitochondrial respiratory capacity. It is however clear that 
mitochondrial respiratory capacity in response to pyruvate may be reduced in obese 
conditions (Boudina et al. 2005) given the reduced LV mechanical function observed 
in obese rat hearts when perfused with glucose alone.   
 
Mitochondrial susceptibility to ischaemia/reperfusion was also evaluated by exposing 
isolated mitochondria to hypoxia followed by reoxygenation. The results of the 
present study showed that the recovery of state 3 respiration following anoxia was 
not influenced by obesity. This finding is also in contrast with the reduced post-anoxia 
recovery of state 3 respiration observed in isolated ventricular mitochondria from 
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obese insulin resistant rats reported by Essop et al. (2009). These differences may 
again be explained by the greater degree of systemic insulin resistance in the obese 
rats used in the Essop et al. (2009) study.  
 
7.4.2 The impact of the oxidative substrate on ventricular mitochondrial 
function 
Comparisons between the different substrates used revealed that ventricular 
mitochondria incubated in the presence of palmitoyl-L-carnitine as substrate had 
higher rates of state 2, 3 and 4 respiration, while the oxidative phosphorylation rate 
was similar to that obtained with glutamate as an oxidative substrate. Interestingly, 
the recovery of the mitochondrial state 3 respiration after exposure to hypoxia was 
lower in the palmitoyl-L-carnitine groups compared to the glutamate groups (Table 
6.13). As the ADP/O and RCI ratio’s were similar between mitochondria incubated 
with glutamate or palmitoyl-L-carnitine as substrate, the higher respiration rates 
noted in the presence of palmitoyl-L-carnitine may simply reflect an adaptive ability of 
mitochondria to use FA as a fuel source due to the greater reliance of cardiac tissue 
on FA. Compared to glutamate, the use of palmitoyl-L-carnitine as an oxidizable 
substrate results in the formation of more reducing equivalents (the use of FA leads 
to the formation of reducing equivalents produced during both FA β-oxidation and the 
Krebs cycle, whereas the use of glutamate only produces reducing equivalents via 
the Krebs cycle). Bugger and Abel, (2010) have further proposed that enhanced FA 
oxidation resulting from increased myocardial FA supply characteristic of type 2 
diabetes leads to a greater production of reducing equivalents. This elevated supply 
of reducing equivalents to the respiratory chain may lead to increased ROS 
production which may induce uncoupling protein activation, with a concomitant 
increase in mitochondrial oxygen consumption. Although the present study failed to 
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demonstrate mitochondrial uncoupling in the presence of palmitoyl-L-carnitine 
(ADP/O and RCI ratio’s), it is however still be possible that a slight build up of ROS 
during the normoxic period may contribute to the reduced recovery of state 3 
respiration following the anoxic period. However, this remains to be further 
investigated.  
 
7.4.3 Obesity and mitochondrial biogenesis 
In certain instances insulin resistance may be associated with a defective 
mitochondrial biogenic response characterised by an increased mitochondrial content 
without a concomitant increase in total mitochondrial respiration rates, while ATP 
synthesis is reduced (Duncan et al. 2007). Although the present study did not assess 
mitochondrial quantity, our research group has previously shown that the ventricular 
mitochondrial content is reduced in HCD fed rats after 16 weeks (N Bezuidenhout, 
MSc dissertation, 2011). Since the mitochondrial oxygen consumption values were 
expressed in terms of mitochondrial protein, the present data suggest that despite 
the possible lower total myocardial mitochondrial content in the obese group, their 
mitochondria are still able to maintain normal respiration rates. This does however 
portray a delicately balanced system which may become maladaptive with time. 
 
7.5 The impact of insulin administration on myocardial susceptibility to 
ischaemia/reperfusion injury 
 
The cardioprotective effects of insulin in the setting of ischaemia/reperfusion injury 
are well documented (Baines et al. 1999; Jonassen et al. 2000a, b; Jonassen et al. 
2001; Nawata et al. 2002; Van Rooyen et al. 2002; LaDisa et al. 2004; Hafstad et al. 
2007; Fuglesteg et al. 2008; Yu et al. 2008; Oates et al. 2009; Xing et al. 2009; Ji et 
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al. 2010; Wong et al. 2011). Insulin (insulin alone or a glucose-insulin-potassium 
combination) has previously been shown to elicit cardio-protection when 
administered 5 minutes prior to reperfusion (LaDisa et al. 2004; Jonassen et al. 
2000a; Jonassen et al. 2001; Fuglesteg et al. 2008; Yu et al. 2008; Ji et al. 2010; 
Wong et al. 2011) and in certain instances when present during the entire perfusion 
protocol (Jonassen et al. 2000a; Nawata et al. 2002; Van Rooyen et al. 2002; Oates 
et al. 2009; Xing et al. 2009). Insulin administered as a preconditioning stimulus also 
induces cardio-protection (Baines et al. 1999; Fuglesteg et al. 2009).  
 
Despite the substantial amount of evidence supporting a cardioprotective role for 
insulin, few studies have sought to determine the extent of insulin’s cardio-protective 
effects in insulin resistant animals. While Hafstad et al. (2007) have shown that 
insulin can improve post-ischaemic LV function (aortic output) in diabetic mouse 
hearts, the cardioprotective effects of insulin and especially insulin’s impact on 
myocardial infarction remained to be documented in models of diet induced obesity 
and insulin resistance. In contrast to the findings obtained regarding insulin 
administration times in a previous study (Jonassen et al. 2001), the present study 
has demonstrated that insulin administration 10 minutes prior to and during regional 
ischaemia improved myocardial tolerance to ischaemia/reperfusion. This was 
reflected by reduced myocardial infarct size (except for the 50μIU/ml insulin perfusion 
in the control group) and improved post-ischaemic LV functional recovery (except for 
the 30μIU/ml insulin perfusion in the control group) in isolated hearts from control and 
obese animals after 16 weeks of feeding (Figure 5.3a, b). These observations are in 
agreement to a similar study from Baines et al. (1999) where insulin was used as a 
preconditioning agent. In the latter study reduced infarct sizes were reported 
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following 10 minutes insulin perfusion followed by a washout period prior to the 
induction of regional ischaemia in isolated hearts from healthy animals. 
 
While it was demonstrated that all concentrations of insulin protected hearts from 
obese animals, only physiological concentrations of insulin were able to reduce 
myocardial infarct size in the control group (Figure 5.3a). The failure of elevated 
insulin concentrations (50μIU/ml) to induce cardioprotection (infarct size reduction) in 
the control group of the present study and those of others when administered 10 
minutes prior to ischaemia (Jonassen et al. 2001), while being protective in hearts 
from obese animals in the current study may suggest possible metabolic thresholds 
of protection in normal and diseased animals. The fact that the higher dose was still 
effective in hearts from obese animals, may yet be another indicator of the reduced 
responsiveness to insulin in these hearts. The time of administration and the insulin 
dosage used, appear to be important determinants in the outcomes obtained. While 
elevated levels of insulin are cardioprotective when administered upon reperfusion, 
insulin administered prior to and during ischaemia at doses ranging from 0.3 – 
5mU/ml have been shown to have no effect myocardial infarct size (Jonassen et al. 
2001). In contrast when insulin is administered prior to global ischaemia at 40U/ml it 
has a detrimental effect on post-ischaemic outcomes (Schaefer and Ramasamy, 
1997). These opposing outcomes emphasizes the importance of assessing 
cardioprotective interventions in both normal and diseased animal models at various 
concentrations as appropriate treatment doses may differ between these groups 
depending on their metabolic status.  
 
Although the present study did not determine the mechanism of insulin (insulin alone 
or glucose-insulin-potassium combination) induced cardioprotection, protection 
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elicited by insulin has previously been shown be associated with or to occur via 
improved glucose metabolism (glycolytic flux rates) (van Rooyen et al. 2002), early 
activation of PKB/AKT and p70s6 kinase during reperfusion (Jonassen et al. 2001), 
activation of (sarcolemmal or mitochondrial) KATP channel activity (LaDisa et al. 
2004), improved re-synthesis of myocardial high energy phosphates upon 
reperfusion (Nawata et al. 2002), anti-adrenergic effects during β-adrenergic 
stimulation (Yu et al. 2008), inhibition of peroxynitrate formation during reperfusion (Ji 
et al. 2010) and activation of Signal Transducer and Activator of Transcription 3 
(Fuglesteg et al. 2008).  
 
The study of Baines et al. (1999) reported that insulin’s cardioprotective effects may 
be related to enhanced PI3K signalling and the results from the present study 
suggest that insulin’s cardioprotective effects may in part relate to the metabolic side 
of PI3K signalling (increased glucose uptake). This is evident by the marked increase 
in glycolytic flux rates following insulin stimulation in hearts from both groups of 
animals (Figure 5.2a, b). Although a model of severe ischaemia (40 minutes coronary 
artery ligation) was used in the present study, the regional ischaemic zone of a rat 
heart may receive up to 6.1% collateral flow (coronary collateral flow as a percentage 
of the non-ischaemic coronary flow) during the ischaemic episode (Maxwell et al. 
1987), suggesting that insulin, when administered 10 minutes prior to ischaemia, will 
continue to penetrate the ischaemic zone at a low rate during the ischaemic period 
and exert its beneficial effects. In addition, the inclusion of simulated in vivo 
concentrations of FA (control: 30μIU/ml insulin with 0.7mM FA; obese: 50μIU/ml 
insulin with 1.5mM FA) concentrations in the perfusate prior to and during regional 
ischaemia was shown to increase infarct size and reduce functional recovery to 
values comparable with the glucose perfused hearts (Figure 5.4, 5.5). This indicates 
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that the protection elicited by insulin in the current study may have been in part due 
to metabolic effects. For example, insulin may increase myocardial glycogen levels 
prior to ischaemia, an effect which has been proposed to be associated with 
beneficial post-ischaemic outcomes (Van Rooyen et al. 2002). The reversal of the 
beneficial effects of insulin by inclusion of FA’s may be due to the profound effects 
that FA’s have on myocardial glucose metabolism (Liu et al. 2002 Lopaschuk et al. 
1993).  
 
7.5.1 Future directions 
It is recommend that future experiments should aim to administer super-physiological 
concentrations of insulin in combination with physiologically relevant concentrations 
of glucose, and FA when assessing insulin’s cardio-protective effects. The timing of 
insulin administration is also important. Although the present study has demonstrated 
a cardioprotective role for insulin when administered prior to and during ischaemia in 
hearts isolated from obese insulin resistant rats, most interventions are applied upon 
reperfusion of the ischaemic myocardium and as such future studies aiming to 
investigate insulin’s cardioprotective effects should do so.  
 
7.6 The impact of obesity on myocardial susceptibility to ischaemia/reperfusion 
injury 
 
Although obesity is associated with a higher risk of developing myocardial infarction 
(Yusuf et al. 2005), clinical outcomes post infarction are controversial (Rea et al. 
2001; Rana et al. 2004; Lopez-Jimenez et al. 2004; Nikolsky et al. 2006; Eisenstein 
et al. 2005; Clavijo et al. 2006; Shiraishi et al. 2007). Animal studies are not always 
able to mimic human obesity and its associated cardiovascular disease entirely, and 
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as such, extrapolation of animal data to the clinical setting is difficult. Nevertheless, 
the use of rodent studies allows for the investigation of obesity related cardiovascular 
disorders in the absence of confounding factors such as age and diet. 
 
Obese diabetic animals (db/db mice) have been shown to be more susceptible to 
ischaemic injury (reduced LV pump function) and this is thought to result from altered 
myocardial substrate metabolism coupled with reduced cardiac efficiency (Hafstad et 
al. 2007). Indeed post-ischaemic LV mechanical function in these animals correlates 
positively with pre-ischaemic myocardial glucose oxidation rates and negatively with 
pre-ischaemic myocardial palmitate oxidation rates (Hafstad et al. 2007), implying 
that an insulin resistant myocardium associated with diabetes may predispose the 
heart to poorer post-ischaemic LV function. In contrast to the reduced LV pump 
function reported in diabetic mice, the insulin resistant myocardium from non-diabetic 
obese mice display normal post-ischaemic LV mechanical function (Aasum et al. 
2008). Although post-ischaemic LV mechanical function is a valid index of 
ischaemia/reperfusion induced injury, myocardial infarct size, which is independent of 
LV stunning and loading conditions, is thought to be a better predictor of future 
clinical events (Wu et al. 2008). Few studies have assessed the impact of diet 
induced obesity coupled with insulin resistance on post-ischaemic infarct size, and 
even then these findings are inconclusive (Thim et al. 2006; Clark et al. 2011).  
 
After 16 weeks of HCD feeding, hearts from glucose perfused obese animals 
developed larger infarct sizes and poorer functional recoveries following regional 
ischaemia compared to hearts from control animals (Figure 5.3a, b). These data are 
in agreement with previous studies indicating increased post-ischaemic damage in 
isolated glucose perfused hearts from obese insulin resistant rats (Du Toit et al. 
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2005; Huisamen et al. 2011; Nduhirabandi et al. 2011) and in vivo data from obese 
and non-obese insulin resistant rats (Morel et al. 2003; Clark et al. 2011). 
Interestingly, after 16 weeks of feeding, it was further demonstrated that in response 
to simulated in vivo levels of insulin and FA present in the perfusate prior to and 
during regional ischaemia (but not during reperfusion), hearts from control and obese 
animals had comparable infarct sizes (Figure 5.4). As the addition of FA’s at various 
stages of the perfusion protocol may differentially influence indices of 
ischaemia/reperfusion injury (Lopaschuk et al. 1992), it is vital that insulin and FA be 
present in the perfusate during the entire perfusion protocol to make sound 
comparisons. Regardless of this, when comparable levels of insulin and FA were 
present through the perfusion protocol, obesity did not impact on either myocardial 
infarct size or functional recovery (18 week fed animals) (Figure 6.13a, 6.14a, Table 
6.9). Furthermore post-ischaemic comparisons within the control and obese groups 
in the presence of normal and high levels of insulin and FA revealed that the 
concentration of these factors did not have a significant effect on myocardial infarct 
size within these individual groups (Figure 6.15) (18 week fed animals)). 
 
Altering myocardial substrate and hormonal supply in present study allowed 
interesting observations to be made between the myocardial ischaemic remodelling 
response in hearts from control and obese animals. The observation of similar infarct 
sizes between the control and obese groups in the presence of comparable levels of 
glucose, insulin and FA in the perfusate was indeed interesting.  Whereas insulin had 
an infarct sparing effect in the present study, the observation that differences in 
infarct size existed between the control and obese group when glucose was the sole 
substrate would suggest that the ischaemic remodelling response in hearts from 
healthy lean animals is more sensitive to the inclusion of FA in a glucose and insulin 
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containing buffer. While the negative effects of the inclusion of FA into a glucose and 
insulin supplemented perfusate on post-ischaemic LV function have previously been 
reported in isolated hearts from lean healthy animals (Folmes et al. 2006), one may 
speculate that hearts from obese animals have become accustomed to the elevated 
in vivo FFA supply and have developed an adaptive mechanism buffering the harmful 
effects of FA’s during and following ischaemia. Indeed in obese rodents, increased 
mitochondrial uncoupling induced by HFD feeding has been proposed to be an 
adaptive response in preventing excess ROS formation and the subsequent 
development of cardiac dysfunction in these animals (Wilson et al. 2007). It is 
therefore feasible that in hearts from obese animals, during the early stages of 
myocardial insulin resistance a similar protective/adaptive mechanism exists, 
enabling these hearts to effectively utilize FA during the ischaemic and reperfusion 
periods.  
 
When comparisons of myocardial infarct size were made between control and obese 
animals in the presence of normal and high insulin and FA concentrations (control 
normal and high Ins+FA and obese normal and high Ins+FA) using a one-way 
ANOVA followed by the Dunnetts post-test (data not shown) (The Dunnets post-test 
makes comparisons between all the groups relative to the control which in this case 
was the control heart perfused with normal insulin and FA levels), infarct sizes did not 
differ between the various groups. As obese animals in the current study had 
elevated levels of circulating insulin and FA’s compared to their lean littermates, an 
attempt was made to determine what the possible impact of this altered substrate 
environment on myocardial infarct size in vivo would be. Consequently myocardial 
infarct size was compared between hearts from control animals perfused with 
glucose and normal insulin and FA levels and hearts from obese animals perfused 
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with glucose and high insulin and FA levels (insulin and FA being present throughout 
the experimental protocol). These experiments revealed a modest, yet significant 
increase in myocardial infarct size in the obese group relative to the control group 
(Figure 6.16). Considering the results of the One-Way ANOVA, the effects of 
elevated insulin and FA levels on infarct size in the obese animals are small, and 
may thus only in part explain the increased susceptibility of the obese animal to 
ischaemia/reperfusion injury in vivo. It is likely that other factors present in the obese 
animal in vivo, may further impact on post-ischaemic outcomes. This may include 
elevated catecholamine and angiotensin II levels noted in these HCD fed obese rats 
(W. Smith, MSc dissertation, 2005), both of which have previously be shown to 
contribute to ischaemia/reperfusion injury (Waldenström et al. 1978; Schwartz et al. 
1997).  Nevertheless, our data suggests that should FFA levels be elevated in obese 
insulin resistant patients with AMI, that interventions be employed aimed at reducing 
myocardial FFA supply.  
 
The observations noted in figure 6.16 are in agreement with recent findings from our 
laboratory where 18 week HCD fed rats developed greater infarct sizes compared to 
control animals after 45 minutes of regional ischaemia and 2 hours of reperfusion in 
vivo (Clark et al. 2011). Consequently the observations of the present study may help 
explain the contrasting post-ischaemic observations between our research group’s in 
vivo study, and that of Thim et al. (2006) where the lipid profile of the obese animals 
differed markedly. In our research group’s rodent model, obesity was associated with 
elevated circulating Trig and FFA levels (determined in the present study), while 
myocardial infarct size following in vivo regional ischaemia was greater compared to 
lean control animals. In contrast, obese rats in the study of Thim et al. (2006) had 
lower fasting circulating Trig levels and similar non-fasting FFA levels compared to 
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the lean control group, while infarct sizes following regional ischaemia (induced in 
vivo) were comparable between the two groups.  
 
Although the adverse effects of an elevated supply of FA on post-ischaemic LV 
mechanical function are well documented (Lopaschuk et al. 1990; Liu et al. 2002; 
Gambert et al. 2006), to our knowledge, this is the first study to suggest a role for 
elevated levels of insulin and FA’s as a contributor to increased post-ischaemic injury 
(specifically infarct size) in diet induced obese insulin resistant animals. This implies 
that while obesity is a risk factor for cardiovascular disease (Hubert et al. 1983) and 
specifically acute myocardial infarction in obese humans (Yusuf et al. 2005), the 
present data suggest that the unique metabolic milieu associated with obesity, 
characterised by elevated insulin and FA levels may itself contribute to exacerbate 
post-ischaemic outcomes. This notion agrees with many studies demonstrating 
improved post-ischaemic outcomes following the attenuation of FA metabolism or 
stimulation of glucose metabolism upon reperfusion (Lopaschuk et al. 1990; Liu et al. 
2002). Further supporting our hypothesis is the observation that healthy hearts 
perfused with serum isolated from hypertriglyceridaemic hypertensive rats have 
reduced post-ischaemic LV functional recoveries (Carvajal and Baños, 2002).   
 
Despite the role that elevated levels of FFA’s may play in influencing post-ischaemic 
outcomes in obesity, the controversy regarding clinical outcomes following AMI 
between obese and lean patients cannot be ignored (Rea et al. 2001; Rana et al. 
2004; Lopez-Jimenez et al. 2004; Nikolsky et al. 2006; Eisenstein et al. 2005; Clavijo 
et al. 2006; Shiraishi et al. 2007). It has however recently been proposed that sleep 
apnea, which is highly associated with obesity, may afford a cardioprotective role in 
these individuals (Ozeke et al. 2010). The presence of sleep apnea may contribute to 
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improving post-ischaemic events in the obese population by acting as a pre-
conditioning stimulus, subsequently masking the detrimental effects of myocardial 
insulin resistance and elevated FFA supply on post-ischaemic outcomes.  
 
7.7 The impact of chronic PPARα agonist treatment on biometric and metabolic 
outcomes in control and obese animals 
 
PPARα agonists are well suited for treating the metabolic manifestations associated 
with the metabolic syndrome, primarily due to their lipid (Trig) lowering (Robins et al. 
2001) and insulin sensitizing effects (Guerre-Millo et al. 2000; Ide et al. 2004; 
Bergeron et al. 2006; Tsunoda et al. 2008). Unfortunately, the fibrate class of PPARα 
agonists requires administration of high doses to achieve clinically beneficial effects 
and while they can effectively activate PPARα they may also activate PPARγ albeit to 
a much lesser degree (Willson et al. 2000; Shek and Ferrill, 2001). New PPARα 
agonists are consequently being developed to aid in the treatment of obesity, 
diabetes and the related metabolic syndrome. 
 
Although various biometric and metabolic outcomes related to K-111 treatment have 
been investigated in normal animals, obese rhesus monkeys and genetic modified 
animals displaying obesity and diabetes (Meyer et al. 1999; Pill and Kϋhnle, 1999; 
Aasum et al. 2002; Bodkin et al. 2003; Schäfer et al. 2004; Aasum et al. 2005; 
Ortmeyer et al. 2005; Bratkovsky et al. 2006), the present study is the first to 
document the effects of chronic K-111 administration in an animal model of diet 
induced obesity and insulin resistance (8 week old rats were obese and insulin 
resistant before treatment commenced). Similar to the previously mentioned studies, 
it was demonstrated that chronic K-111 treatment (10mg/kg/day) was able to 
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significantly ameliorate biometric and metabolic perturbations associated with obesity 
and the metabolic syndrome (Table 6.2). This was reflected by the prevention of 
general and visceral fat weight gain and the lowering of non-fasting glucose, insulin 
(consequently improved HOMA-IR), Trigs and FFA levels associated with obesity in 
our model of HCD feeding. Interestingly while K-111 had a favourable effect on 
serum lipids in the obese treated animals, chronic K-111 treatment did not alter the 
intramyocardial triglyceride content. This is however in agreement with a previous 
study where obese mice treated chronically with fenofibrate developed an improved 
lipid profile, while there was no change in intramyocardial Trig content (Aasum et al. 
2008).  
 
A concern regarding insulin sensitizing drugs such as the Thiazolidinedione’s is that 
of weight gain (body weight and fat mass) (Miyazaki et al. 2001; Miyazaki et al. 
2002). However the current study demonstrated that K-111’s insulin sensitizing effect 
in obese treated animals was rather associated with weight loss. The insulin 
sensitizing effects afforded by K-111 in obese animals (as indexed by reduced insulin 
levels and a lower HOMA-IR index) in the present study corroborate findings in 
obese insulin resistant monkeys and db/db mice treated with K-111 (Pill and Kϋhnle, 
1999; Schäfer et al. 2004), while the Trig lowering effects have previously been 
reported in healthy rats and obese diabetic mice (Pill and Kϋhnle, 1999; Meyer et al. 
1999).  
The impact of chronic K-111 treatment on the insulin sensitivity (glucose and insulin 
levels and HOMA-IR index) and blood Trig levels of control animals in the present 
study was less significant. While K-111 reduced non-fasting blood glucose levels, 
there were tendencies for K-111 to reduce non-fasting insulin and Trig levels, but 
these were found to be non-significant. Whereas the lipid lowering (Trig’s) effects 
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observed in K-111 treated animals have previously been reported in healthy animals 
(Meyer et al. 1999), failure to observe similar changes in our study could be 
explained by the reduced sensitivity of the CardioCheck machine for rodent use, as 
all measured Trig values in the K-111 treated groups fell below the detection limit of 
the apparatus. Lastly chronic K-111 treatment significantly attenuated HDL-C levels 
in both the control and obese treated groups, which is strongly contrasted by findings 
reported elsewhere in obese pre-diabetic rhesus monkeys (Bodkin et al. 2003). This 
finding may however be specific to rodents as it has been reported that fibrate 
treatment reduces the circulating levels of apolipoproteins A-I and A-II in rodents 
(Staels et al. 1992). 
 
K-111 did however significantly increase the percentage glycosylated haemoglobin in 
the lean animals, however the values were maintained within the normal range of 
healthy animals, suggesting that blood glucose was well managed and controlled 
under these conditions. Indeed K-111 reduced non-fasting blood glucose levels in 
both the control and obese treated groups. 
 
One concern regarding the applicability of the present studies’ data to those in 
humans would be the higher hepatic PPARα receptor density known to be present in 
rodents compared with other species including humans (Palmer et al. 1998; Holden 
and Tugwood, 1999). As such, extrapolation of the beneficial effects of K-111 on 
body weight, lipid levels and insulin sensitivity reported in this study need to be done 
with caution. The novel assessment of K-111 in a model of diet induced obesity does 
however support the current body of evidence advocating the usefulness of K-111 in 
treating systemic metabolic complications associated with obesity and type 2 
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diabetes. It will be interesting to see whether the beneficial effects of K-111 noted in 
the present and other studies are mirrored in the clinical trials.     
   
7.8 The impact of chronic K-111 treatment on cardiac function, substrate 
metabolism and susceptibility to ischaemia/reperfusion injury 
 
Obesity, insulin resistance and diabetes are generally associated with an altered 
metabolic profile, which extends to the myocardium, where enhanced FA utilization 
and reduced glucose utilization predominates (Wilson et al. 2007; Hafstad et al. 
2007; Aasum et al. 2008; Zhang et al. 2010). As previously discussed, these 
myocardial metabolic alterations associated with obesity and diabetes are thought to 
impact on myocardial mechanical function, mitochondrial function and tolerance to 
ischaemia/reperfusion induced injury. Metabolic modification/manipulation of 
carbohydrate and lipid utilization often done by genetic or pharmacological 
interventions has been shown to influence LV mechanical function (Aasum et al. 
2008) and post-ischaemic outcomes (Vik-Mo et al. 1986, Lopaschuk et al. 1988; 
Hafstad et al. 2007; Aasum et al. 2008) in healthy, obese and diabetic animals. The 
application of metabolic modulators has also proved useful in treating diabetic 
patients with ischaemic cardiomyopathy resulting in the improvement of LV function, 
glucose metabolism and endothelial function (Fragasso et al. 2003). It is therefore 
vital to determine the impact of new metabolic manipulators on these endpoints. This 
is especially true with regards to PPARα agonists since genetic over-expression of 
PPARα in the heart has been shown to induce a metabolic phenotype characteristic 
of the diabetic heart coupled with cardiac dysfunction (Finck et al. 2002). 
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7.8.1 The impact of chronic K-111 treatment on basal cardiac function 
In the present study, chronic K-111 treatment did not alter basal ex vivo LV 
mechanical function in either the control or obese treated animals in comparison to 
their untreated counterparts irrespective of the insulin and FA concentrations present 
in the perfusate (Table 6.5, 6.6). This finding concurs with other studies using K-111 
that have previously reported a lack of LV functional effects in healthy and diabetic 
animals (Aasum et al. 2002; Aasum et al. 2005). In contrast, Aasum et al. (2008) 
demonstrated that obese mice treated chronically with the PPARα agonist 
fenofibrate, had improved myocardial LV function, whereas Zungu et al. (2009) 
demonstrated that healthy rats treated with the PPARα agonist Wy-14,643 for 14 
days exhibited significantly attenuated LV functional parameters. The disparity in 
functional outcomes between the previously mentioned studies (including the present 
study) and that of Zungu et al. (2009) (i.e. no effect or protective vs. detrimental) may 
be due to the differences in PPARα agonists used (fenofibrate and K-111 vs. Wy-
14,643). In addition, only Wy-14,643 was able to induce changes in myocardial 
PPARα regulated response genes (mRNA levels) in contrast to the present study (K-
111 failed to induce alter myocardial CPT-1 expression) and those of others (Aasum 
et al. 2002; Aasum et al. 2005, Aasum et al. 2008). Although the majority of evidence 
suggests that chronic PPARα agonist treatment does not impact negatively on 
myocardial function, murine models of cardiac specific PPARα over-expression 
exhibit cardiac dysfunction (Finck et al. 2002). From the observations made by Zungu 
et al. (2009) the possibility therefore exists, that agonists of the PPARα family 
capable of augmenting myocardial PPARα response genes may predispose the 
myocardium to contractile dysfunction.   
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7.8.2 The impact of chronic K-111 treatment of myocardial substrate 
metabolism 
Studies using cardiac specific PPARα over-expressed mice further suggest that 
myocardial PPARα activation increases myocardial FA oxidation rates (Finck et al. 
2002; Park et al. 2005; Sambandam et al. 2006). In the present study, it was 
demonstrated that chronic K-111 administration had no impact on control treated, 
while limited outcomes were observed in the myocardial substrate metabolism profile 
of obese K-111 treated animals (Table 6.3, 6.4). Hearts from K-111 treated obese 
animals achieved reduced palmitate oxidation rates prior to global ischaemia in 
relation to the untreated obese and K-111 treated control rat hearts, but only in the 
presence of high insulin and FA levels in the perfusate. Although the reduction in 
myocardial palmitate oxidation rates in the K-111 treated obese group was 
unexpected, the present data agree with that of Aasum et al, (2002; 2005; 2008) who 
demonstrated similar myocardial metabolic changes in palmitate oxidation rates in K-
111 treated db/db mice (Aasum et al, 2002; 2005) and fenofibrate treated obese 
insulin resistant mice (Aasum et al. 2008).  
 
Interestingly Carroll and Severson (2001) and Aasum et al. (2005) reported an 
inhibitory effect of K-111 on cardiac lipoprotein lipase activity. The present study 
further noted that K-111 lowered circulating Trig’s and FFA levels in the obese rat, 
which would imply that the K-111 treated obese rat heart would be accustomed to 
being exposed to lower circulating FFA supply in vivo. In accordance with what was 
proposed by Aasum et al. (2005), it is thought that the systemic effects of K-111, 
coupled with the absence of K-111 related myocardial effects (the absence of PPARα 
target gene up-regulation in the present study) may explain the reduced myocardial 
FA oxidation rates observed in the K-111 treated obese group compared to the 
Stellenbosch University http://scholar.sun.ac.za
245 
 
untreated obese group. A similar conclusion to that of Aasum et al. (2008) can be 
made, namely that the myocardial metabolic effects associated with chronic PPARα 
agonist treatment may result primarily from the drugs’ systemic lipid lowering effects.  
 
Contrary to what has been described in the previous paragraph, rodent 
cardiomyocytes cultured with K-111 have increased FA oxidation rates (Aasum et al. 
2005). In the same study, when K-111 was administered in vivo, it was shown to 
induce changes in the gene expression of certain PPARα related gene targets in 
hepatic tissue but not cardiac tissue. The discrepancies observed between the lower 
FA oxidation rates observed in isolated perfused hearts (current study; Aasum et al, 
2002; 2005) and higher FA oxidation rates reported in cultured cardiomyocytes 
(Aasum et al. 2005) in response to K-111 treatment, suggest that K-111 primarily 
acts on the liver and not the heart when administered in vivo (as described by Aasum 
et al. 2005).   
 
Although obese rats in the present study maintained euglycaemia, primarily due to an 
elevated insulin secretion, glucose has been shown to potentiate the effects of 
PPARα agonists by increasing their binding to co-activators and DNA (Hostetler et al. 
2008). The discrepancy regarding the myocardial metabolic effects of chronic K-111 
treatment in control and HCD fed animals could possibly also be explained by the 
higher carbohydrate content of the experimental diet which could aid in potentiating 
PPARα’s hepatic effects. This hypothesis however remains to be established. 
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7.8.3 The impact of chronic K-111 treatment on the expression of myocardial 
metabolic proteins 
As previously mentioned, myocardial CPT-1 expression was not upregulated in both 
K-111 treated groups. It was further interesting to note that chronic K-111 treatment 
did no influence the expression or phosphorylation of PKB or the p85-subunit of 
PI3K. While phosphorylation of these two proteins may relate to the degree of tissue 
insulin sensitivity and more specifically the degree of glucose uptake (Summer et al. 
1998; Florian et al. 2010), previous studies have documented the lack of induction of 
PDK4 (inhibits the PDH complex and consequently will influence myocardial glucose 
oxidation rates) mRNA expression by both fenofibrate and K-111 (Aasum et al. 2005; 
2008). It therefore seems that certain groups of PPARα agonists have no effects on 
myocardial gene regulation while others do (Zungu et al. 2009). Alterations in ex vivo 
myocardial substrate metabolism seen with certain PPARα agonists may thus reflect 
the conditioned changes brought about by altered in vivo myocardial substrate supply 
(systemic effects) and not direct myocardial transcriptional effects. 
 
Various authors have documented an inability of fenofibrate and K-111 to induce 
myocardial target gene expression (Aasum et al. 2002; Aasum et al. 2005, Aasum et 
al. 2008). Although K-111 was unable to upregulate myocardial CPT-1 levels in the 
present study, which is in agreement with the finding of the previously listed authors, 
the conclusion that K-111 does not upregulate the protein expression of myocardial 
PPARα taget genes in the present rodent model needs to be further evaluated by 
measuring additional PPARα regulated proteins following chronic K-111 treatment.  
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7.8.4 The impact of chronic K-111 treatment on isolated ventricular 
mitochondrial function 
While synthetic ligands for PPARα are used to combat the metabolic abnormalities 
associated with obesity and type II diabetes, it is disputed whether these compounds 
have beneficial effects on mitochondrial function (Scatena et al. 2004). Indeed 
PPARα agonists administered in vivo and in vitro have been shown to attenuate ADP 
dependent oxidative phosphorylation in cardiomyocyte mitochondria (respiring in the 
presence of glutamate, pyruvate or palmitoyl-L-carnitine) isolated from healthy 
animals (Zungu et al. 2006; Khalid et al. 2011), while having no effect on 
cardiomyocyte mitochondria isolated from diabetic animals (Khalid et al. 2011). 
 
Results obtained in the present study showed that lean and obese insulin resistant 
animals treated chronically with the PPARα agonist K-111 have normal ventricular 
mitochondrial function irrespective of the oxidative substrate used (Table 6.11, 6.12). 
Although no effects were observed on mitochondrial function, these findings are 
novel with respect to both the drug and model in which the drug was used.  
 
The mitochondrial functional findings identified in a model of diet induced obesity 
could be clinically relevant. Both the PPARα agonists fenofibrate and Wy 14,643 
when administered to isolated mitochondria from either skeletal muscle or cardiac 
ventricles have been reported to inhibit complex I respiratory activity (Brunmair et al. 
2004; Zungu et al. 2006), coupled with reduced rates of oxidative phosphorylation in 
vitro (Zungu et al. 2006). While the possibility exists that K-111 may produce similar 
effects in vitro, the present study has demonstrated that chronic in vivo administration 
of K-111 to lean and obese animals does not adversely influence oxidative 
phosphorylation rates of mitochondria isolated from myocardial tissue. It may 
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however be necessary to investigate the impact of chronic K-111 treatment on the 
respiratory capacity of hepatic mitochondria since this tissue may be the primary site 
of action for K-111 (Aasum et al 2005). Nevertheless this data provides additional 
support for the clinical use of K-111.  
 
7.8.4.1 Future directions 
Although the aim was to measure mitochondrial respiratory capacity, the present 
study did not assess mitochondrial respiratory function in the presence of pyruvate. 
As mitochondrial respiration in the presence of this substrate may be compromised in 
obese conditions (Boudina et al. 2005), it would be interesting to see whether the 
improved systemic insulin sensitivity associated with K-111 treatment in obese 
treated animals would be associated with improved mitochondrial respiratory 
capacity in the presence of pyruvate.  
 
Although the present study could not show a detrimental effect of chronic in vivo K-
111 administration on mitochondrial oxidative phosphorylation rates, the fact that 
similar agonists inhibit complex I respiration and the rates of oxidative 
phosphorylation in mitochondria are concerning (Zungu et al. 2006). Since the 
primary site of action for K-111 may be the liver (Aasum et al. 2005), future studies 
should aim at investigating the impact of chronic PPARα agonism on hepatic 
mitochondrial respiration. 
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7.8.5 The impact of chronic K-111 treatment on myocardial susceptibility to 
ischaemia/reperfusion injury 
Although K-111 had favourable systemic and at times metabolic (lowering palmitate 
oxidation rates in the presence of high insulin and FA perfusion conditions) effects in 
obese treated animals, chronic treatment with the drug did not afford cardioprotection 
(infarct size or post-ischaemic LV functional recovery) following coronary artery 
ligation and subsequent reperfusion in either the control or obese treated groups, 
independent of circulating insulin and FA levels present in the perfusate (Figure  
6.13a, 6.14a, and Table 6.7, 6.8). This data is in agreement with the findings of 
Aasum et al (2003b; 2005) and together with their observations would suggest that 
attenuated myocardial FA oxidation prior to ischaemia is not always associated with 
cardioprotection during reperfusion. 
  
Aasum et al. (2003b) previously noted that K-111, when administered at 0.24mg/ml 
for 3 weeks, was not able to protect isolated hearts from type 2 diabetic db/db mice 
against ischaemia/reperfusion injury (pump function). The authors speculated that 
protection from ischaemia/reperfusion injury may be limited to PPARγ activation in 
the heart. Despite this, PPARα agonists have subsequently been shown to induce 
cardioprotection in response to ischaemia/reperfusion induced injury in both healthy 
and diseased animal models (Tabernero et al. 2002; Wayman et al. 2002; Yue et al. 
2003; Bulhak et al. 2006; Yeh et al. 2006; Aasum et al. 2008; Bulhak et al. 2009). In 
contrast, only a few studies have noted no or enhanced post-ischaemic injury 
following PPARα agonism/activation (Aasum et al. 2002; Xu et al. 2006; Hafstad et 
al. 2009). It may be that the lack of protection (LV pump function) afforded by K-111 
in the study by Aasum et al. (2002) was influenced by the short duration of drug 
treatment (3 weeks). In addition, the myocardium of type 2 diabetic mouse may be 
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more prone to irreversible ischaemic injury compared to that of the obese insulin 
resistant animal. However neither of these possibilities may be correct as db/db mice 
of a similar age as used in the study of Aasum et al. (2002), when treated with the 
pan-PPAR ligand Tetradecylthioacetic acid (which has a high affinity for PPARα) for 
eight days showed enhanced cardiac output recovery following low flow ischaemia 
(Khalid et al. 2011). In contrast to the present study, Aasum et al. (2008) using a 
similar HCD to that used in the current study, demonstrated increased post-
ischaemic LV mechanical function in hearts from obese insulin resistant mice 
following chronic treatment with the PPARα agonist fenofibrate. Thus the absence of 
protection afforded by K-111 in a similar model of diet induced obesity may be 
related to the specific nature of the drug, which may differ subtlety from other classes 
of PPARα agonists demonstrating cardioprotection from ischaemia/reperfusion injury 
(Tabernero et al. 2002; Wayman et al. 2002; Yue et al. 2003; Bulhak et al. 2006; Yeh 
et al. 2006; Aasum et al. 2008; Bulhak et al. 2009). The difference in cardioprotection 
between the present study and that of Aasum et al. (2008) (using mice fed a similar 
HCD treated with fenofibrate) could also be explained by the different endpoints used 
(infarct size vs. functional recovery) or species differences (rat vs. mouse). 
 
 The current study is the first to investigate post-ischaemic outcomes as indicated by 
myocardial infarct size following chronic K-111 treatment in both normal and diet 
induced obese animals. Since adverse myocardial post-ischaemic outcomes have 
been reported in mice with enhanced PPARα activation (Sambandam et al. 2006), 
the current study is clinically significant given the high risk for developing coronary 
heart disease and myocardial infarction in the obese and diabetic population (Hubert 
et al. 1983; Grundy et al. 1999; Yusuf et al. 2005), a population that is likely to 
receive metabolic modulators such as PPARα agonists. Thus the present 
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observation that chronic K-111 treatment did not augment post-ischaemic injury is 
extremely important.  
 
7.8.5.1 Future directions 
Despite the absence of an infarct lowering effect afforded by chronic K-111 treatment 
in the present study, the outcomes of these experiments may be confounded by the 
ex vivo nature of the experiments as perfusions performed using similar FA and 
insulin levels did not simulate the specific in vivo environments of the untreated and 
treated obese animals. In line with the study’s hypothesis that the altered metabolic 
environment associated with obesity may play a role in augmenting post-ischaemic 
outcomes, combined with the observation that K-111 treatment attenuated FFA and 
triglyceride levels while improving whole body insulin sensitivity, it is tempting to 
speculate that chronic K-111 treatment may reduce myocardial infarct size in obese 
animals in vivo. Although hearts from obese K-111 treated rats perfused with 
“normal” insulin and FA levels did not have smaller infarct sizes compared to the 
untreated obese group perfused with high levels of insulin and FA (comparison not 
shown), an in vivo study would better explain this relationship. Consequently such an 
in vivo study is warranted to further explore the cardioprotective role of chronic K-111 
treatment in models of obesity. Furthermore due to the uncertainty of the post-
ischaemic outcomes associated with PPARα agonist treatment, the clinical use of 
novel PPARα agonists in the treatment of the obesity/diabetes/metabolic syndrome, 
a population with a high risk for developing AMI, should proceed with caution prior to 
their post-ischaemic impact being fully investigated.  
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CONCLUSIONS 
 
The present study made used of a rodent model where obesity was induced by 
hyperphagia. These obese animals had more retroperitoneal and gonadal fat mass, 
displayed an altered lipid profile and developed insulin resistance which did not 
progress to type 2 diabetes even after long term feeding (32 weeks). 
 
While it is known that an oversupply of oxidative fuels characteristic of obesity 
impacts on cardiac energy metabolism and eventually may contribute to cardiac 
dysfunction, the present study suggests that prior to the development of cardiac 
dysfunction, hearts from obese insulin resistant animals (32 week fed rats) are more 
dependent on physiologically relevant concentrations of FFA to maintain LV 
mechanical function and functional reserve than hearts from lean animals. This may 
be due to the ineffective or reduced capability of the insulin resistant heart to utilize 
glucose as a fuel source.  
 
The impact of obesity on post-ischaemic outcomes is controversial. When obesity 
was induced over shorter feeding periods myocardial mitochondrial respiration and 
susceptibility to anoxia were normal. Although hearts from obese animals had larger 
infarct sizes when perfused with glucose alone, obesity did not impact on myocardial 
post-ischaemic injury in the presence of similar substrate and hormonal supply in the 
perfusate. An ex vivo simulation, using in vivo predicted insulin and FA levels 
specifically relevant to the control and obese state however suggest that the specific 
metabolic environment found in the obese state may aid to reduce myocardial 
tolerance to an acute myocardial infarction. However it is feasible that other factors 
present in vivo in the obese condition may additionally contribute to these outcomes. 
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Thus on the one hand, obese insulin resistant hearts rely more readily on elevated 
FFA as a fuel source to maintain normal LV mechanical function and functional 
reserve, but at the same time, this metabolic environment may contribute to adverse 
post-ischaemic outcomes. As such metabolic strategies aimed at reducing 
myocardial supply of circulating FFA in obese patients at risk for AMI are essential. 
While these strategies may lower the risk for adverse post-ischaemic outcomes, they 
may additionally improve myocardial insulin sensitivity enabling more effective use of 
glucose as a fuel source in maintaining LV mechanical function and functional 
reserve. Data from the present study in conjunction with other studies additionally 
suggest that the insulin resistant heart in the setting of myocardial infarction may be 
responsive to and protected by exogenous insulin administration when attempting to 
revascularize the ischaemic myocardium.  
 
The present study was the first to investigate the cardiovascular effects of the PPARα 
agonist K-111, in a model of diet induced obesity. While K-111 improved various 
biometric and systemic metabolic parameters (hyperlipidaemia and insulin 
resistance) associated with obesity, it did not improve any of the measured 
cardiovascular outcomes (besides attenuating myocardial palmitate oxidation in the 
obese group when perfused with high insulin and FA concentrations). Amid the 
controversy surrounding the impact of PPARα agonists on especially mitochondrial 
function and post-ischaemic outcomes, the present findings have significant clinical 
value as it appears that chronic administration of K-111 does not adversely impact on 
normal myocardial mitochondrial respiration or post-ischaemic infarct size following a 
simulated acute myocardial infarction. The absence of an infarct sparing effect 
afforded by K-111 may however be due to the ex vivo nature of the experiments as 
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mimicking the in vivo substrate environment of obese and obese K-111 treated 
animal was not possible.  
In conclusion, hearts from obese animals in the present study show no signs of LV 
contractile dysfunction or mitochondrial dysfunction. The metabolic environment 
associated with obesity may however contribute to exacerbate post-ischaemic 
outcomes. In vivo studies investigating the effects of metabolic modulators on post-
ischaemic outcomes in models of obesity and or diabetes are however warranted.  
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FINAL COMMENTS 
 
A final search in PubMed revealed no additional articles related to the use of K-111. 
An internet search however revealed that phase II clinical trials involving K-111 have 
been discontinued (http://diabesitydigest.com/targets.php?id=62). The reasons for 
the discontinuation of this trial are not available. 
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